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Abstract 
 
Lung cancer is a worldwide health problem associated with poor prognosis. The survival at 
5 years remains between 5% and 15% in spite of the development of new drugs. One of the 
main reasons for this is the disease being diagnosed in late stages when curative treatments 
might not be available. Therefore, some of the most important factors within improving 
prognosis are both refining diagnostic techniques for early detection, and better assessing 
tumour response to treatment. Here lies a need for novel diagnostic tools for lung cancer. 
Spectroscopic and spectrometric analysis of the molecular underpinnings of the disease may 
provide biochemical signatures for use in diagnostics. Selected Ion Flow Tube – Mass 
Spectrometry (SIFT-MS) and Fourier Transform Infrared (FTIR) Spectroscopy may provide 
the gold standard of diagnostic assessment that is needed. Given both techniques previous 
contributions and technological advancements, their clinical requirements are being 
increasingly met. This is leading towards the opportunity for the study of lung cancer to 
benefit from the rapid, non-destructive and sensitive qualities they have to offer. In this 
thesis, both techniques have been used with the aim of improving the diagnosis and 
management of lung cancer. 
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Chapter 1 Introduction 
1.1 Lung Cancer 
Worldwide, lung cancer was estimated to be responsible for a staggering 1.8 x 106 accounts 
in 2012, with an estimated 1.59 x 106 people dying from the disease in the same year. In the 
UK, 44.5 x 103 new cases were diagnosed and 35.4 x 103  people died from the disease the 
same year (Cancer Research UK). Lung cancer can be divided in 2 main subgroups, non 
small cell lung cancer (NSCLC) and small cell lung cancer (SCLC) (Appendix 1). The 
former accounts for around 87% of lung cancer cases and the latter for around 12% (Cancer 
Research UK). Staging of lung cancer has been summarised in Appendix 2. 
 
1.1.1 Incidence 
Globally, lung cancer is the most predominantly occurring cancer site in males affecting 
17% of those diagnosed with cancer. It also accounts for 23% of total male cancer deaths 
(Jemal, B. 2011). In economically developed countries, lung cancer is responsible for the 
highest number of male cancers, except for prostate cancer. 
 
In the global female population, 8.5% of new cases of cancer were lung cancer in 2008. 
Among females, the mortality burden of lung cancer in developing countries accounts for 
11% of total female cancer deaths – on par with cervical cancer (Jemal, B. 2011, Siegel, N. 
2013). Within developed countries however, lung cancer rates are two to five times higher, 
perhaps due to improved diagnosis and lifestyle choices (Jemal, B. 2011). 
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1.1.2 Tobacco/non-tobacco 
"More people smoke today than at any other time in human history. One person dies every 
ten seconds due to smoking-related diseases"  
- (Tabish, S.A. 2007). 
 
The association of smoking with lung cancer has been established since the 1950s, pioneered 
by Sir Richard Doll who first established a relationship between smoking and increased risk 
of heart disease and lung cancer. The risk of dying from lung cancer is associated with 
particulars of cigarette smoking, which are the duration, regularity, tar concentration and age 
of initiation (Ostroff, R. M. 2010). It therefore comes as a surprise to find that despite the 
lower prevalence of smoking among Chinese women, at less than 4 % of adult smokers 
within the population, Chinese females have higher lung cancer rates than those within 
European countries (Mackay, J. 2004). Thus, we cannot attribute all lung cancer occurrences 
to smoking alone.  
 
Other risk factors are clearly at play if we are to consider the unusual rates amongst 
populations that do not have high numbers of smokers. In the case of Chinese women it has 
been thought to reflect the presence of indoor air pollution caused by poorly ventilated coal 
stoves (Lam, W.K. 2004). Further sources of risk include occupational and environmental 
hazards; such as asbestos, arsenic, radon and polycyclic aromatic hydrocarbons 
(Boffetta, P. 2003). Boffetta et al. (2003) conclude and warn that whilst there is a relatively 
small risk of cancer following direct exposure to environmental carcinogens, they are not to 
be ignored. Given a causal relationship, a large number of cases would be caused as a result 
of high level prevalence of exposure.  
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Lam et al. (2004) comment that despite other etiological factors identified as having a 
relationship with lung cancer, the effect of tobacco smoke on incidence is overwhelming, 
calling for a concerted effort against tobacco use and a drive for scientific research into lung 
cancer. Global statistics back up Lam et al.'s conclusions; 80% of the lung cancer burden in 
males and 50% in females is attributed to smoking (Ezzati, M. 2003). Understanding the root 
of lung cancer may hold the key to overcoming the disease. Despite the obvious risks of 
smoking, and as Tabish et. al. (2007) has stated, more people smoke today than ever, 
meaning that lung cancer will be a growing problem to be tackled by scientists and clinicians 
for years to come. 
 
1.1.3 Lung Cancer Diagnosis 
Kendall et al. (2009) state that the most important factor in the prevention of the disease's 
progression is early detection, and identifying and removing the pre-malignant cells before 
systematic invasion.  
 
If a patient presents with suspected lung cancer (through cough, breathlessness, haemoptysis 
–coughing up blood-, and pain), they are sent for an evaluation using imaging techniques. 
This is a vital stage as the diagnosis of the tumour type and stage will affect the treatment 
strategy applied and inevitably the prognosis of the disease. The first stage is typically 
imaging, through chest x-ray, computerised tomography (CT) scan, and positron emission 
tomography (PET).  
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The CT scan remains the main technique used to stage tumours and for post therapeutic 
evaluation, assessing location, size and anatomical characteristics. The widely recognised 
limitations of the CT scan are the uncertainty of detecting metastasis within normal sized 
lymph nodes and the difficulty in differentiating between tumour adhesion and tumour 
infiltration (Schrevens, L. 2004). The assessment of pulmonary nodules is conducted using 
PET, which is considered significantly more accurate than CT scan (Schrevens, L. 2004). 
Both methods have been used in tandem to overcome the movement of tumours with 
breathing motion, creating a 4D scan (Wolthaus, J.W.H. 2005). An alternative to CT and 
PET scans is magnetic resonance imaging (MRI). However, despite recent advantages in 
MRI, using the technique to assess the staging of tumours remains limited. This is because 
MRI is susceptible to motion artefacts and the lung parenchyma (there is a poor signal here 
due to low proton density) (Schaefer-Prokop, C. 2002)(Figures 1A an1B). 
 
 
Figure 1. (A) Chest x-ray and (B) CT scan of chest. 
 
The images in Figures 1A and 1B are of a chest x-ray and a CT scan, respectively. They 
demonstrate the difficulty in using these techniques to make a firm diagnosis. Figure 1A 
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depicts a tumour in the left upper lobe while Figure 1B illustrates a faint nodule in the right 
lung. The inability to image the entire lung with a resolution high enough to detect pre-
invasive tumours and the lack of biochemical information about the disease is holding 
current imaging techniques back (Wardwell Jr. N.R. 2005). By the time the tumour is visible 
using conventional diagnostic techniques, the cancer might be diagnosed in advanced stages 
(Kendall, C. 2009). Following imaging, the tumour needs to be confirmed through tissue 
diagnosis. This can be done through sputum cytology, thoracentesis, lymph node biopsy, 
bronchoscopy, transthoracic needle aspiration (also known as fine needle aspiration) and 
video assisted thoracoscopy (Collins, L.G. 2007). 
 
1.1.4 Cytology 
Sputum cytology has been shown to lead to the early detection of lung cancer and improve 
the 5 year survival rate (Miller, L.M. 2005). The nature of obtaining the sputum, which can 
be done through application of a saline mist (induced sputum) and aspiration of forced 
coughing, is recommended for patients who may not be suitable candidates for invasive 
methods. The largest drawback to sputum cytology is that it is dependent on the quality of 
the sample obtained, which in some circumstances can be minimal due to size and location 
of the tumour (Collins, L.G. 2007). Despite this, sputum cytology could hold promise with 
the refinement of monolayering, preserving the preparations, and improving the automation 
of staining (Miller, L.M. 2005). 
 
Sputum cytology provides several advantages over surgical specimens other than the 
obvious lack of invasive procedure. Firstly, the application of Papanicolaou (Pap) staining- 
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which is routine. Secondly, the stain has a high sensitivity for keratinization which aids the 
distinction between squamous cell carcinoma and adenocarcinoma.  
 
The distinction between the two forms of NSCLC has become increasingly important as 
advancements in personalised therapies have evolved to include the identification of 
Epidermal Growth Factor Receptor (EGFR) and Kirsten Rat Sarcoma Viral Oncogene 
Homolog (KRAS), which dictate management and treatment response. Recent studies 
suggest that cytology is keeping up with this advancement in oncology, supporting the 
identification of KRAS and EGFR to a high standard even within high-volume 
histopathology practices (Rekhtman, N. 2011). However, most of these studies ignore the 
issue of the identification of early stage carcinoma, focussing mostly on sub-typing rather 
than sensitivity of tumour detection. By its own admission, the above study states that the 
impact on survival of this new approach towards diagnosis has yet to be confirmed. On the 
other hand, the cytological diagnosis of cancer is still, up to certain extent, dependent on the 
subjective decision of the appropriate pathologist.  
 
Further drawbacks to cytology (sputum and aspirated) based samples are the low cellularity 
of the specimens and the non-cancer cells within the suspension (French, C.A. 2009; 
Rekhtman, N. 2011) Figure 2 demonstrates the difficulty of cytology diagnosis, other non-
cancer cells within the specimen is hindering a clear view of cells that may be cancerous. 
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1.1.5 Histopathology 
Biopsy specimens (tissue samples) have been compared to fine needle aspirations (FNA) 
used for cytology diagnosis. Biopsy samples also yielded other biological constituents (such 
as clotted blood, lung/fibrous tissue) as well as the desired cellular components. Overall, 
biopsy and FNA yielded specimens with similar cell content (in 83% of cases), making 
neither sampling method particularly advantageous over the other for diagnostic purposes 
(Yazdi, H.M. 1987). 
 
Once obtained, tissue samples are typically stained with Haematoxylin and Eosin (H&E). 
Haematoxylin colours the nuclei of cells, centrioles, fibrin, and red blood cells blue, and the 
Eosin colours protein based (eosinohilic) structures a red/pink/orange, including collagen, 
reticulin fibres and cartilage (Avwioro, G. 2011; Langer, C.J. 2010). 
Figure 2. A cytological sample displaying an 
epithelial cell (pink, filled arrow) and lung 
cancer cells (blue, non-filled arrow) (bottom 
left).  
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There is an ongoing dispute to the value of histology and cytology, and which one offers the 
highest levels of sensitivity and specificity, histology suffering from the same drawbacks as 
cytology with regard to sample quality and subjectivity applied to the diagnosis. When 
compared, it is often concluded that both cytological and histopathological tools should both 
be performed routinely in cases of suspected malignancy (Jones, A.M. 2001). 
 
1.1.6 Diagnostic Conclusions 
Overall, it is clear that the current diagnostic practises for lung cancer do not provide a 
comprehensive view of the disease and present with many problems, such as poor resolution, 
false negatives and the lack of biochemical information needed to detect cancerous cells. 
Both cytological and histopathological practises are reliant on the subjective diagnosis from 
a pathologist, again at a cost of sensitivity and specificity, with the risk of the patient having 
to undergo further biopsies to reach a conclusive result. 
 
It is clear that further understanding of the molecular pathways, biochemical signals and 
behaviour of cancerous cells will only stand to benefit the study of the disease and help to 
refine the current diagnostic practises. This could be ascertained through in vitro studies that 
have already contributed to clinical practises and what we know about cancer today.  
1.1.7 Treatment of Non-Small Cell Lung Cancer 
The treatment of NSCLC can be split into four subgroups; surgery, radiation, 
chemotherapy and targeted treatments. Each group can be used in combination, cause 
different side effects and are used to teach NSCLC in different stages (Refer to Appendix 2 
for staging guidelines). Surgery is used to treat stage I and stage II cancers. Chemotherapy 
can be applied after surgery to try to prevent the cancer from returning, this is known as 
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“adjuvant chemotherapy” and is particularly effective in those patients with stage II and 
stage IIIA disease. Radiation and chemotherapy treatment is often given in combination for 
stage III cancer that cannot be removed surgically. For stage IV cancer chemotherapy is 
used as the main treatment. Stage IV disease is treated with radiation, for palliative care 
(National Institute for Health and Care Excellence, 2011).  
The chemotherapy drugs used in the treatment of lung cancer are often used in 
combination. Cisplatin, carboplatin, docetaxel, gemcitabine, paclitaxel, vinorelbine and 
pemetrexed are commonly used. Dependant on tumour response to the drugs, differing 
numbers of courses are prescribed for the patient (National Institute for Health and Care 
Excellence, 2011).  
In some cases chemotherapy is used prior to other treatments, such as before surgery or 
radiotherapy, in the hope that the drug may shrink the tumour, this is known as 
neoadjuvant chemotherapy). Continued treatment with the same drug following the 
surgical procedure is more likely to aid in successful treatment (National Institute for 
Health and Care Excellence, 2011).  
Targeted treatments refer to those treatments that specifically target lung cancer cells – 
differing from chemotherapy drugs which are not specific. Targeted therapies also differ in 
that they are cytostatic, blocking cancer cell proliferation instead of cytotoxic 
chemotherapy. Examples of targeted treatments for NSCLC are erlotinib, afatinib, 
gefitinib, bevacizumab, crizotinib and ceritinib. Such therapies are often used in 
combination with a chemotherapy drug (Cancer.org, 2016). 
1.2 Lung Cancer in Vitro:  3D Cell Cultures 
Most cell cultures are developed and maintained within a 2 Dimensional (2D), monolayer 
environment. Within the cellular engineering community there has now been a surge of 
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evidence substantial enough to demonstrate the advantages of cell culture within a 3D one. 
At face value, this has come as no surprise given that within mammalian tissues cells are 
supported and maintained within a 3D extracellular matrix (ECM), in populations that are 
functionally diverse. The populations also have a specific balance of functionality and spatial 
configuration in order to create healthy living tissue, with tissue engineers striving to mimic 
the natural environment as closely as possible; 3D scaffolds that mimic the ECM are 
therefore desirable. 3D cultures generally house the cells within a homogenous colony that 
is supplied with a nutrient rich medium and good gas exchange, allowing the diffusion of 
nutrients and waste products.  
 
Whilst 2D environments still allow a substrate in which the cells may be able to develop the 
communication they require between each other, the culture may not be able to facilitate this 
in the same manner as they are able to in a 3D matrix. One obvious limitation of a 2D culture 
is the lack of representation of stroma, which has an important role to play within cancer 
development. The tumour stroma is comprised of non-malignant cells and extracellular 
matrix. Non-malignant cells are specialised mesenchymal cells (specific to tissue area), 
endothelial cells and pericytes. The extracellular matrix consists of the structural proteins 
collagen and elastin along with specialised proteins (fibronectin, fibrilin, elastin) and 
proteoglycans (Ronnov-Jessen, P. 1996). 
 
It has been shown that the stroma provides a base in which tumours can create 
vascularisation. NSCLC cells have been found to release angiogenic factors leading to the 
creation of blood vessels. The interaction of these factors with the stroma is less well known 
about. Anderson et al. (2000) investigated the expression of interleukin-8 (IL-8) (a known 
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angiogenic factor secreted by cancer cells) and the role the stromal layer plays. Co-cultures 
of NSCLC cells and pulmonary fibroblasts were created. IL-8 was consistently induced 
within the fibroblastic culture (Anderson, I.C. 2000). The study highlights the importance of 
the cancer – stroma interaction and the high level of influence cancer cells have over their 
environment. As the preliminary data here suggests, there are unidentified soluble factors at 
play, influencing both the cancer cells and the cells within their surroundings. It is therefore 
vital to include a representation of the stromal layer within in vitro cultures or provide a 
scaffold which could go some way into encouraging a realistic interaction for cancer cells 
with their environment.  
 
Cell adhesion and growth will also be affected by the differences in microenvironment 
between in vivo and in vitro studies (Xu, F. 2007). This is because receptors on the surface 
of cells (integrins) attach the cells to the substrate that they are on. Through integrins, cells 
also determine the biochemical information received from their immediate surroundings. 
Interpretation of such information determines cell behaviour such as differentiation, 
proliferation, apoptosis and metastatic capacity (Smalley, K.S.M. 2006). 
 
Implementation of 3D cultures will inevitably produce more clinically relevant research, 
which is particularly relevant with regard to cancer studies. In vivo, tumours are comprised 
of a relatively complex structure consisting of dividing, hypoxic and necrotic tumour regions 
(Friedrich, M.J. 2003). 
 
Studies looking at anti-tumour activity are strong examples of how the use of 3D cultures go 
some way to reflecting the impact of the structure of a tumour growth on experimentation, 
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over the use of previously conventional 2D cultures. In 2005 Bissell and LaBarge examined 
how the structure of a tissue would impact the resistance of malignant and non-malignant 
cells to chemotherapeutic agents. The results indicated that the structure of the tumour 
played an important role within the emergence of resistance to the chemotherapeutic agents 
alongside the genetic and growth factor signalling of the cells. Bissel and LaBarge conclude 
that no cell is able to function without instruction from its microenvironment, which in vivo 
is a product of the cell's own genetic instructions. 
 
In vitro culture imposes an artificial microenvironment on the cells and so it comes as no 
surprise that earlier studies by Weaver et al. (1997) found that breast cancer cells changed 
behaviour, characteristic morphology and patterns of growth when grown on 3D constructs 
(Weaver, V.M. 1997). The study also utilised the inhibitory effects of beta 1-integrin 
antibody, illustrating that a cell's interaction with its microenvironment (via integrins) is 
significant enough to change a cell's phenotype. Reversal of the effects was created once the 
antibodies were removed, restoring the original cancerous phenotype (Weaver, V.M. 1997). 
Also, when dissociated from the 3D construct, that is mimicking the basement membrane, 
into a culture suspension, cell’s phenotype changed or suffered anoikis, (a form of apoptosis 
caused through lack of anchorage (Frisch, S.M. 2001).  
 
Having defined a suitable environment to study lung cancer cultures, the next step in tackling 
the issues associated with the disease would be to look at the diagnosis process that hinders 
the overall outcome of patients. The 3D cultures could be implemented into the work of a 
new form of diagnosis. It is obvious from the data collected on lung cancer that the disease 
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is not being identified early enough. Could cell cultures provide any chemical information 
that could allow earlier identification within a clinical setting? 
 
1.3 Spectrometry 
1.3.1 SIFT-MS 
One avenue in which to explore this challenging area is to look at the volatile metabolites 
that may be given off by cancer cells both in vivo; that is to examine the breath of patients 
with cancer, and in vitro; through examination of the volatile organic compounds (VOCs) 
that are given off from cell cultures. SIFT-MS allows such an examination, being a long 
established method of gaining insightful quantitative and qualitative information about the 
headspace of biological substances, having being developed primarily for real-time analysis 
of trace gases in breath/air (Smith, D. 2005). Despite emphasis of study being placed upon 
biological analysis, SIFT-MS was originally used to examine fundamental ion-molecule 
interaction at thermal energies (Adams, N.G. 1976), plasma reactions within the terrestrial 
atmosphere (Smith, D. 1980) and interstellar clouds (Smith, D. 1992). The instrument has 
made considerable progress since those early studies in capacity, sensitivity and 
transportability (Španěl, P. 2011). SIFT-MS can easily lend itself to the study of biological 
samples given the unusual capability of the machine to cope with the relatively large amount 
of water vapour often present in biological and breath samples. Although care should be 
taken to avoid direct contact of the SIFT-MS sampling arm with water.1 
 
                                                          
1 Upon contact, the SIFT-MS sampling arm will draw water into the instrument, where it is kept under 
vacuum. Under vacuum, water boils rapidly (at ~20 mbar, the vapour pressure of water). As the vacuum 
reduces atmospheric pressure, the boiling point for water is reached at a much lower temperature. At this 
point the energy for boiling starts to come from water molecules, consequently its temperature reduces 
and so with a reducing pressure the water starts to freeze, becoming ice. Ice then blocking the instrument. 
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SIFT-MS relies on a chemical ionisation technique to determine the molecules present 
within a sample. Chemical ionisation is the process where new ionization species are created 
when gaseous molecules interact with ions. This involves electron, proton or other charged 
species transfer between the reactants. (IUPAC, 1997). Acidity is an example of how 
ionization takes place. Acids are chemical species that have the tendency of donating protons 
(Bronsted, J.N. 1923). Strong acids will completely dissociate into ions, completely ionizing, 
when placed in water. However weaker acids will only partially ionize. The degree of which 
an acid ionizes can be worked out using the acid ionization constant (Ka), this is the 
equilibrium constant for the ion dissociation in water (ie., The point in which the 
concentration of each chemical species does not change over time).   
HA + H2O ⇌ H3O
+ + A-    Ka = 
[𝐻3𝑂
+][𝐴−]
[𝐻𝐴]
 
SIFT-MS works on similar principles, with the interaction of selected precursor ions, 
undergoing proton donation or a charge transfer process. That is reagent ions collide with 
the unknown analyte ions within the sample, the electrons present ionising the reagent gas 
molecules. In this case H3O
+, NO+ and O2
+ reactant ions are used. H3O
+ reactions follow 
proton transfer, H+ is transferred from the H3O
+ precursor ion to the analyte compound M. 
Product ions formed from this reaction also undergo hydration as the samples are humid, 
that is H2O molecules will associate with the protonated MH
+. NO+ reactions are charge 
transfer reactions, that is an electron is drawn from the analyte (our sample molecule), M, by 
the positively charged reactant ion neutralising the NO+ ion to the neutral NO. As the 
samples are humid hydride ion transfer occurs; H- is transferred from the analyte molecule 
to the precursor ion. O2
+ reactions are also charge transfer reactions, like with NO+, an 
electron is drawn from the analyte molecule and accepted by O2
+ leaving an O molecule that 
is neutral.  SIFT-MS utilizes the reaction of mass selected precursor ions with sample ions 
that are introduced into a flow tube via a helium gas carrier. The subsequent product ions 
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are then studied by a downstream mass spectrometer (See Figure three). Mass selected 
precursor ions are created using a microwave resonator, as mentioned, commonly selected 
ions are H3O
+, NO+ and O2
+ ions, for the simple reason that they do not react readily with 
the common constituents of air (Španěl, P. 2011). A downstream mass spectrometer is then 
used to select the correct ions generated by the microwave generator. A series of pumps and 
sampling orifices are used to maintain the correct pressure and to focus the ions along the 
SIFT-MS. The downstream mass spectrometer operates at around 5-10 Torr, the proceeding 
flow tube operates at 0.5 Torr in order to achieve articulate gas reactions. Venturi inlets are 
used to sustain such changes in pressure but maintain a focussed flow of ions. Once a stream 
of defined precursor ions has been established the sample of interest is then injected into the 
flow tube through a helium carrier gas; the gas again being specific for this purpose due to 
its inert nature at a pressure of around 1 Torr. The introduced ion species from the sample of 
interest then reacts with the precursor ions (preselected by the upstream quadrupole) as they 
travel across the flow tube at high speed (Španěl, P. 2011). Product ions and precursor ions 
travel through a final sampling orifice where they are met by the downstream quadrupole. 
An electron multiplier then amplifies the signal given from the final quadrupole. In brief, a 
quadrupole mass analyser is compiled of four parallel rods, with associated positive and 
negative charges. They have fixed direct current (DC) and alternating radio frequency (RF) 
potentials applied to create an electric field that ions with a particular m/z are able to pass 
through. This is because the electric field only allows those ions with a stable trajectory to 
pass through to the detector. The alternating RF potential changes, functioning as a tool to 
focus ions with differing m/z into a stable trajectory and to be “in focus”, therefore passing 
through the column of rods to the detector. As this potential changes, a mass spectrum can 
be built up of ions with differing m/z (Paul. W, 1983). 
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An on-line computer is then able to calculate the relative concentration of trace compounds 
from the reaction of product ions and sample gas (Smith, D. 2005; Španěl, P.  2011; 
Smith, D. 2011). 
 
 
Figure 3. Schematic diagram of the SIFT-MS. 
 
Given that the mass to charge ratio (m/z) of the precursor ions is known, along with flow 
rate and size of the flow tube (typically 5 cm in modern SIFT-MS instruments) it is possible, 
using this kinetic information, to determine the rate coefficient of product ions of the sample, 
in real-time, with a relatively large molecular weight range (10 m/z to 180 m/z) and a higher 
sensitivity (in Profile 3 instruments) (Španěl, P.  2011), something that gives the SIFT-MS 
advantage over other forms of mass spectrometry also used to study cancer.  
 
With regard to lung cancer, SIFT-MS studies can be split into two groups; firstly the study 
of breath from patients diagnosed with cancer (ex vivo studies) and secondly the study of 
cancerous and non-cancerous cell cultures (in vitro studies). In support of breath diagnosis, 
it is important to have a grasp of where potential volatile biomarkers of cancer could lie. In 
vitro studies are a good place to find a focus for this work. 
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Earlier studies of the lung cancer cell lines CALU-1 and SKMES, found that the release 
acetaldehyde VOC is proportional to the cell number within a two dimensional culture 
(Smith,D. 2003). The study was extended to include a comparison of lung cancer cell lines 
to normal lung epithelial cells, NL20 and 35FL121 (Tel+) lung fibroblastic 
cells (Sulé-Suso, J. 2009). Again, acetaldehyde was found to be produced in proportion to 
the cell numbers for CALU-1 and NL20. However, the 35FL121 cell line was seen to 
consume the compound. Interestingly, carbon dioxide was produced by respiration by the 
CALU-1 and 35FL121 cell lines as expected but in lower amounts by the NL20 cell line 
(Sulé-Suso, J. 2009), suggesting that the lower levels of CO2 produced maybe due to an 
inhibited metabolism. There has also been some preliminary evidence to suggest that 
elevated acetic acid levels are produced by the CALU-1 cell line when cultured in acidic 
conditions (Smith, D. 2003). Given that the non-cancerous cell lines are also seen to produce 
acetaldehyde, the study provides insufficient evidence to identify acetaldehyde as a 
biomarker of cancer (Smith, D. 2003). Further exploration into the scale and nature of this 
production is needed to define the role acetaldehyde has to play within cancer metabolism. 
 
Whilst 2D cultures have provided us with a spring board into the examination of lung cancer 
(the cells studied were all grown as a monolayer within a culture flask) it is important to 
endeavour to mimic human physiology as closely as possible. The development of collagen 
hydrogels within the tissue engineering community has provided a suitable scaffold in which 
cells are able to be expanded as a 3D tissue-like sample (Petersen, M.C. 2007). SIFT-MS 
would provide a strong comparison for how cancer cells behave in a traditional 2D in vitro 
setting compared to those grown within a 3D hydrogel construct. On a broader scale, SIFT-
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MS could provide key knowledge about the interaction cells have in general for a widely 
used scaffold and the volatiles the scaffold gives off.  
The interaction of in vitro cell culture studies and SIFT-MS poses some issues in itself that 
need to be overcome in the methodology. The conditions needed to maintain cell populations 
incorporate VOCs that may interfere with the identification of a biomarker. It has been found 
that foetal calf serum contained in the medium of the cell culture contributes to acetone and 
ethanol, (Sulé-Suso, J. 2009) and serves as a warning of the complexities brought with cell 
culture investigation. This also demonstrates the value of using SIFT-MS, which is 
addressing interactions within cultures between cells and the growth medium in real time. 
 
In recent years there has been a strong shift towards the development of SIFT-MS as a 
clinically accessible bedside tool (Smith, D. 2010). This would have multiple advantages for 
a disease such as lung cancer. As mentioned before, the earlier lung cancer can be diagnosed 
the better the prognosis for the patient. Current diagnostic techniques need to be refined in 
order to fulfil this remit. Ideally, a new approach to lung cancer screening should also be 
developed. SIFT-MS has the potential to do so through the detection of early stage volatile 
biomarkers that cancerous cells may give off, as do other sources of analytical instruments 
that also measure breath volatiles; such as Gas Chromatography-Mass Spectrometry (GC-
MS). There is a wealth of reviews that offer a summation of the work completed so far in an 
effort towards the improvement of lung cancer diagnosis (Amann, A. 2011; Poli, D. 2005; 
Smith, D. 2010); all come with speculation over some of the requirements that need to be 
met by breath testing and the analysis of volatile biomarkers if the challenges of this disease 
are to be met. 
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First and foremost is perhaps the sensitivity of such instrumentation. Can bedside analytical 
methods be sensitive enough to detect small early stage tumours that may only give off 
relatively minimal amounts of volatile compounds? Early stage SIFT-MS studies are 
promising, to the extent that analyses of single breath exhalations are able to generate 
sufficient sensitivity to detect VOCs in other diseases such as renal failure and cystic fibrosis 
.(Smith, D. 2010; Enderby, B. 2009; Davies, S. 1997; Gilchrist, F.J. 2012) However, GC-MS 
studies have revealed potential biomarkers such as alkanes, present at very low 
concentrations, in parts-per-trillion, in the breath of patients with primary lung cancer 
(Phillips, M. 1999; Phillips, M. 2003; Phillips, M. 2004), a challenging level for SIFT-MS 
instruments. With the identification of possible biomarkers at such a low level it is important 
to take into account the large levels of compounds that are present within the ambient air we 
breathe. A distinction must be made between endogenous compounds, produced by the body 
or cancerous tissues, and the exogenous compounds that are inhaled by the subject of 
interest. With further research and development, the SIFT-MS could offer insight into these 
questions (Smith, D. 2015; Smith, D. 2010) 
  
In addition to sensitivity, SIFT-MS has also met the challenge of timing. Real-time analysis 
of single breath inhalations of dozens of patients have been analyzed in a single day, with 
immediate results (Smith, D. 2010). Calibration of the instrument is also extremely quick. 
Other analytical instruments often require time consuming and costly calibration methods 
that require the user to obtain commercially available standards, such as with the GC-MS. 
 
SIFT-MS is improving all the time. The new Profile 3 instrument (Instrument Science 
Limited) has an increased sensitivity when compared to previous models due to the fine 
tuning of the instrument. For example, the size of the flow tube (5 cm) (Španěl, P. 2011), 
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incorporating refined pump systems and dynamic quadrupoles. The use of alternate ion 
sources with the later SIFT-MS instruments has not only increased the sensitivity but has 
also brought with it the challenges of additional ion chemistry. One particular challenge to 
our studies is the adduct ions formed as a product of three-body reactions. A three-body 
reaction is a reaction that yields a single product from two reaction species and a third body 
to stabilize the product ion. Equations are being utilized within the kinetics library for each 
compound in order to give an increasingly realistic quantitative measurement that accounts 
for such ion interferences (Španěl, P. 2011). 
 
So far, SIFT-MS has given us a glimpse of what to expect from the instrument as an 
analytical tool having already been used to identify VOCs in the headspace of bodily fluids. 
The urine of patients with bladder and prostate cancer was analysed, revealing that 
formaldehyde is clearly elevated in the urine of cancer sufferers over that of the healthy 
controls (Španěl, P. 1999). From breath samples we have gained insight into diabetes 
(Davies, S. 1997), where acetone levels were found to be ten times greater in diabetic 
individuals when compared to the rest of the population, even exceeding 5 x 103 part-per-
billion-by-volume (ppbv) when under insulin control. The focus of the study was to monitor 
the breath of patients undergoing haemodialysis. The renal patients were found to have high 
ammonia levels in their breath (prior to dialysis) exceeding 10 parts-per-million (ppm) when 
compared to the healthy population that has around 1 ppm. SIFT-MS found that the levels 
of both ammonia and acetone fell during dialysis demonstrating how the instrument could 
be implemented in monitoring the efficiency of the treatment. This too could lend itself to 
the study of lung cancer – providing information about the efficiency of chemotherapy 
during the treatment process as opposed to the post hoc method.  
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1.3.2 GC-MS 
GC-MS has proved a popular choice amongst the breath analysis community, having been 
used to identify VOCs secreted from gastric cancers and the bacteria associated with the 
disease (Buszewski, B. 2008). Solid-phase microextraction (SPME), which utilizes a sorbent 
fibre that captures the compounds of interest when exposed to the liquid or gaseous 
environment that they are in, has identified a higher amount of 1-propanol and carbon 
disulfide given off by cancerous stomach tissue when compared to non-cancerous stomach 
tissue (Buszewski, B. 2008). The study also found that bacteria Helicobacter pylori, 
associated with gastric cancer, may cause an increase in the concentration of these 
compounds released by the cancerous tissue. The same principles could be applied to the 
study of lung cancer – could certain compounds linked with smoking correlate with the 
VOCs given off by cancerous lung tissue? 
 
Lung cancer has been the focus for many GC-MS studies. As early as 1985, GC-MS has 
demonstrated the detection of VOCs from the breath of lung cancer patients and compared 
them to the breath profiles of those without the disease. Despite a limited patient population 
and the production of one hundred and fifty peaks of VOCs, it has been found that the 
GC/MS was able to detect profiles of lung cancer distinct from those without lung cancer. 
The initial study found that acetone, methyl ethyl ketone and n-propanol were clinically 
significant compounds, providing a classification accuracy of 93% (Gordon, S M. 1985). 
Further studies also found that the analysis of breath was going to be complex due to the 
production of many compounds. O'Neill et al. (1988) found a myriad of VOCs within the 
eight patients they screened, with results containing up to 386 individual components. 
Conclusions were drawn to focus on the 45 components that occurred at a 75% occurrence 
level and the 28 components that were greater than 90% in occurrence level of the total 
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composition of expired air samples. The study also noted that compounds of interest were 
often representative of environmentally related pollutants, highlighting the complexity of 
this form of analysis (O'Neill, H.J. 1988).  
 
Later studies compared the VOCs found in the breath of patients with lung cancer and the 
VOCs found to be given off by in vitro cell cultures. Some metabolic products did correlate 
between the 2 study groups, 11 VOCs from the breath of patients were identified as possible 
biomarkers of cancer (Chen, X. 2007). This previous study, that utilized samples taken 
directly from the breath of lung cancer patients, has so far used small sample populations, 
largely comprised of smokers, of 15 lung cancer sufferers (Chen, X. 2007) and so cannot 
offer a realistic prediction of what to expect from a clinically representative population. 
 
In vitro studies, as already discussed, may offer an insight into lung cancer and provide a 
good platform for larger scale studies. The cell line CALU-1, a non-small cell lung epithelial 
carcinoma, was studied using the SPME method of GC-MS. An increase of 
2, 3, 3-trimethylpentane, 2, 3, 5-trimethylhexane, 2, 4-dimethylheptane and 4-methyloctane 
was found in the headspace of the cell cultures. Interestingly, there was a decrease of 
acetaldehyde in the culture, which is in contrast to the VOCs found through SIFT-MS 
sampling. One explanation for this discrepancy could be the difference in culture methods. 
The studies utilising the SIFT-MS technique allowed for the attachment of the CALU-1 cells 
to a culture flask, an attachment that would mimic the natural environment of the tumour 
cells. However, the GC-MS examined cells that had been cultured within a fermenter where 
cells were kept in suspension (Filipiak, W. 2010). The cell line NCI-H2087, a non-small cell 
lung adenocarcinoma, was also cultured within a fermenter and was also found to consume 
acetaldehyde, 2-methylpropanal, 3-methylbutanal, 2-methylbutanal and butyl acetate 
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(Sponring, A. 2009). The difference across studies highlight the importance of a refinement 
of a suitable cell culture environment – do the cells give off VOCs according to different 
environmental status? 
 
An expansion of the study of in vitro cell lines included A549, a lung adenocarcinoma cancer 
cell line, to be compared to two non-cancerous cell lines, HBEcC (a bronchial epithelial 
sample) and hFB (human fibroblasts). The VOCs detected from all cell lines exhibited a 
similar pattern of behaviour, that is an increase of 2-pentanone and 2, 4-dimethyl-1-heptene. 
Differences were seen with regard to branched hydrocarbons, that were principally given off 
by the non-cancerous cell lines. Of note, aldehydes were decreased within the headspace of 
the hFB and HBEcC when compared to the A549 cells, which may be more akin with the 
SIFT-MS results, despite also being grown within a fermenter (Sponring, A. 2009). 
 
It is clear that further comparison across the different forms of mass spectrometry need to be 
facilitated if we are to be able to draw firm conclusions about the possible biomarkers of 
lung cancer. Sample populations also need to be significantly increased in size if we are to 
get an accurate grasp of what to expect from clinically relevant populations of cancer patients 
and control cases. 
 
Mass spectrometry has a diverse range of contributions to make towards improving the 
diagnosis of lung cancer. Despite other methods such as the GC-MS providing a more 
comprehensive analysis of chemical compounds, the SIFT-MS is perhaps the most clinically 
relevant. As mentioned, the instrument functions in real time, with many user friendly 
applications – such as the on-board kinetics library. Given the absence of sample preparation 
and the portability of the instrument above the heavier GC-MS, the SIFT-MS is perhaps the 
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right choice for the bedside diagnostic tool. Other instrumentation is perhaps geared towards 
the laboratory setting – providing deeper knowledge into cancer cell behaviours but being 
less suitable for a hospital setting which requires the rapid turnover of many samples.  
 
1.4 Vibrational Spectroscopy 
Another tool that also offers both clinical and scientific application is vibrational 
spectroscopy. As a whole, vibrational spectroscopy has a number of potential advantages for 
the ex vivo assessment of lung cancer and to assist the current histopathological classification 
currently applied. The comprehensive studies are able to offer rapid, high resolution, non-
destructive molecular examination without staining, possibly aiding prognostic information. 
(Kendall, C. 2009) 
 
Within molecules, there are different vibrational modes as a result of the energy and nature 
of the bonding between each molecule (see Figure 4). This allows the atoms to move 
in dimensions, keeping the molecule in continuous movement. The energy of a given 
molecule is partitioned into 3N degrees of freedom that describe the molecule’s 
3 translational and 3 rotational motions. The degrees of freedom for vibrational modes of 
linear molecules is 3N-5 and for nonlinear molecules 3N-6, N being equal to the number of 
atoms within the molecule. 
25 
 
 
Figure 4. The different vibrational modes of molecules. 
 
Photons (light energy) interact with the different vibrations via absorption or Raman 
scattering. The study of this interaction allows us to gain qualitative and quantitative 
information on the sample of interest within the portion of the light spectrum, in this case 
infrared spectrum. Infrared spectroscopy provides us with this information through 
measuring the loss of energy from a known frequency of incident light or the level of 
absorbance, once it has interacted with the molecule/molecules. Absorbance occurs if the 
energy of the incident radiation is the same size as the vibrational mechanism of the molecule 
it collides with. Raman spectroscopy utilises Raman scattering; the inelastic scattering of a 
photon, to observe the molecular vibrations (Griffiths, P. R. 2002). When monochromatic 
light makes contact with a molecule the cloud of electrons around the nuclei is polarised, 
forming a temporary virtual state. Most photons are elastically scattered from the 
atom/molecule, differing in only a very small frequency, with the same energy as the incident 
photons. This is called Rayleigh scattering. However, if the incident photons cause 
oscillating polarisation, energy is then transferred either from the incident photon to the 
molecule or from the molecule to the incident photon. This is dependent on whether the 
molecule was excited from the ground state or from a higher vibrational state (Figure 5). 
This inelastic scattering and the energy of the scattered radiation is different from that of the 
Bending Rocking Wagging Twisting Symmetrical 
Stretching 
Asymmetrical 
Stretching 
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incident photons. If during Raman scattering the scattered photon has a longer wavelength 
than the incident photon, the molecule has absorbed the energy and is promoted from the 
ground state to the first excited vibrational state. This is known as Raman stokes scattering. 
If during Raman scattering the molecule loses energy and the scattered photon has more 
energy than the incident photon, this is known as anti-stokes Raman scattering 
(Keresztury, G. 2002). 
 
 
Figure 5 Diagram of Rayleigh and Raman scattering. 
 
The infrared spectrum is a portion of the electromagnetic spectrum that is split into different 
regions; the mid-, near and far infrared. The spectrum itself is primarily organised along the 
x-axis, which is a frequency scale (in cm-1) directly proportional to the energy of the 
vibrational bond within a molecule. The focus of this literature review will be on the mid-
infrared region. This is because the wavelengths studied here are in the 4000-400 cm-1 
wavenumber region, this corresponds to wavelengths of 2.5 to 25 μm, a relevant size when 
looking at cellular samples.  
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1.4.1 FTIR microspectroscopy to Study Biological Molecules 
Fourier Transform Infrared (FTIR) microspectroscopy can be used to study components of 
biological structures, such as human tissue and cells. These samples are made of several 
crucial biomolecules; lipids, proteins, carbohydrates and nucleic acids. As mentioned before, 
each biomolecule will produce its own spectral signature based on the nature of the bonds 
within it and therefore each kind of cell will produce an individual spectrum. A typical 
spectrum of a biological sample can be seen below in Figure 6. 
 
 
Figure 6. A typical FTIR spectrum of a cell. Biological bands of interest are 
labelled. 
 
Lipid structures appear within the region between 3000-2800 cm-1 due to the C-H stretching 
vibrations (both asymmetric and symmetric) of the CH3 and CH2 groups of acyl chains as 
seen within the sample spectra above. C=O groups produce peaks at 1740 cm-1, CH2 at 1465 
cm-1, a range of strong bands at 1070 cm-1 – 1050 cm-1 and weaker bands at 1400-1250 cm-
1 as a result of the C-O-C groups (Lewis, R.N.A.H. 2006). 
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Protein structures were first determined at atomic resolution in the 1950s using x-ray 
crystallography (Hodgkin, D.C. 1950). FTIR microspectroscopy can provide some detail 
into structure and function of proteins within human tissues. Proteins are comprised of amino 
acids and distinguished from each other by the number and order of amino acid units that 
they contain. The structure of a protein is folded into primary and three dimensional 
structures, secondary and tertiary. FTIR microspectroscopy is able to provide information 
about the secondary structure of proteins, that is the stretching vibrations of the C=O bond 
within the Amide I band and bending vibrations of the N-H bond with C-N stretching within 
Amide II. Amide I appears within the 1700-1600 cm-1 region of the mid-IR spectra, with an 
intense peak at 1650 cm-1 defined within the broader peak, whilst Amide II manifests itself 
within the 1530 cm-1 region. Proteins are also characterised by bands appearing at 3300 cm-
1 – the Amide A band (N-H stretching). Amide III bands also occur as a result of intracellular 
proteins at 1400-1230 cm-1. The peaks result from weaker protein vibrations from a 
combination of C-N stretching and N-H bending vibrations, like Amide I, but are dependent 
on the side chain structures of the protein between 1310 – 1450 cm1. Proteins are a good 
example of the complex overlapping that can occur within FTIR spectra when trying to 
examine biomolecules (Gauglitz, G. 2014).  
 
Carbohydrates produce broad bands around 3400-3380 cm-1 due to the OH stretching 
vibrations and another band at 2930-2900 cm-1 due to the presence of CH2 groups and C-H 
stretching. Further peaks are seen at 1200-950 cm-1 from the C-O, C-C stretching and C-OH 
bending modes. At the lower end of the mid-IR spectrum, 950-700 cm-1 bending vibrations 
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produce peaks due to the presence of C-OH, C-CH, O-CH and C1-H bending vibration 
(Kacurakova, M. 1996; Brandenburg, K. 2002). 
 
How do the vibrational modes of a biomolecule result in peaks on an infrared spectrum? In 
order to absorb the photons a change within the dipole of the molecule must occur. During 
the activation of different vibrational modes (Figure 4), the dipole of the biomolecule is 
changed. The change in dipole is based on the nature or strength of the bonds between the 
groups so the stronger bonds with lighter atoms result in a higher frequency of vibration. 
The higher frequency in vibration will appear as a peak at the top end on the mid-IR 
spectrum. Within biomolecules we see a higher level of overlap between spectral bands due 
to the similar absorption of different molecules within the cell samples, as demonstrated by 
the description of peaks for each component. 
 
The complicated interactions between the molecules and their vibrational modes results in a 
fingerprint spectra that could be used to identify, diagnose and explore biological samples 
for medical applications. Applying vibrational spectroscopy to the study of disease has been 
practised since the 1950s. Vibrational spectroscopy could help us to improve screening, 
diagnosis, our ability to predict a response to therapies, intraoperative monitoring and 
follow-up studies (Fisher, S. E. 2011). In order to fulfil this clinical remit, vibrational 
spectroscopy must be able to provide rapid, consistent and reliable techniques to a wide 
sample population. A technique that will be able to do this is FTIR spectroscopy. FTIR 
spectroscopy utilises a Michelson Interferometer (Figure 7) which splits the infrared light 
source (A) into 2 optical beams using an intermediate semi-transparent mirror. Half of the 
beam is directed towards Mirror 1 (B) which reflects the beam back, through the semi-
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transparent mirror, to the detector. The other half of the beam (C) passes through the semi-
transparent mirror to Mirror 2 where it is reflected back, joining beam B before being 
reflected back to the detector. Both beams undergo different surface reflections. Mirror 2 
will be moveable and Mirror 1 is fixed, adjustments in the path of the beam caused by Mirror 
2 create an interference which is then recorded by the detector. This movement also provides 
FTIR with a unique property, the ability to measure all infrared frequencies simultaneously 
(Griffiths, P. R. 2007). This is a major advantage of using FTIR spectroscopy for clinical 
applications – simultaneous measuring of frequency allows the instrument to make fast 
measurements. 
 
 
 
 
 
 
 
 
                    Figure 7. Michelson Interferometer. 
The interferogram acquired will require further interpretation if the frequency spectrum is 
required. This decoding comes from a well-known technique called Fourier Transformation. 
This is usually completed digitally producing as outcome the IR spectrum we are familiar 
with.  
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1.4.2 Sources of Infrared 
The first and perhaps most obvious reason to choose FTIR spectroscopy is the sensitivity of 
the instrument. Benchtop FTIR instrumentation has a Globar source; a silicon carbide rod, 
which is heated electronically to ~1300 °K. Such a high temperature reduces the signal to 
noise ratio within the spectrum, providing continuous mid-infrared radiation. The choice of 
a Globar as a source is a compromise – higher temperatures provide a reduced signal to noise 
ratio within the spectra but must also be kept stable within the local atmosphere, have a good 
lifespan and must limit saturating the detector. Commercially available Globars are cooled 
using water jackets to avoid the over-heating of electrical components within the system but 
are limited by this aspect of use. Despite the limiting factor, Globars have been used to 
divulge the chemical make-up of a variety of different materials, such as minerals, plant and 
animal tissues, polymers laminates and pharmaceuticals (Griffiths, P.R.  2007). 
 
The main competitor of the Globar source of IR is Synchrotron radiation. The radiation is 
produced by electrons travelling in a synchrotron ring at relativistic velocity. The ring is 
created through the use of magnetic fields which bend the path of electrons into a focussed, 
closed orbit. This source size is around 100 μm in size, producing a light source with very 
high brightness (Carr, G.L. 1999). The brightness generated is 100-1000 times brighter than 
the Globar sources (Miller, L.M. 2005). The narrow range of angles for emission of the 
source is coupled with a small sample area (by the aperture), this in turn decreases the level 
of flux that will reach the detector and the signal to noise ratio is reduced. The advantage of 
using a synchrotron source is based around the 10-20 μm area. Miller et al. (2005) 
demonstrated that due to the high brightness, if an aperture is set to a throughput of 10 μm, 
80% of the infrared light is still able to pass through reaching the detector. Smaller amount 
of Globar light is able to pass through at this aperture. However, at 70 μm, it is worth noting 
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that a synchrotron light source will lose its advantage given that the source produces no more 
power than a Globar (Diem, M. 2004). 
 
Biological samples such as cellular components are therefore well suited to benefit from the 
synchrotron’s brightness due to the small scale of these samples. Many studies have already 
started to utilize these advantages to examine the molecular chemistry of disease. 
 
1.4.3 Lung Cancer Studies and FTIR spectroscopy 
Previous studies have already applied FTIR spectroscopy to the study of cancers in various 
formats, such as colon and skin (Ly, E. 2008), leukaemia (Di Giambattist, L. 2010), 
oesophageal (Quaroni, L. 2009), prostate (Baker, M. J. 2009), breast; including lymph node 
mestastasis (Bird, B. 2009) and ovarian (Krishna, C.M. 2007) to name a few. Some, with a 
focus on the diagnostic applications, or to focus on the study of the effects of drugs on the 
cancers themselves. The same has been seen for the study of lung cancer, 
 
Early studies into the structural changes associated with lung cancer within the pleural fluid 
were conducted using microscopic FTIR spectroscopy (Wang, H.P. 1997). The infrared 
spectra demonstrated differences between the normal, malignant and tuberculous cells 
within the pleural fluid, taken as a primary source from cancer patients. The significant 
findings were between the peak intensities of 1030 and 1080 cm-1 – mainly associated with 
the glycogen and phosphodiester groups. The work demonstrated an overall reduction of 
glycogen and hydrogen bonding of C-OH groups of amino acids (in proteins) in the 
abnormal cells and an increase of the hydrogen bonding of the phosphodiester groups of 
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nucleic acids, warranting that pleural fluid may be of some diagnostic value (Wang, H.P. 
1997). Lobectomized lung specimens of squamous, adenocarcinomas and corresponding 
non-cancerous counterparts were directly analysed by FTIR spectroscopy. Again, glycogen 
was a feature within the analysis of the spectra. The analysis had a focus on the height of the 
peaks formed during the sampling, attributing a ratio of cholesterol and glycogen to be of 
most significance when identifying discriminatory factors of cancerous tissues (Yano, K. 
2000). Microscopic mapping was also used to show areas of cancerous and non-cancerous 
tissue – providing information on the spatial distribution of the cancerous cells, FTIR 
spectroscopy being used in conjunction with other techniques for this method – although this 
would not be clinically necessary to make a diagnosis, this knowledge could be applied 
scientifically to further our knowledge about cancer behaviour.  
 
Not all studies examine primary tissue sources, such as biopsy/lobectomized samples. FTIR 
spectroscopy has been used to assess a lung cancer cells' response to chemotherapy agents 
(Sulé-Suso, J. 2005). Gemcitabine was applied to the commercially available cell lines 
CALU-1 and A549 (both epithelial lung carcinoma). Following the addition of gemcitabine 
to the in vitro cultures, FTIR spectra produced changes within the 950-1150 cm-1 region. 
The ratio 1080/1050 cm-1 peaks, corresponding to the vibrations of PO2 and C-O stretching 
associated with glycogen and carbohydrate moieties were found to increase with the levels 
of gemcitabine added. The data also determined information about the survival rates of the 
cells. At the lethal doses (LD) of 75 (for A549) and 50-75 (CALU-1) the ratio of interest 
reaches a plateau phase – correlating the changes in peaks with cell survival (Sulé-Suso, J. 
2005).  
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So far the studies already mentioned utilised a Globar source radiation for FTIR 
spectroscopy. As already discussed, FTIR spectroscopy has now advanced into higher 
brightness capabilities using synchrotron IR radiation. So what does this mean for the 
diagnosis of lung cancer? Having already considered the problem of staining samples for 
diagnosis, it is also important to assess the contribution of the stain to any spectra produced 
by FTIR spectroscopy, especially if FTIR is to be used as a complementary service to this 
form of diagnosis. Clinical preparations of the cells should also be taken into account – are 
the specimens prepared using a cytospin or smear methods (such methods are currently used 
to apply samples to substrates for analysis, and are described in the methods sections of this 
thesis)? The effects of haematoxylin and eosin (H&E) and Papanicolau (Pap) stains were 
examined at single cell level. The aim of the study was to see if the stains interfered with the 
spectra and also to assess if the technique could still detect a difference between the 
cancerous and non-cancerous counterparts. Again, in vitro cell cultures of CALU-1 
(epithelial carcinoma) and NL20 (normal lung epithelial cells) were used and indeed the 
FTIR spectra could detect differences between the two cell types. The staining showed 
changes within the lipid and amide II band regions but this did not impede the correct 
identification of the cancerous and non-cancerous cells. In one case, differences between 
cells stained at different centres were seen (Pijanka, J. 2010). Such application of FTIR 
technology, the assessment of clinical procedure, would have some value to the medical 
community in itself.  
 
The study of cancer using synchrotron based FTIR microspectroscopy has also gone some 
way to evaluate one of the problems associated with FTIR spectroscopy. Mie scattering 
effects are an inevitable occurrence due to the size of sample and probe wavelength. S-FTIR 
microspectroscopy is able to look at the isolated cell nuclei due to its improved resolution. 
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A study examined the resulting spectra detailing the separation of optical (Mie) and chemical 
effects from the samples having compared single cell spectra and just the nuclei areas 
(Pijanka, J.K. 2009). Changes were seen within the lipids, proteins and DNA absorption 
bands, also demonstrating that the Mie effects were caused primarily by the nucleus of the 
cells. Unfortunately, although it was not the aim of the study, the authors did not include the 
normal lung cell counterparts to the cancerous ones, an aspect that should be included in 
further study in order to help characterize possible biomarkers for cancer 
diagnosis (Pijanka, J.K. 2009). 
 
It is clear that FTIR spectroscopy (both Globar and synchrotron sourced) has a lot to offer 
to the study of lung cancer. Both within a scientific setting; to explore the mechanisms 
underpinning cancer cell behaviours but also within the clinical setting; for better diagnosis 
and the assessment of drug resistance. Therefore further work is needed; some biomarkers 
have been identified as having potential, such as glycogen, but no clear conclusions can be 
confirmed. The need for further ground work is obvious given the complex molecular 
activity within the cells but that is not to say that a useful clinical diagnostic tool is not within 
the capabilities of this technology which is able to offer a rapid, non-destructive and cost 
effective application to the study of lung cancer.  
 
1.5 Conclusions 
Spectroscopy could contribute greatly to the facilitation of a new gold standard diagnostic 
tool, which could exclude the current problems of subjectivity, cost effectiveness and poor 
resolution. The technique could potentially replace and/or complement currently available 
techniques to improve the management of those suffering with lung cancer. It is clear that 
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both FTIR spectroscopy and SIFT-MS have strong clinical applications, the first with a niche 
towards the support for histopathological diagnosis and the latter with the aim of breath 
diagnosis. Both provide obvious advancements to the scientific study of in vitro cultures and 
tumour response to cancer treatments, the value of which should not be underestimated to 
the study of lung cancer.   
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Chapter 2 Materials and Methods 
2.1 Cell Culture Methods 
2.1.1 Cells 
The cell lines used in this thesis were: 
A549 is a human lung adenocarcinoma cell line, (Figure 8A) derived from the epithelial lung 
tissue of a 58 year old Caucasian male. A549 was purchased from the European Collection 
of Cell Cultures (Salisbury, UK). 
 
CALU-1 is a squamous lung cancer cell line, purchased from the European Collection of 
Cell Cultures Figure 8B). It was derived from a 47 year old Caucasian male with epidermoid 
cancer of the lung2. 
The different types of lung cancer have been listed in Appendix 1.  
 
35FLP are parental, normal lung fibroblast cells, derived from a 35 year old female. 35FL121 
cells are those derived from the parental 35FLP cells, immortalized via infection with a 
retrovirus containing hTERT3, catalytic subunit of telomerase (Forsyth, N. 2003). Both cell 
lines were a gift from Dr Nicholas Forsyth (Figure 8c). 
 
NL20 cells are a nontumorigenic cell line, consisting of immortalized human bronchial 
epithelial cells derived from a 20 year old Caucasian female. They were established through 
                                                          
2 Squamous and epidermoid are terms used for the same type of cancer. 
3 Human Telomerase Reverse Transcriptase is a subunit of telomerase, the enzyme. It is used to prevent 
telomere shortening and overcome telomere-controlled senescence (Lee K. M., 2004). 
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the transfection of the replication-defective SV40 large T plasmid, p129 and purchased from 
the American Collection of Cell Culture (ATCC, CRL-2503) (Figure 8D). 
 
 
 
 
 
 
 
 
 
 
 
2.1.2 Culture Conditions 
Below is a table of culture conditions for each cell line and media used. Each different culture 
condition is numbered for ease of identification throughout this thesis, particularly as media 
used on cell lines are interchanged across chapters for different experimental setups.  
Figure 8. Light microscope images of (A) A549, (B) CALU-1, (C) 35FL121 and (D) 
NL20. 
A B 
C D 
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Table I Cell culture conditions. 
Conditions Cell Line (s) Base Medium Supplements Dissociation Medium 
C
u
lt
u
re
 C
o
n
d
it
io
n
s 
1
 
A549/ CALU-1 
/35FL121 
DMEM, High 
Glucose 4.5 g/L  
10% Foetal Bovine Serum (FBS) 
8:6 Trypsin - EDTA Solution 
(10x) : Phosphate Buffered Saline 
(1x) 
1% Antibiotic/Antimycotic (100x) 
1% L-Glutamine (200 nM) 
1% Hepes Buffer Solution (1M) 
1% Non-Essential Amino Acids (100x) 
1% Sodium Pyruvate (100nM) 
 
NL20 
Ham's F12, 
Glucose 2.7 g/L 
1.5 g/L NaHCO3 
21 mg EDTA, 5.3 mL FBS, 
100 mL Hank's Balanced Salt 
Solution (1x) 
2 nM L-Glutamine (200 nM) 
0.1 mM Non-Essential Amino Acids (100x) 
5 µg/ mL Insulin (10 mg/ mL) 
10 µg/ mL Epidermal Growth Factor (EGF) 
1 µg/ mL Transferrin 
0.5 µg/ mL Hydrocortisone 
4% FBS 
1% Antibiotic/Antimycotic (100x) 
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Conditions Cell Line (s) Base Medium Supplements Dissociation Medium 
C
u
lt
u
re
 C
o
n
d
it
io
n
s 
2
 
A549/ CALU-1 
/35FL121 
DMEM, without 
Glucose 
10% Foetal Bovine Serum (FBS) 
8:6 Trypsin - EDTA Solution 
(10x) : Phosphate Buffered Saline 
(1x) 
1% Antibiotic/Antimycotic (100x) 
1% L-Glutamine (200 nM) 
1% Hepes Buffer Solution (1M) 
1% Non-Essential Amino Acids (100x) 
1% Sodium Pyruvate (100nM) 
4.5 g/L Glucose  
NL20 
DMEM, without 
Glucose 
1.5 g/L NaHCO3 
8:6 Trypsin - EDTA Solution 
(10x) : Phosphate Buffered Saline 
(1x) 
2 nM L-Glutamine (200 nM) 
0.1 mM Non-Essential Amino Acids (100x) 
5 µg/ mL Insulin (10 mg/ mL) 
10 µg/ mL Epidermal Growth Factor (EGF) 
1 µg/ mL Transferrin 
0.5 µg/ mL Hydrocortisone 
4% FBS 
1% Antibiotic/Antimycotic (100x) 
4.5 g/lL Glucose 
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Cells were grown in T75/T175 cell culture flasks (Sarstedt, Leicester, UK) in the relevant 
media (Table I) in a 37 °C and 5% CO2 incubator. The media was changed every 3-4 days 
and cells passaged before reaching confluence (typically weekly). 
 
2.1.3 Clonal Isolation 
Clonal isolation was accomplished using the CALU-1 cell line. Cells were passaged before 
reaching confluence from T75 cell culture flasks by adding trypsin-EDTA to flasks after 
removing culture media, and then incubating cells at 37 °C for 4 minutes. The trypsin-cell 
mixture is then quenched with culture medium and the suspension span at 1200 rpm for 
4 minutes. The supernatant is then discarded and the cell pellet is resuspended in 5 mL of 
media and mixed thoroughly. Cells are then counted using the trypan blue exclusion assay. 
Cells were then seeded at 0.5 cells/well within a 96 flat bottomed well plate using a 
multichannel pipette and topped with 200 µL of culture medium. As an example, and for 
simplicity, for 100 wells, 50 cells were placed in 20 mL of medium and distributed evenly 
in these 100 wells. For each individual experiment, 5 x 96 well plates were setup.  The plates 
were then wrapped in foil, to avoid dehydration, as they were then incubated for two weeks 
at 37 °C with 5% CO2. A media change is completed after the first 7 days of this incubation 
time, by removing 180 µL of media to avoid the disruption of any clonal colonies that might 
be forming and replacing with 180 µL of fresh media. Following a 2 week incubation, the 
plates were then rigorously checked (by inspecting the wells daily with a microscope) for 
suitable clonal colonies, meaning those colonies that had formed within a single rounded 
population and those of a medium – large size. Other populations containing more than 
1 clone or sparse number of cells were discarded, yielding on average 25-30 clones per 
experiment. Figure 9 shows a representative clone.  
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Figure 9. CALU-1 clonal cell populations after (A) 1 week in culture and (B) 2 weeks 
in culture. 
 
2.1.4 The Post-Hoc Detection of Cells Sensitive/Resistant to 
Gemcitabine 
The chemotherapy agent used within this study was the nucleoside analog4 Gemcitabine (2’ 
2’ – difluorodeoxycytidine) (Figure 10). 
 
Figure 10. The chemotherapeutic drug Gemcitabine. 
It was selected as it is a chemotherapy agent used in the management of lung cancer and as 
a locally sourced drug used within the University Hospital of North Midlands. Gemcitabine 
(Lilly, UK) was added to clonal populations of CALU-1 as follows: After the 2 week 
                                                          
4 Nuceosides analogs are nucleosides that contain a nucleic acid analog and a sugar. 
37 
 
incubation period required to produce adequate size clones, each colony of cells was 
detached from its well using 10 µL of trypsin and incubated for 5 minutes at 37 °C. 
Following this, 190 µL of medium was added to each well and mixed thoroughly. Cells were 
collected and seeded proportionally into 5 wells of a flat bottomed 96 well plate, and topped 
to reach 200 µL of medium per well, then incubated for 24 hours. Gemcitabine was then 
added at four different concentrations; 25 nM, 50 nM, 75 nM and 100 nM, leaving a control 
well unexposed to the drug. The drug was added within 100 µL of fresh medium after 100 
µL of medium was removed from each well, to reach the desired drug concentration. The 
control well having 100 µL media change with fresh medium alone. The cultures were then 
incubated for a further 5 days before sensitive and resistant populations could be identified. 
Sensitive clones were identified as those with low cell survival, characterised by wells with 
high amounts of debris and little cell attachment. Resistant cells were identified as cells that 
continued to proliferate and maintain a “healthy” population within the wells. 
 
2.1.5 3D Culturing Techniques 
3D matrices were implemented within the cell culture experiments given their ability to 
mimic in vivo tissue more accurately. The matrices were constructed from rat tail collagen 
type I (10.59 mg/ mL, BD Life Sciences). They were produced to form a gel with a final 
collagen concentration of 1.5 mg/mL, based on previously described work, (Yang, Y. 2005) 
and following the protocol described below (Figure 12). The collagen scaffold is prepared 
by combining, under ice, the neutralised solution of acetic acid extracted collagen with cell 
culture medium and cells. Once combined the gel is poured into a suitable vessel and 
incubated at 37° C in 5% CO2. Neutralising and heating the gel causes the collagen to 
polymerise, forming a fine lattice of fibrils, 10-20 nm, that then trap the cells and fluid inside, 
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forming a hydrogel structure (Bell, E. 2014), Figure 11 depicts the collagen fibres that are 
present within a hydrogel structure. 
 
Figure 11 Scanning electron microscopy (SEM) image of the collagen fibres 
within a hydrogel. Scale bar corresponds to 200 nM (Moreno-Arotzena, O. 2015). 
 
 
Figure 12. The determination of final volumes for 3D collagen model gelation 
protocol. 
 
10x MEM (Gibco Life Technologies, UK) powder was reconstituted with 2.2 g of NaHCO3 
and mixed well with 100 ml dH2O and sterile filtered with a 0.2 µ filter (Whatman, GE 
Healthcare Life Sciences). The process was repeated for 10x F12 (Gibco, Life Technologies, 
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UK) with 1.176 g of NaHCO3 being added to the powder. 10x PBS (Oxoid, UK, BR0014G) 
was reconstituted in dH2O according to the manufacturer’s instructions. 
 
Where cells were to be studied, the constituents that make up the gel were added first and 
mixed well. At this point, the pH of the mixture then becomes suitable not only for gelation 
but for cell growth. The cell population is counted and span down in order to remove any 
previous cell culture media that may alter the final setting conditions of the gel. The cell 
pellet is then added to the gel and mixed well, this is done rapidly to avoid the gel setting 
before the cell population is distributed equally. 3D constructs were given 24 hours 
minimum culture time in order for cells to get used to their new more physiological 
environment.  
 
2.1.6 Survival Assays 
2.1.6.1 Trypan Blue 
Cell viability was determined using the trypan blue exclusion method. 0.4% trypan blue 
solution (Sigma Aldrich, T8154) was added 1:1 to 20 µL of cell suspension and mixed 
thoroughly. A haemocytometer was then loaded with the stained suspension. Healthy cells, 
those that appear bright and unstained are counted as live cells, those cells that take up the 
trypan blue, appearing dark blue under the microscope, are determined as non-viable. 
 
 2.1.6.2 Live/Dead 
In order to assess cell survival in collagen scaffolds, a standard live/dead cell double staining 
kit (Sigma Aldrich) was used. The scaffolds were removed from the SIFT-MS bottles and 
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dissected into 0.5 cm3 portions taken from different areas of the sample (6 sections/scaffold). 
The fluorescence double staining kit utilises calcein-AM to stain live cells green and 
propidium iodide (PI) to stain dead cells red. The stain was diluted according the provider's 
instructions in phosphate buffered saline (PBS) and applied directly to the scaffolds for 1 
hour. Scaffolds were agitated every 15 minutes to ensure a thorough penetration of the stain 
within the sections. Sample imaging was performed using a FV300 confocal microscope 
(Olympus, Japan). 
 
2.1.7 Extraction of Live Cells from Collagen Scaffolds 
Scaled down versions of the 10 mL 3D Collagen gel matrices5 (1 mL) were digested in order 
to assess the cell viability within the culture. Media from the top of each culture was removed 
and collagenase from Clostridium histolyticum (working concentration 1000 units/ mL, 
Sigma Aldrich, C6885) was added to each gel. The gels were mechanically sectioned using 
a pipette and incubated for 1 hour at 37 °C. Once the matrix had dissolved, the trypan blue 
exclusion method was used as described above. 
 
2.1.8 Identification of Cells in fixed Collagen Scaffold  
A DAPI stain (Vectashield Antifade Mounting Medium with DAPI, Vector Laboraties) was 
applied to cryosectioned samples of cells within collagen matrixes. The stain was applied 
for 1 minute, washing 3 times with dH2O after. The samples were then air dried. This process 
was used to confirm the presence of cells within the matrix for S-FTIR analysis. 
Unfortunately, it was unpractical to identify cells by microscopy alone. DAPI was also 
                                                          
5 The justification of downscaling collagen scaffolds is explained in the corresponding chapter. 
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applied to 2D cytospun samples, using the same method here, to confirm the absence of 
differences in the spectra produced by the cells.   
2.2 Spectrometry 
2.2.1 SIFT-MS 
2.2.1.1 Instrumentation 
 
Figure 13. The SIFT-MS Profile 3 instrument. 
 
The headspace of cell cultures was measured for VOCs using a Profile 3 SIFT-MS 
instrument (Figure 13), from Instrument Science, UK. As described in the Introduction, 
selected reagent ions were produced from a microwave discharge ion source and sorted using 
a mass quadrupole (Figure 14). In this case, the selected ions were H3O
+ and NO+. They are 
injected into a stream of helium- the inert carrier gas for the reaction, thus obtaining an 
absolute concentration of product ions (10-180 m/z). The humid headspace of the cell 
cultures was taken via a heated sampling line, a hypodermic needle puncturing the septum 
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of the culture bottles connecting the headspace directly into the inlet port of the Profile 3. 
During the sampling, the cell culture bottles were maintained within a water bath at 37 °C. 
 
 
 
 
 
 
Figure 14. Schematic diagram of the SIFT-MS Profile 3 instrument. 
 
The headspace is met by the flow of reagent ions within the carrier gas and travels along the 
flow tube during a well-defined reaction time. The instrument was used in multi-ion 
monitoring mode (MIM), to study chosen analytes, or on full scan mode (FSM), to study 
analytes in the range between 10 -180 m/z. After mass analysis using a mass spectrometer, 
they are detected and counted by an electron multiplier/pulse counting system and the on-
board computer immediately calculates the concentrations of the trace gases (metabolites) 
in the sample with the aid of a kinetics database library compiled from numerous studies of 
ion-molecule reactions. 
 
2.2.1.2 Sample Preparation 
In this thesis, the headspace to be examined with the SIFT-MS was obtained in 2 ways. 
Either a 3D cell culture created matrix, within a sealed glass bottle with septum (Figure 15A) 
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or breath samples that have been exhaled by participants directly into a Nalophan 
bag (Figure 15B). 
 
 
 
 
 
Figure 15. Sampling methods for the SIFT-MS (A) Bottle samples and (B) a bag 
sample. 
 
For bottle samples, gels containing cells and control gels without cells were allowed to 
solidify by incubating them at 37 °C and 5% CO2 with the lids open for 2 hours. After this 
incubation time, 10 mL of media were added to the top of the gels and incubated for a further 
22 hours with the lids open. Following this incubation time, for a remaining 16 hours before 
SIFT-MS sampling in order to allow the headspace to develop, as previously described 
(Sulé-Suso, J. 2009). The lids contain a central rubber septum which can be punctured to 
study the headspace.  
 
For bag sampling however the air is sampled immediately, the bags being punctured directly 
with the SIFT-MS sampling needle. Nalophan tube sheeting is cut into 30 cm length and a 
3 cm poly-tubing length is inserted into one end, fixing into place with a cable tie before 
being sealed with parafilm. The opposite end is sealed using a cable tie and parafilm. Once 
the breath sample is collected, a syringe is used to seal the tube end of the sampling bag and 
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a further layer of parafilm is used to seal the connection. All participants were asked to fill 
each bag with at least 3 breaths, exhaling normally (ethical approval for this study had been 
obtained). 
 
All samples, bottle and bag were stored at room temperature, under ambient conditions until 
they were to be sampled using the SIFT-MS. At this point samples were placed into a 37 °C 
water bath (for bottles) or incubator (bags) for 10 minutes, allowing them to reach that 
temperature and sampled from within these storage containers.  
 
2.2.1.3 Data Processing 
  6% Water Correction 
During the SIFT-MS measurements using H3O
+ precursor ion, humidity of each sample and 
environment can differ (relative humidity and temperature). This has a relative effect on the 
quantification of compounds derived by the kinetic library. To overcome this variation a 6% 
water correction is used on measurements obtained using the H3O
+ precursor. That is, each 
measurement is brought up to a standard 6% water level using the flow rate adjustment 
incorporated into the software. The kinetic library then quantifies the VOCs on this 
percentage of water (Smith, D. 2011). 
 
 2.2.1.4 Data Analysis 
Data analysis was performed using the SIFT-MS software to produce an ASCII file that was 
then analysed within Microsoft Excel. PCA was performed to examine differences where 
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relevant using The Unscrambler software (Camo, Norway) and visualised using Graph Pad 
Prism 6. 
 
2.3 Spectroscopy 
2.3.1 S-FTIR Spectroscopy 
S-FTIR data were obtained from two different synchrotron sources, Diamond Light Source 
(Oxford)(Figure 16A) and Soleil Synchrotron (France)(Figure 16B). 
 
 
 
 
 
Figure 16. Synchrotron sites (A) Diamond Light Source, Oxford and (B) Soleil 
Synchrotron, France. 
 
The SMIS station at Soleil Synchrotron was equipped with a Nicolet Continuum IR 
microscope and Nicolet Nexus FTIR spectrometer (Thermo Nicolet), with a MCT/A detector 
cooled with liquid nitrogen (Figure 16). Spectra and images were obtained via a 32x infinity 
corrected Schwarzchild objective, and managed by Omnic Software (Thermo, Omnic 
ver 8.2). 
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Figure 17. The end station at SMIS beamline, Soleil Synchrotron. 
 
B22 or MIRIAM is the beamline station used within Diamond Light Source (Figure 18). The 
station is equipped with a Hyperion 3000 microscope (Bruker) and a Bruker 80V FTIR 
spectrometer, coupled with a liquid nitrogen managed 100 x 100µm2 MCT/A detector. 
Spectra and images were obtained via a 36x Schwarzchild objective, managed by Opus 
software (Bruker). 
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Figure 18. The end station at B22, MIRIAM at Diamond Light Source. 
 
For each sample, the size of the aperture was considered per experiment, and was dependant 
on sample size. Typically, cytospun cellular samples were measured using a 15x15 µm 
aperture, placing the beam centrally onto a cell. For some cell types that were difficult to 
identify within a collagen matrix a smaller, 12x12 µm aperture was used to focus on the 
centre of a cell.  
 
Spectral parameters were ascertained following initial test measurements. Following these a 
standard resolution of 4 cm-1 was used, 128 co-added scans per cell spectrum taken and 
256 scans for background measurements (a higher scanning number taken to minimise the 
signal to noise). Background measurements were taken every 15 cells, and taken from areas 
of substrate that were clear of any sample material. All measurements were taken in 
transmission mode, using a CaF2 substrate, 0.5 mm thick (Crystan). Where possible with 
48 
 
time restraints and sample condition, between 50 - 70 cells were measured per sample. The 
maximum number of cells were taken for those samples lacking in population, such as those 
that had been exposed to higher doses of a chemotherapy drug. 
 
2.3.2 Sample Preparation 
2.3.2.1 Substrates 
UV grade CaF2 (Crystan) windows (0.5 mm thickness) were used for the S-FTIR work. CaF2 
windows were selected due to their suitability for S-FTIR transmission work. 
 
2.3.2.2 Fixatives 
All cell samples for spectroscopy were fixed using 4% paraformaldehyde (PFA) in 0.9% 
NaCl at room temperature for 20 minutes in the case of 2D samples and for 1 hour for 3D 
samples. This was followed by 3 washes with 0.9% NaCl and 1 wash with deionised water. 
2D samples were then left to air dry under ambient conditions. 3D samples were then 
cryosectioned. 
 
2.3.2.3 Cytospinning 
Following relevant cell culture methods, cells that were to be deposited on slides in a single 
monolayer were re-suspended in 0.9% NaCl. Cell suspensions were cytospun onto CaF2 
slides for 1 minute at 700 rpm, through a cytofunnel and filter card (Shandon, UK). Once 
the cells had been deposited on CaF2 slides, samples were placed in a petri dish and fixed 
using 4% PFA. 
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Cytospinning was an obvious choice for sample preparation for S-FTIR analysis. The 
technique is widely used within the clinical environment for cytology. It would be obviously 
beneficial if our techniques could be applied to pre-existing methods currently being used. 
The second value to using cytospinning as a technique is that it yields samples with flatter 
cell bodies. Mie scattering effects can alter the spectra gained from S-FTIR analysis if a 
sample is too rounded. Quite often, cell samples produce characterised shifts within the 
amide I region, which would then need to be corrected for. Although not excluding the Mie 
scattering entirely, cytospinning does appear to reduce this artefact (Pijanka, J.K. 2009). 
 
2.3.2.4 Cryocutting 
For 3D samples that are prepared as tissue slices a Clinicut 60 microtome-cryostat was 
used (Bright, UK) to produce 15 µm thick slices. 3D collagen gel samples were fixed in 4% 
PFA (see fixatives subheading) as standard. Following this, the samples were then flash 
frozen in liquid nitrogen for 20 seconds and then mounted in OCT (optimum cutting 
temperature) mounting medium. The samples were maintained as frozen within the cryostat 
where they were then sectioned into the slices and placed straight onto the substrate to be 
analysed (CaF2). Samples were then left to defrost onto the slides momentarily, after which 
they were submerged in water for 1 minute to remove the OCT medium as much as possible 
in order to be suitable for spectroscopic analysis. Samples were then left to air dry. 
 
A 15 µm thickness of tissue was selected as this was an optimal range to produce 
uninterrupted slices of tissue. Thinner slices became unmanageable due to the nature of the 
collagen gel. 
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2.3.3 Data Processing 
2.3.3.1 Corrections and Software 
Matlab (Matlab 7.5 Mathworks, Natick, USA) was used to apply an Extended Multiplicative 
Signal Correction (EMSC) in order to correct for Mie scattering effects using an algorithm 
created by Dr Achim Kohler (Kohler,  A. 2008). Mie scattering is an effect that presents 
itself as a well-defined change in a cell spectrum (often as a shift in the amide I peak) due to 
the rounded shape of the cell body. EMSC aims to correct this artefact, which has also been 
reduced by the choice of cytospinning as a form of sample preparation. That is, the samples 
are flatter than those that would be grown straight onto the substrate. 
 
S-FTIR Spectra were processed using The Unscrambler 
software (Version X, Camo, Oslo, Norway) to correct for baseline (linear-offset), normalised 
(Standard Normal Variate (SNV)) and smoothed (Savitzky-Golay).  
 
Following the baseline correction and EMSC application, spectra were cropped to the area 
of interest for that particular analysis. For the lipid region, spectra were cropped to the region 
of 2700-3100 cm-1 and for the fingerprint area, spectra were cropped to 1000-1800 cm-1. 
Then, the SNV normalisation was applied, which subtracts the mean spectrum and then 
divides by the standard deviation for each spectrum. This removes the effect of sample 
thickness and any baseline offset that may have occurred.  
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2.3.4 Data Analysis 
2.3.4.1 Principle Component Analysis 
Principle Component Analysis (PCA) was performed using The Unscrambler software 
(version X, Camo, Oslo, Norway). PCA is an unsupervised analysis that allows us to reduce 
large numbers of variables (our spectral wave vectors) into a few principle components (that 
are calculated from the covariance of the data set we are analysing). Therefore we are able 
to comprehend and see where differences in our data sets lay. This is repeated in a number 
of principal components (PC)s, the first PC is the one that contains the highest variance, 
PC1. Variance then reduces as the PCs continue, PC2, PC3, all decreasing in variance.  
 
PC scores are also derived from data sets and are used to plot the variance onto a 2D axis. 
As the positon of the score on the axis represents the relative position of variance in relation 
to the other plots of variance we can visualise groups of data starting to emerge on the axis 
(Figure 19A shows a representative example). Loading plots are representative of how much 
a variable participates within each PC. It is used here to show where the high levels of 
variance are within a spectrum (Figure 19B shows a representative example). 
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Figure 19. An example PCA, showing (A) Scores plot and (B) Loading plot. 
 
The same software was also used to visualise the spectra, having translated the spectra from 
the support software used to obtain the data at Synchrotron facilities (Omnic and Opus). 
Descriptive statistics were also produced from The Unscrambler software. Graph Pad Prism 
6 was used to create plots of the data. 
  
PC1 
PC2 
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Chapter 3 The Quantification, by SIFT-MS, of Acetaldehyde Released 
by Lung Cancer Cells in 3D Models. 
3.1 Introduction  
As discussed in Chapter One, lung cancer is a worldwide health issue with poor prognosis 
rates (typically 5-15% at 5 years) despite the introduction and constant refinement of new 
drugs and therapies into the management of the disease (Reck, M. 2013; 
Molina, J.R. 2008; Gkiozos, I. 2007) Screening for the disease using sputum cytology, chest 
x-rays or CT Scans may offer, in some cases, increased survival rates but it is not clear yet 
whether this has translated into decreased lung cancer death rates overall (Bach, P.B. 2012). 
The assessment of tumour response to treatment also relies heavily on these imaging 
processes, the pitfalls of which have been discussed in depth in chapter 1. This has lead for 
the need for a cheaper, real-time based, radiation free and non-invasive technique. SIFT-MS 
could offer these advantages to the field.  
 
Early lung cancer diagnosis is currently a very popular topic within the breath analysis 
community. Gaining much attention is the hypothesis that lung cancer could be detected 
through the analysis of VOCs produced internally and then found within the exhaled breath 
of patients. If these biomarkers could be identified, they could be applied as a diagnostic tool 
to clinically assess a tumour response to treatment as well as identify those afflicted with the 
disease. Again, the SIFT-MS technique could be the diagnostic tool needed. The instrument 
is able to assess the humid, volatile breath provided by patients that have poor lung function 
capabilities and can perhaps only provide single exhalations, measuring in real time 
concentrations of volatiles that occur in few ppbv concentration. This obviates any sample 
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preparation needed and any invasive procedures required by other 
techniques (Van't-Westeinde, S.C. 2011). 
 
Although direct breath analysis is an ideal technique to be applied in the diagnosis of lung 
cancer, it would also be of strong advantage to be able to diagnose the humid head space 
developed by in vitro cell cultures. This would have a number of advantages, firstly to be 
able to discriminate between cancerous and non-cancerous cultures but also to assess the 
possible markers given off during the tumour response to a treatment, for example the 
assessment of sensitivity to chemotherapy agents. 
 
In the previous studies of lung cancer by the SIFT-MS (Filipiak, W. 2008; Smith, D. 2003) 
it has been shown that acetaldehyde6 is a VOC of interest with regard to the study of both 
malignant and non-malignant lung cells. Unfortunately these studies have produced 
conflicting results about acetaldehyde and its release. Given that this work was conducted 
within a 2D matrix, it is reasonable to consider that the study of lung cancer should be 
completed within 3D matrices that would provide a more physiological environment. 
Tumour growth within the physiological state is more than just a monolayer of a single type 
of cells, but rather a complex tissue of varying cell types and conditions built within a 3D 
structure. The work in this chapter is conducted using collagen 3D models that provide an 
improved platform to study lung cells, creating a 3D scaffold in which the lung cells will be 
able to grow and proliferate into the further dimension that they would naturally be able to 
                                                          
6 Acetaldehyde is known for being an intermediate in the metabolism of ethanol in humans. It is formed 
from the oxidation of ethanol by alcohol dehydrogenase. Outside of the human body, it is a widespread, 
naturally occurring liquid. It is found in plants, fruits, vegetables, cigarette smoke, petrol and diesel exhaust. 
It is reasonably anticipated as a human carcinogen (National Cancer Institute, 2015). 
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access. The chapter shall also explore the growth of different types of lung cell, including 
cancerous and non-cancerous cells, and to analyse if there are any notable changes between 
the volatiles each population would produce. 
 
As this chapter explores not only cell type but also how the cell culture environment 
contributes to the VOCs produced or consumed by populations during cell metabolism it 
makes sense to examine not only a more physiological (3D) environment but also the media 
in which cells are grown. Commonly, studies have applied the suggested growth medium to 
cell cultures indicated by cell line providers. These media have differing components that 
could influence the metabolical processes undergone by cells and therefore the VOCs 
processed as a result. Although not commonly discussed across the previous studies, this 
chapter hopes to shed some light on the impact of specific growth conditions on the release 
of acetaldehyde.  
 
This chapter discusses the published work on the quantification of acetaldehyde by lung 
cancer cells (CALU-1) compared to the acetaldehyde released by non-cancerous cells 
(NL20), both within a 3D model. This chapter also discusses the consequences of media 
choice in cell culture. The study broadens to look at 4 lung cell types and 2 different kinds 
of media used to prepare the cell samples, also grown within a 3D model. 
 
3.2 Aims 
1. To widen the examination of the release of acetaldehyde from differing lung cell types. 
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2. To improve the physiological environment that these cells are maintained in through the 
incorporation of a collagen 3D matrix. 
3. To investigate the impact of differing media on the metabolism of VOCs by lung cell 
lines. 
 
3.3 Materials and Methods 
3.3.1 Cell Culture – Acetaldehyde comparison between CALU-1 
and NL20 
In order to compare between a cancerous and non-cancerous population the non-small cell 
lung cancer cell line CALU-1 (European Collection of Cell Cultures, Salisbury, UK) and the 
non-malignant lung epithelial cell line NL20 (ATTCC,UK) were used in this study. CALU-1 
cells were cultured in Dulbecco’s Modified Eagle Medium (DMEM) with 10% Foetal 
Bovine Serum (FBS) and glucose (4.5 g/L) within both the T75 Flask and the 3D collagen 
matrix. For NL20, Ham’s F12 medium supplemented with FBS (4%), glucose (2.7 g/L) and 
growth factors (according to the provider’s instructions) were used to culture the cells within 
the T75 flasks and the 3D collagen matrix. The tissue culture flasks (Starstedt, UK) were 
seeded with the relevant cell line and stored in a 37 °C, 5% CO2 incubator. Culture medium 
was changed every 3-4 days (See Table I, Culture Conditions 1). Cells were first passaged 
and seeded at a density of 5 x 105/T75 and held in 2D culture for 1 week, in order to build-up 
the desired population. After this time the cells were dissociated (see Table I, culture 
conditions 1) and counted. 
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The desired number of cells was then seeded into a 20 mL 3D collagen matrix, rat tail 
collagen type I (BD Life Sciences, UK) at a collagen concentration of 1.5 mg/mL. Please 
see chapter 2, materials and methods for a detailed account on the production of collagen 
matrices). The suspended cell concentrations (106 cells per gel) were transferred into a 
150 mL glass SIFT-MS bottle, fitted with a cap and septa. Bottles were placed within the 
incubator for 1 hour to solidify (caps partially open to allow for air flow). After this 
incubation time, the now solid scaffolds containing the cells were topped with 20 mL of 
freshly prepared liquid media (please see Table 1, culture conditions 1). A control gel 
without cells was also formulated at the same time point to be measured with the SIFT-MS 
to form a baseline measurement of the culture conditions. After the addition of fresh media 
to the cellular and control scaffolds, the gels were then left within the incubator, caps loose, 
for a further 24 hours. This was to ensure the cells had access to a suitably pH balanced and 
oxygenated air supply. The bottles were then air purged with dry bottled cylinder air 
(BOC, UK) and the caps closed tightly. A further 16 hour incubation time followed before a 
SIFT-MS measurement was taken, in order for a headspace to develop with VOCs from the 
cell population. 
 
3.3.2 Cell Culture – Acetaldehyde comparison between 2 media 
and 4 cell types. 
In order to make a comparison between 2 media and broaden the study of the effect of media 
on VOCs produced by cells, 4 cell lung cell lines were studied. A549, a lung adenocarcinoma 
cell line; CALU-1, a squamous lung cancer cell line; 35FL121, lung cell fibroblasts and 
NL20, a normal lung epithelial cell were included in this study. Further details of which are 
in chapter 2 Materials and Methods. 
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In order to assess the role of media within the VOCs given off by lung cells, each 1 of 4 cell 
lines were cultured in 1 of 4 ways. That is; firstly cultured in 2D with DMEM and moved 
into a DMEM gel. Secondly, cultured in 2D with DMEM and moved into a Ham’s F12 gel. 
Thirdly, cultured in 2D in Ham’s F12 and moved to a Ham’s F12 gel. Finally, cultured in 
2D in a Hams F12 gel and moved to a 3D DMEM gel. Please see Table 1, culture conditions 
2 for the detailed components of each medium). 
 
The culture conditions for the first part of the cell culture method here is the same as in 
culture conditions 1 (Table I). There only difference here being that NL20 media was 
changed slightly to incorporate the same concentration of glucose. This is because previous 
work has shown that the interaction with FBS and glucose and the metabolic influence of 
glucose on cells will produce an effect on the VOCs given off by cell 
lines (Sulé-Suso, J. 2009). 
 
3.3.3 Survival Assays 
In order to assess survival, the gels were scaled down into 200 µL gels containing 5 x 104, 
105 or 2 x 105 populations of cells to broadly cover the cell numbers used in this study for 
SIFT-MS analysis. The samples were created within a 48 well plate, in triplicate, and left for 
an hour to set. Following this time, they were then topped with 1 mL of fresh media and 
cultured for 24 hours. Following a dry air purge the well plates were then sealed using 
parafilm before incubating within a 37 °C, 5% CO2 incubator for 16 hours, mimicking the 
conditions used to create SIFT-MS samples. A standard live/dead cell double staining 
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kit (Sigma Aldrich) was used to stain the samples as per provider’s instructions (For a more 
detailed instruction, please see chapter 2, Materials and Methods).  
 
In order to assess cell survival using tyrpan blue, gels were downscaled by a factor of 10. 
The process above was repeated, this time scaling the gels down to 1 mL gels and seeding 
105 cells per gel. Following the incubation times as above, the gels were then exposed to 
200 µL of collagenase, placed on a rocker within the incubator and allowed to dissolve. A 
standard trypan blue exclusion method was then followed to count the live/dead cells. 
 
A live/dead double staining cell kit (Fluka, 04511) was used to identify live and dead cells 
within the 3D models and imaged using a confocal microscope (Olympus, Japan). The 3D 
models used were 20 mL collagen gels, with a range of 10 – 40 x 106 cells seeded into each 
model. The models were those used in the SIFT-MS analysis and so underwent the same 
growth and preparation conditions for SIFT-MS experiments, but were then dissected and 
stained (as per the staining kit instructions) in order to be able to access the samples 
confocally. 
 
Figure 20 is an example of (A) 1 mL scaled down gels, within a small SIFT-MS sampling 
bottle. (B) 200 µL gel scaled down, within a 24 well plate. (C) A dissected 10 mL collagen 
gel used for live/dead imaging of the cells and (D) the dissected and stained samples of the 
3D model. 
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Figure 20. 3D collagen models in different formats. (A) A scaled down bottle 
sample. (B) 200 µL gel, (C) a dissected 10 mL gel and (D) dissected and stained 
samples. 
 
3.3.4 SIFT-MS Spectra 
Spectrometry measurements for both Part 1 and 2 were taken using the Profile 3 SIFT-MS 
instrument (Trans Spectra Limited, UK, described in detail within chapter 2). The reagent 
ions selected for analysis were H3O
+ and NO+ given their suitability to react with the organic 
volatiles that could be given off by the cell cultures, known from previous studies. 
 
A standard list of selected compounds were scanned in the “MUI” mode software, each 
headspace being sampled for approximately 1 minute. Compounds were chosen based on 
previous work completed using the SIFT-MS (Sulé Suso, J. 2009; Smith, D. 2003; 
Smith, D.  2011). The on-board kinetics library was able to ascertain the reaction rate and 
therefore quantity of the specified compounds (Smith, D.  2011) A “full scan” range was 
also collected for each sample, a mass range of 10 – 180 m/z was collected from 3 repetitions 
of 20 seconds each; 1 minute scanning in total for both reagent ions. For all samples, the 
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septa contained within the cap of each 150 mL bottle was punctured by the heated sampling 
needle of the SIFT-MS. 
 
3.3.5 Processing 
Once the profile of each headspace has been ascertained using the “MUI” software, the data 
is extrapolated into excel. Although the library has corrected the data for interactions and 
overlaps between some of the product ions (for example acetaldehyde and CO2 having an 
overlap at m/z 63 in the presence of H3O
+), it does not account for a slight variation in the 
humidity within the samples or in the laboratory environment. Humidity is what the 
quantification of product ions is based on and so here we “correct” the samples by bringing 
all values of products ions to what they would be if all were collected within an environment 
based on the humidity found within the breath of a patient (6% H2O). This allows us to better 
mimic the conditions of the breath of a patient as opposed to the fluctuations seen within the 
bottle and laboratory environments. 
 
3.3.6 Analysis  
The analysis of the data was performed within excel (Microsoft) and GraphPad (Prism 6), to 
plot relevant tables and graphs.  
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3.4 Results 
3.4.1 Survival within Collagen 3D models 
The trypan blue exclusion method provided evidence that cells were alive and proliferating 
within the 3D models that they were seeded into. The average survival was always above 
76 % for all four cell lines grown under both DMEM and Ham’s F12 media. 
 
Table II Average survival rates of 4 different cell lines grown in 2 different kinds 
of cell culture medium (mean of 3 independent samples). 
 Average % Survival 
Media DMEM Ham's F12 
Cell No. 5 x 104 10 x 104 20 x 104 5 x 104 10 x 104 20 x 104 
 % SD % SD % SD % SD % SD % SD 
A549 81.39 7.50 83.08 8.14 81.77 3.97 79.37 11.00 88.33 7.26 91.32 4.85 
CALU-1 79.37 8.84 81.21 9.15 79.42 1.00 91.07 7.78 89.95 9.08 95.08 5.00 
35FL121 85.00 13.23 88.33 12.58 76.77 8.75 84.72 16.84 93.45 6.27 91.82 5.29 
NL20 84.87 4.50 83.02 2.87 87.67 7.14 82.65 2.38 89.68 9.01 92.72 4.68 
 
As seen in Figure 21 the survival rates within the gels kept under SIFT-MS conditions were 
good. The figure provides two examples of (A) CALU-1 at 10 x 106 cells and (B) NL20 at 
10 x 106 cells taken using a 10x objective. The green colour (live cells) is appearing at a far 
higher level than the red (dead cells) and is also highlighting a healthy cell morphology. That 
is, that the cells are making use of their new 3D environment and appear to be spreading 
along the collagen fibres as opposed to the limited 2D morphology they are restricted to in 
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flasks. We can also observe the larger size of the CALU-1 (A) compared to the smaller NL20 
(B) and the characteristic clustering that CALU-1 are known for in culture. 
 
Figure 21. Live/Dead images of (A) CALU-1 and (B) NL20. Live cells are shown in 
green and dead cells are shown in red. 
 
3.4.2 Acetaldehyde Release 
The first observation to be made is perhaps a comparison to the earlier 2D studies performed 
on CALU-1 lung cancer cells that were grown directly in the SIFT-MS sampling bottles 
(Sulé-Suso, J. 2009). The earliest of these studies showed that AC release was directly 
proportional to cell population. acetaldehyde levels being produced at 106 molecules/minute 
of incubation time per cell. 40 x 106 cells that were cultured in 50 mL of fresh media 
produced acetaldehyde at a level 300 ppbv greater than the media alone was producing. In 
2009, Sulé-Suso et al. found similar results within the headspace, acetaldehyde being at a 
concentration of 400 ppbv per 50 x 106 CALU-1 cells and increasing to 500 ppbv for 
80 x 106. The level of acetaldehyde above the DMEM medium controls being 250 ppbv 
(Sulé-Suso, J. 2009). Interestingly, the NL20 cells used within this study (NL20 being a 
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normal lung cell line) produced lower levels of acetaldehyde, 50 x106 cells producing 
300 ppbv and their media, Ham’s F12 baseline extruding 100 ppbv. 
 
The 2D results mentioned above also show an obvious trend, that with decreasing cell 
number the levels of acetaldehyde steadily decrease (however not for NL20). This is not the 
same trend that we see with the CALU-1 3D samples (Figure 22). Starting with the cell 
number most similar to those used within the 2D studies we can see that at cell populations 
of 20-40 x106 produce dramatically higher levels of acetaldehyde within their 3D 
environment than the 2D, by a factor of 2. 
 
Following the observation of these differences further experiments were conducted to 
examine lower cell numbers. Figure 22 is a representation of the data in Table III, clearly 
illustrating the trend of acetaldehyde release for cells grown in 3D models. 3D Calu-1 cell 
populations of 106 are still producing double the ppbv of acetaldehyde than 40 x 106 cell 
populations grown within a 2D environment. 106 cells cultured within the 3D environment 
in fact produce the largest amount of acetaldehyde out of all cell populations, at a mean of 
1973 ppbv (SD 122). This level then dramatically tails off to a mean value of 
1304 ppbv  (SD 219) at 105 and as illustrated in Figure 22. It continues to do so until reaching 
the baseline levels measured in the headspace of medium and 3D a-cellular scaffolds. 
Maximum to minimum concentrations of acetaldehyde levels obtained from 2D and 3D 
counterparts were calculated to range from a factor of 1.15 and 2.16, this being far greater 
than the inherent variability of the SIFT-MS instrument itself, which is less than 5%. 
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Figure 22. Average acetaldehyde release (ppbv) of 2 different cells lines, CALU-1 
and NL20 grown in a 20 mL 3D collagen model. 
 
Table III Acetaldehyde release (ppbv) by CALU-1 and NL20 cell lines grown in a 
20 mL 3D collagen model. 
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Regarding NL20, and conforming to the trend previously seen in the 2D studies discussed 
here; that acetaldehyde production steadily increases with the cell population. We still see 
dramatically elevated levels of acetaldehyde within the 3D cultured cells, compared to the 
2D, acetaldehyde being produced by around a factor of 2. 
 
2.3.2.1 Average acetaldehyde release (ppbv) comparison 
between 2 medias and 4 cell types. 
Figure 23 illustrates the average acetaldehyde release in 10 mL collagen gel scaffolds, by 
106 cells. The first, m\ost obvious, observation to make is that there is a dramatic increase of 
AC given out by those cells grown in DMEM media and then seeded into DMEM based gels 
(DMEM – DMEM). This is most pronounced in the cell line A549, where a 165 times 
increase is seen above those cells that are cultured in DMEM and transferred into a Ham’s 
F12 based gel (DMEM – Hams). There is a 7 times increase above those grown in Ham’s 
F12 and put into a DMEM gel (Hams – DMEM) and an 18 times increase seen above those 
that are cultured and transferred in Ham’s F12 (Hams – Hams).  
 
The trend seen within CALU-1 is that in DMEM media DMEM gel cultured cells, there is 
an 18 times increase of acetaldehyde production compared to those DMEM – Hams cultured 
cells. Only a 4 times increase over that of the Hams –DMEM cultured cells and a 22 times 
increase above the Hams- Hams model. 
 
The normal lung fibroblasts, 35FL121, mimic a similar trend to that seen within the 
CALU-1. A 31 times increase in DMEM – DMEM grown cells is seen above those cells  
67 
 
 
D
M
E
M
 -
 D
M
E
M
D
M
E
M
 -
 H
a
m
s
H
a
m
s  
-  
D
M
E
M
H
a
m
s  
-  
H
a
m
s
0
2 0 0 0
4 0 0 0
6 0 0 0
8 0 0 0
1 0 0 0 0
G r o w t h  C o n d it io n s  (S o r te d  b y  m e d ia )
A
C
 (
p
p
b
)
A 5 4 9
C A L U -1
3 5 F L 1 2 1
N L 2 0
 
Figure 23. Acetaldehyde release in 4 cell types, A549, CALU-1, 35FL121 and NL20, 
grown in 10 mL 3D collagen models. 
 
grown in DMEM – Hams conditions. Cells cultured in Hams – DMEM conditions produce 
a similar abundance of acetaldehyde as DMEM – DMEM grown cells. A 12 times increase 
is seen from those grown in a Hams – Hams model. 
 
The NL20 cell line, again also elicits the same behaviour, DMEM – DMEM cells producing 
a 9 fold higher acetaldehyde level that those grown in DMEM – Hams. Hams – DMEM 
grown cells produce a similar amount of acetaldehyde as DMEM – DMEM grown cells. A 
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13 fold higher acetaldehyde level is produced in DMEM – DMEM than those grown in Hams 
– Hams models. 
3.5 Discussion 
The study of 3D CALU-1 and NL20 cells, within a 20 mL 3D collagen gel has raised many 
questions about the production of acetaldehyde from cells. 
 
It is widely known that acetaldehyde is formed from ethanol metabolism via the alcohol 
dehydrogenase (ADH) enzyme present within the cells themselves (Figure 24). During this 
metabolic process acetaldehyde is also lost during metabolism, resulting in acetic acid 
(largely occurring as acetate ions in neutral solutions). Co-enzymes nicotinamide adenine 
dinucleotide (NAD+) also participate in this process (Kalapos, M.P. 2003; 
Riveros-Rosas, H. 1997).  
CH3 C
OH
H
H
CH3 C
O
H
CH3 C
O
OH
Ethanol Acetaldehyde Acetic Acid
ADH ALDH
NAD+ NADH NAD
+ NADH
 
Figure 24. Ethanol metabolism by ADH, acetaldehyde being produced as an 
intermediate of acetic acid production by ALDH. 
 
Saturated hydrocarbons (eg. ethane, pentane) and aldehydes are also products created during 
the lipid peroxidation process, undertaken within the cell membrane (Mazzone, P. J. 2008). 
During the SIFT-MS measurements, several compounds aside from acetaldehyde were also 
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measured during the analysis. Ethanol was also found to be rather prevalent within the 
headspace of the 3D cultures, at a level of around 2000 ppbv. Previous studies have indicated 
that it originates for the most part from FBS that is added to the medium as it is prepared 
(Sulé-Suso, J. 2009). Therefore, ethanol which could play a role within the production of 
acetaldehyde within the headspace, is already intrinsic to the cell culture environment. 
Acetaldehyde can also be measured in the headspace of DMEM of the media itself, being 
present at a level of 100 ppbv on average.  
 
A major question surfacing from the results is also the cause of the dramatic increase in 
acetaldehyde production within 3D environments when compared to 2D. The remit behind 
using the 3D system is of course to mimic more readily the in vivo environment in which the 
cells would naturally reside without having to include the disadvantages direct in vivo study 
of organ systems could bring (Petersen, M.C. 2007). Figure 21 demonstrates the aptitude for 
the CALU-1 cells to survive within the collagen 3D models, however it has not been possible 
at this stage to identify whether cells are proliferating within this system. However, earlier 
work has also shown that CALU-1 cells will also readily invade a collagen based hydrogel 
and proliferate within the same type of system (Yang, Y. 2005). 
 
It is not yet clear as to why there is a decrease in the acetaldehyde production of cell number 
beyond 106 but we could hypothesise that with increasing cell populations being put into the 
same environment, the proliferation rate of the cells would decrease, or perhaps slow down 
the metabolic processes involved in the release of acetaldehyde due to the consumption of 
nutrients from the media provided to the population. Further work would be needed to clarify 
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whether cell death, proliferation changes or changes to metabolism could be behind the 
change in acetaldehyde production. 
 
Through standard deviations within the results we can also observe the variation of 
acetaldehyde release within the samples, when in previous work variation was fairly limited 
(Smith, D. 2003; Sulé-Suso, J.  2009). The culture methods behind the studies differ slightly. 
In this study, cells were left within the 3D environment for an extra 24 hours, this was to 
allow cell populations to acclimatise to the new gels, having being transferred from a 2D 
flask system. This extra culture time could perhaps explain the variation seen in acetaldehyde 
levels. 
 
The study has produced two notable points based on the data presented here. Firstly that the 
VOCs produced by lung cancer samples are dependant heavily on the cell culture conditions 
and the experimental parameters under which the samples are produced (namely the 2D vs 
3D growth conditions). Secondly, the difference in the levels of acetaldehyde produced 
between lung cancer and normal lung cells is so high, by a factor of 3, that further work will 
be required to extend the analysis of acetaldehyde to more lung cell types. 
 
The study of 4 different lung cells lines grown in one of 4 growth conditions, within a 10 mL 
3D model, has suggested that the role media has to play on the VOCs released by cells is 
great. The difference in acetaldehyde release of those cells grown in DMEM media and 
DMEM gel compared to those under the influence of Ham’s F12 media is marginally larger, 
across all four cell lines, suggesting that a component of the media is influencing the cell’s 
metabolism of acetaldehyde in some way.  
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Importantly the first observations here are that a cancerous cell line, CALU-1, may produce 
greater levels of AC than the normal counterpart, NL20, is fortunately extended to A549 (an 
adenocarcinoma) within those cells grown in DMEM media and transferred to a DMEM gel. 
Unfortunately this is not a pattern seen across the other 3 culture conditions. This could have 
implications for using acetaldehyde as a diagnostic marker for cancer, as there could be a 
component of the media required to see this difference. It is therefore increasingly necessary 
to try and identify this mechanism.  
 
As discussed previously, the presence of acetaldehyde in mammals is as an intermediate in 
the metabolical pathway of ethanol (Riveros-Rosas, H. 1997). But acetaldehyde can also be 
found elsewhere. Threonine aldolase (TA) catalyses a pyridoxal-dependant, reversible 
reaction between threonine and acetaldehyde plus glycine (Ogawa, H. 2000) and is a 
common metabolical pathway studied in microbial subjects (Figure 25). Literature suggests 
that the role of TA within animal tissues is relatively unexplored, especially when compared 
to a second enzyme, serine hydroxymethyltransferase (SHMT) which has been found to be 
responsible for a majority of threonine degradation in animal tissues. Interestingly, both 
pyridoxal and threonine are components within the cell culture media within this study 
(Please see Appendix for a full list of media components) and could be serving to trigger a 
metabolic process involving TA.  
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Figure 25. The reversible reaction of threonine with pyridoxal to produce glycine 
and acetaldehyde. 
 
Table IV illustrates the levels of both pyridoxal and threonine found within the media and 
3D model used within this study. The “10x MEM powder” and the “10x Hams F12 powder” 
being the base medium used to create the 3D model gel used here.  
Table IV Levels of pyridoxal and L-threonine found within 2 different cell culture 
medium types (mg/L). 
 Concentration mg/L 
 L-Threonine 
Pyridoxal 
Hydrochloride 
DMEM  95 4 
Ham's F12 11.9 - 
10x MEM Powder 48 1 
10x Ham's F12 
Powder 11.9 0.06 
 
If the metabolical pathway being triggered here is TA dependant, the table goes some way 
to explaining the results that have been found with the differing culture methods. The cells 
have the most contact with 3D model as they are embedded into it, although there is an 
exchange flow with the medium in this model. The table shows clearly that DMEM has 
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higher levels of both threonine and pyridoxal, compared to the Ham’s F12 media, this 
correlates with the levels of acetaldehyde production found within the cell containing 
samples. Interestingly, the cells grown in DMEM – Hams models did not yield much 
acetaldehyde and cells cultured within Hams – DMEM models produced around half the 
amount of acetaldehyde as those cultured in DMEM – DMEM models. This could be due to 
the higher prevalence of threonine and pyridoxal in DMEM – DMEM models and also due 
to the direct contact cells have with higher levels within the Ham – DMEM model over that 
of the DMEM – Hams model. Further work is needed to explore these finding and investigate 
the TA pathways that may be being triggered here.   
 
Each media was also assessed for components that may inhibit ADH or ALDH action. 
Appendix 5 is comprised of both activator and inhibitors of ALDH and ADH enzymes for 
reference. None of the media contain any inhibitors of either enzyme, except for 
L-tryptophan. Ham’s F12 was found to contain 2 mg/L, 10 mg/L in 10x MEM and 16 mg/L 
in DMEM. Previous studies in mammalian tissues have already identified L-tryptophan as 
an inhibitor of ALDH2 specifically (Badawy, A.A. 2011; Badawy, A.A.B. 2007). ALDH2 
is one of the 19 isozymes of ALDH, with the highest affinity for acetaldehyde oxidation than 
other isozymes from the same family (ALDH1A1 and ALDH1B1) that have also been 
known to contribute to acetaldehyde `metabolism (Koppaka,V. 2012; Badawy, A. A. B. 
2007; Wang, M. 2009). Badawy, A.A. et al (2011) found that an acute exposure of 
L-tryptophan (and its metabolites) in rat livers at doses between 1-10 mg/kg were effective 
after as little time as half an hour. It is therefore reasonable to assume that the L-tryptophan 
present in the media used here could have an effect on the ALDH2 activity in the cells. 
Further work is needed to examine the quantity of ALDH2 enzymes present within the 3D 
models used in this thesis, to establish the significance of the level of L-tryptophan dosage 
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being applied here. Although non-specific to ALDH2, the ALDEFLUORTM Kit (Stemcell 
Technologies) which utilises flow cytometry techniques to identify ALDH activity, would 
be a practical starting point to help quantify this level in the cell lines used. 
 
The results presented here are of significance not only to a cell culture community but also 
to the oncology community. ALDH levels have been found to be elevated in cancer stem 
cell populations (Tanei, T. 2009) and have been examined as functional marker/markers of 
tumour initiator cells for various cancers such as bone (Wang, L.  2011), breast (Croker,  A. 
K,  2009), colorectal (Dalerba, P. 2007), thyroid (Todaro, M. 2010) liver (Ma, S. 2008), 
prostate (van den Hoogen, C. 2010), pancreatic (Kim, M. P. 2011), head and neck (Clay, 
M.R. 2010) and lung cancers (Ucar, D. 2009; Moreb, J.S. 2008) to name a few. Several 
studies have related ALDH activity to the resistance of cancer to chemotherapy agents, 
alluding to a cause for relapse in cancer patients (Kim, M. P. 2011; Honoki, K. 2010). Many 
of these studies have not examined the role of ALDH2 specifically, often opting to look at 
the ALDH family (non-specially) or the more commonly expressed ALDH enzymes seen 
mammalian tissues (ALDH1A1 and ALDH1B1). This study has the potential to provide a 
new technique that could identify ALDH activity through the acetaldehyde produced by the 
cell cultures here and detected with SIFT-MS. It has also raised important questions about 
the effect of the cell culture conditions used in the previous studies listed here that have 
utilised cell lines in their methodologies.  
 
3.6 Conclusive Remarks 
The role that acetaldehyde could play as a biomarker within the clinical setting to help 
identify cancerous populations is justifiable. Acetaldehyde is a known carcinogenic and 
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mutagenic agent; that is, it is disruptive to the synthesis of DNA (Jelski, W. 2008), binding 
to proteins causing both structural and functional alterations (Guo, R. 2010) of the enzymatic 
processes involved in DNA repair (Seitz, H.K. 2007). All these being factors that could 
contribute to the development of a tumour.  
 
ADH activity is also significantly higher within some cancerous tissues than within healthy 
ones, for example in the liver, stomach, oesophagus and colorectal (Jelski, W. 2008), which 
could suggest that cancer cells here would have a greater ability to undergo ethanol 
oxidation, producing higher levels of acetaldehyde. The same cancer cells are also noted to 
have decreased activity levels of ALDH when compared to ADH and so are less efficient at 
removing the acetaldehyde that they have created (Jelski, W. 2008). The data presented here 
conforms to the findings from the Jelski et al. (2008) group, that acetaldehyde is released in 
far higher levels than that found within the normal lung samples. 
 
This work should be continued, acetaldehyde production clearly being dependant on some 
aspect of the cell culture conditions used in the study. This has implications not only for 
acetaldehyde’s use as a practical way to identify lung cancer but also as a methodological 
consideration for cell culture experiments. The data from all of the SIFT-MS studies within 
this chapter is promising, but further work would be required to assess if such a large 
differential in acetaldehyde is identifiable within the breath of patients and control cases 
without lung cancer.   
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Chapter 4 The Application of Labelled Compounds for use with VOC 
Analysis using SIFT-MS 
4.1 Introduction 
SIFT-MS (Profile 3) is a highly sensitive technique that is able to assess changes in VOCs 
in real time (Smith, D.  2011; Smith, D. 2011; Španěl, P. 1996). This increased sensitivity is 
able to pick-up subtle differences in the change of VOCs given out by cells that could be due 
to a change in their metabolic processes. Already we have seen, as discussed earlier, that 
literature has reported two differences in the metabolism of acetaldehyde in the cancerous 
cell line CALU-1 (Mazzone, P. J. 2008; Sulé-Suso, J. 2009; Rutter, A.V. 2013). It has also 
been reported that the interaction between the components in the culture medium can also 
generate a VOC signature that will contribute to the headspace of cell cultures (Please see 
chapter 3). Both ethanol and acetone baseline levels seen in a-cellular samples (containing 
only DMEM media and supplements) have been attributed to the FBS (10%) content (Sulé-
Suso, J. 2009). In fact baseline levels of acetaldehyde, ethanol and acetone were present in 
these controls. Further investigation in this study concluded that these compounds originate 
from the FBS over than of the glucose within the medium, through the sampling of headspace 
from neat FBS serum alone. This is an unsurprising conclusion as these compounds are 
already known as being produced endogenously within mammals. Acetaldehyde was also 
reported in the CALU-1 cell line containing samples, by a markedly higher level, indicating 
that the cells themselves are in fact responsible for this production. 
 
Studies like this highlight the importance of the contribution made by the components of the 
medium to our VOC profiles. Chapter 3 has already identified some of the issues associated 
with using different medium in cell culture for the same cell lines. In this chapter the 3D 
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model will again be utilised to increase the physiological aspect of the lung cell culture, with 
a focus on the glucose metabolism seen within these models. 
 
Further to these studies, the role of glucose metabolism in cancer is a hot topic and has been 
for some time. The Warburg effect being one of the oldest and hotly debated cancer 
phenomenon (Warburg, O. 1956; Warburg, O. 1924). 
 
The Warburg effect hypothesises that cancer metabolism differs from normal tissue by rate 
of glucose metabolism. In fact metabolising glucose up to 10 times faster and undergoing a 
rate of glycolysis over 200 times higher in cancerous tissues, producing lactic acid under 
aerobic conditions (Kim, J.W. 2006; Koppenol, W. H. 2011). The study of this key metabolic 
change in tissue behaviour is mainly characterised through inferred gene/protein expression, 
and whilst useful does not provide a complete story of the metabolic changes that occur 
within a malignant phenotype, and also the lack of a real-time in situ 
practise (Fisher A.B. 1984; Fan, T.W. 2009) for the diagnosis or disease monitoring that 
lung cancer so desperately needs.  
 
One such avenue to study glucose metabolism is to utilise 13C labelled compounds, as 
diagnostic tests for human metabolic studies. The use of a diagnostic probe in the form of 
the stable isotope7 13C can be applied to identify changes in metabolism in the presence of a 
disease or the activity change of a specific enzyme. This can be identified through the 
observation of 13CO2 after the application of a labelled 
13C compound. This is a relatively 
                                                          
7 Isotopes are elements that have the same number of protons in each atom, but differ in neutron number. 
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old practise, the 13C labelled compounds first being used by Lacroix in 1973, who utilised 
13C labelled glucose to study oral glucose tolerance tests and the isotopic ratio of expired 
CO2. The ingestion of a labelled compound (glucose) produced a markedly increased ratio 
of the isotope 13CO2 to 
12CO2 in the expired breath of their participants (Lacroix, M. 1973). 
13C studies are hugely attractive to the clinical world, being non-invasive, non-radioactive, 
simple, safe, fast and economic (Amann, A. 2013).  
 
Lung cancer specifically has also been studied through the ingestion of 13C labelled glucose. 
Metabolic changes were investigated in lung cancer patients through the infusion of 13C 
labelled glucose into lung tissues, following which, nuclear magnetic resonance (NMR) and 
GC-MS techniques were used to investigate extracts from tissues and blood plasma (Fan, 
T.W. 2009). The study found many metabolites to be considerably upregulated within the 
lung cancer tissues and notably showed the upregulation 13C-2,3 Glu isotopomer – leading 
to the conclusion that pyruvate carboxylation (PC) was activated in the cancerous tissues. It 
is thought that this upregulation occurs to fulfil a high anabolic demand of a rapidly 
proliferating tumour tissue (Fan, T.W. 2009). This work provides a platform in which to 
apply SIFT-MS to see if these metabolic changes found using previous techniques could be 
seen in the VOCs in human breath or indeed from the cancerous cells in vitro and compared 
to their normal counterparts. SIFT-MS would also provide perhaps a more suitable clinical 
technique than those used in the study above, as no tissue processing is needed and the results 
could be analysed immediately with little expertise. 
 
Encouragingly, 3 13C labelled breath tests are already FDA approved and clinically used in 
the United States, the first being 13C labelled urea for the detection of H.Pylori infection 
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(Graham, D. Y. 1987), the second a test for asthma (Silkoff, C. 2004) and thirdly, an alkanes 
breath test for heart transplant rejection (Phillips, M. 2004). The SIFT-MS therefore should 
be seen as a suitable and exciting clinical candidate. 
 
4.2 Aims 
To improve the overall experimental setup of measuring lung models with SIFT-MS in two 
ways; 
1. Firstly, to improve the lung model, moving to a 3D construct and establish the 
appropriate medium to grow cells in, required for SIFT-MS analysis. 
2. Secondly, to examine a methodology leading to identifying labelled VOCs, in this 
case from labelled glucose, within samples that could then be used as metabolical 
markers. 
 
4.3 Materials and Methods 
4.3.1 Cell Culture Conditions 
Four lung cell lines were investigated in this chapter. A549 is an adenocarcinoma of the lung, 
CALU-1 a squamous carcinoma of the lung, 35FL121 a lung cell fibroblast and NL20 which 
is a normal lung epithelial cell line. Further details are given in chapter 2, Materials and 
Methods. 
 
Prior to SIFT-MS experimental setup, all cell lines were maintained under culture conditions 
1 (Please see Table I in chapter 2), media changes completed every 2 days and passage, as 
listed, weekly.  
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3.4.2 Generation of 3D Collagen Models 
10 mL of 3D model was created from rat tail collagen (10.59 mg/ mL, BD Life Sciences), 
details of which can be found in chapter 2. 10x PBS was used as the base medium for the 
creation of the matrix. Gels were produced to have a final concentration of collagen of 
1.5 mg/mL. Where appropriate, 106 cell populations were incorporated into the solution 
before being set. 
 
Final 3D models were then topped with 10 mL PBS supplemented with 10% FBS and either 
glucose or glucose13 at a concentration of 4.5 g/L.  
 
3.4.3 Survival Assay 
1 mL gels were created to mimic the samples in this study. Gels were created according to 
the same protocol within chapter 2, Materials and Methods. Gels were created in 48 well 
plates, air purged and sealed with parafilm (to mimic the sealing process that the bottles 
undergo) and placed within a 37 °C, 5% CO2 incubator for 24 hours. Following this cells 
were removed from the scaffold (again, please see chapter 2). Cells were then counted with 
trypan blue to determine the percentage viability of the sample. 
 
3.4.4 Preparation of Cultures in SIFT-MS Bottles 
The gelation of the 3D models was completed in SIFT-MS experimental bottles, 150 mL in 
size, fitted with a steal cap and rubber septum that allows the penetration of the SIFT-MS 
sampling needle. Once the liquid model was added to the bottle, the sample is then covered 
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with the cap and put in the incubator to set for 1 hour. Following which, 10 mL of PBS 
medium added to the top of the set gel. The samples are then purged for 1 minute with dry 
cylinder air. The sample bottles were then sealed with the cap and parafilm and placed back 
into the 37 °C, 5% CO2 for 23 hours. 
 
3.4.5 SIFT-MS Analysis 
Following the total 24 hour incubation period, the headspace of the samples was measured 
with a Profile 3 SIFT-MS instrument. Two precursor ions, H3O
+ and NO+ were both used to 
analyse the headspaces using both MUI and Full Scan modes of the instrument. The 
headspaces of each bottle were sampled for 1 minute. 
  
3.4.6 Post Analysis Correction of SIFT-MS data 
Samples were corrected to have 6% water levels within each headspace using the flow rate 
function built into the SIFT-MS software as accurately as possible. Microsoft excel was 
then used to normalise the data to 6% exactly.  
 
3.5 Results 
4.4.1 Survival Data in Unlabelled Glucose (12C) and Labelled 
Glucose (13C) 3D Models 
Survival data for 24 hours in a PBS based model is greater than 70% in all cell lines 
(Table V). 
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Table V. Survival data for 4 different lung cell lines grown in a PBS based 3D 
collagen model with both labelled (13C) and unlabelled (12C) glucose supplemented 
culture medium (mean of 3 independent samples). 
 
  
Average 
(%) 
SD 
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A549 83.70 14.29 
CALU-1 76.49 8.58 
35FL121 75.79 9.55 
NL20 78.87 8.75 
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A549 83.33 14.43 
CALU-1 88.89 19.25 
35FL121 72.70 6.76 
NL20 84.13 16.72 
 
 
4.4.2 Acetaldehyde Release Seen Using H3O+ Precursor 
Figure 26 shows the acetaldehyde released from all cell types under both unlabelled 
(indicated with a 12C) and labelled (indicated with a 13C) glucose conditions. The data are 
taken from MUI sampling profiles using the H3O
+ precursor. 
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Figure 26. Acetaldehyde release from 4 different lung cell types, grown in PBS 
based 3D collagen models, supplemented with labelled (13C) and unlabelled (12C) 
culture media using H3O+ precursor (N=3). 
 
4.4.3 FSM profiles using H3O+ precursor 
Figure 27 displays the average (N=3) plot of FSM profiles taken using the H3O
+ precursor 
ion for the range m/z 10-180. The heat map displays the highest abundance of the 
compound m/z 19, seen as an obvious red line and denotes the H3O+ compound used as 
the precursor ion. The other prominent bands seen clearly in the heat map are at m/z 37, 55 
and 73 which are hydrates of the precursor ion formed on the association with water 
vapour in the sample.  
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Figure 27. Heat map displaying the full scan profiles of 4 lung cell lines, grown in 
a PBS based 3D model analysed with H3O+ precursor ion. The colour denotes the 
abundance of the compounds (red being 6 x 105 counts/sec - blue being 0 
counts/sec). 
 
4.4.4 FSM profiles using NO+ precursor 
Figure 28 displays the average (N=3) plot of FSM profiles taken using the NO+ precursor 
ion for the range m/z 10-180. The heat map displays the highest abundance of the 
compound m/z 30, seen as an obvious red line and denotes the NO+ compound used as the 
precursor ion. Other bands here are not clearly seen and demonstrate the difficulty in 
interpreting full scan data. 
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Figure 28. Heat map displaying the full scan profiles of 4 lung cell lines, grown in 
a PBS based 3D model, analysed with NO+ precursor ion. The colour denotes the 
abundance of the compounds (red being 8 x 105 counts/sec - blue being 
0 counts/sec). 
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4.4.5 Principal Component Analysis of FSM using H3O+ precursor 
 
 
Figure 29 is a PCA of both unlabelled (12) and labelled (13) sample headspaces taken from all cell lines using the H3O
+ precursor ion. The 
loading plot displays PC1 and PC2 loadings for the range of m/z 11 – m/z 180.  
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Figure 29 PCA scores plot of labelled (13) and unlabelled (12) headspaces taken from 4 cell lines, analysed with H3O+ precursor ion.  
Legend 
A = A549 
C = CALU-1 
F = 35FL121 
N = NL20 
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Figure 30. PCA loading plot of labelled (13) and unlabelled (12) headspaces taken from 4 cell lines, analysed with H3O+ precursor ion. 
m/z 
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4.4.6 Principal Component Analysis of FSM using NO+ precursor 
Figure 31 is a PCA of both unlabelled (12) and labelled (13) sample headspaces taken from all cell lines using the NO+ precursor ion. The 
loading plot displays PC1 loadings for the range of m/z 18 – m/z 180. 
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Figure 31 PCA scores plot of labelled (13) and unlabelled (12) headspaces taken from 4 cell lines, analysed with NO+ precursor ion.  
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A = A549 
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PCA loading plot of labelled (13) and unlabelled (12) headspaces taken from 4 cell lines, analysed with NO+ precursor ion.
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Figure 32 PCA loading plot of labelled (13) and unlabelled (12) headspaces taken from 4 cell lines, analysed with NO+ precursor ion. 
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4.5 Discussion 
The first aim of this chapter was to address a suitable 3D model that is improved upon from 
the media based 3D models used previously. This could be, as discussed in chapter 3, 
because media can have a heavy influence on a cell’s metabolism and it is not yet known 
which components of the media could cause, and to what extent, changes in the VOCs 
profile.  
 
It was therefore hypothesised that the use of PBS and the minimum components of media 
used to sustain a healthy cell culture would reduce the influence of the medium on the VOCs 
profile. Figure 30 demonstrates that despite the reduction in components in a PBS based cell 
culture medium, the resulting profile given out by cells is still a complex one, with numerous 
compounds for analysis. 
 
The suitability of the PBS gel as a cell culture substrate was confirmed as apt; Table V shows 
a good standard of viability for these simpler 3D constructs, compared to those in chapter 3, 
for all 4 cell lines used. This 3D model could then be used for further studies to examine the 
metabolism of cells in an increased physiological manner when compared to the previously 
used 2D models (Sulé-Suso, J. 2009). The PBS model does however limit cells to a shorter 
culture time as prolonged exposure to a cell culture medium lacking in vital components 
could limit the cell populations ability to proliferate and even survive in the long term (3 
days plus). Other essential media components could be used to prolong culture time in a PBS 
based medium with components added after the assessment of headspace using SIFT-MS 
has been explored. Overall the impact of exploring PBS based hydrogels for use in cell 
cultures when studying headspaces with mass spectroscopy is important. This study 
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highlights the impact of cell culture medium on the headspace produced by cells and is a 
cautionary message; well thought out cell culture methods should be considered. This 
method should make comparisons across studies more practical, allowing for a higher level 
of reproducibility and cross-study conclusions to be made. 
 
The second aim of this chapter was far more challenging; attempting to see if the use of 
labelled compounds for the study of metabolical markers using the SIFT-MS was possible. 
The labelled compound was the non-radioactive, non-toxic glucose with carbon -13 (13C). 
Each cell line was cultured in a 3D PBS model, supplemented with 10% FBS and 4.5 g/L of 
either 12C glucose or 13C glucose. The viability for each cell line in culture with 13C glucose 
was similar to cells cultured with 12C glucose (Table V). 
 
As suggested by our previous knowledge of acetaldehyde metabolism, and the previous 
studies that have shown this VOC to be of interest (Sulé-Suso, J. 2009), the first examination 
of the SIFT-MS data was to look at the acetaldehyde released by the cell cultures. Figure 26 
shows the acetaldehyde release studied using the precursors H3O
+. There is no discernible 
trend in the metabolism of acetaldehyde seen in 12C or 13C glucose across all cell types. All 
cellular samples have acetaldehyde levels below their a-cellular PBS control, except for 
A549 grown in 12C glucose (unlabelled), implying the metabolism of acetaldehyde is 
underway in a majority of cell samples.  
 
The PCA of the full scan data showed a clear separation between cells cultured in 12C glucose 
and 13C glucose when using either H3O
+ or NO + precursors. In the case of H3O
+, the loading 
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plot showed differences at m/z 33 and 36. m/z 33 is associated with methanol while m/z 36 
has not yet been assigned. In the case of NO+ precursor, the main differences reside in m/z 
45, 46, 57, 63, 66 and 73. m/z 45 is associated with ethanol, m/z 57 is associated with 2-
methyl propane and m/z 73 is associated mostly with 2-butanol and (di)ethyl ether. m/z 46 
has not been assigned yet. 
 
Changes in the levels of CO2 were also measured for. However, m/z 63 contains CO2 
and acetaldehyde. It was not possible to identify any possible changes in CO2 levels 
following the incubation with either 12C glucose or 13C glucose. Further work is needed to 
better clarify this issue. 
The overall impact of the use of labelled components to the mass spectrometry community 
is perhaps smaller. The use of labelled glucose already being explored in the literature. 
This study serves to refresh the concept of using labelled products to explore metabolic 
pathways within cell cultures and with SIFT-MS.  
To summarise; these data not only indicates that it is possible to measure VOCs from lung 
cells incubated in 3D gels made up of PBS. This work now sets up the basis to study 
metabolical pathways of VOCs in different cell lines, using labelled compounds for a basis 
of identification of specific metabolic pathways.  
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Chapter 5 Breath of Patients 
5.1 Introduction 
As discussed previously in the introduction of this thesis, the power of an ideal breath test 
for lung cancer would have multiple advantages over the currently used diagnostic 
techniques, such as x-ray, CT scan etc., namely; non-invasive, real-time, radiation free, 
economical and able to identify the cancer within its early stages. SIFT-MS is a candidate 
technique to offer this wealth of advantages as a tool to analyse people’s breath and 
ultimately identify lung cancer.  
 
Most quantitative research has had a focus on identifying those trace compounds found in 
the healthy population, which is vital if we are to be able to establish a deviation from 
healthy, ie. cancerous breath profiles. With a focus on SIFT-MS specifically, as is the focus 
of this thesis, we can see these studies have examined ammonia, acetone, propanol (Turner, 
C. 2006) and isoprene (Španěl, P.  1999; Turner, C. 2006; Španěl, P. 1999) in healthy 
volunteers across different age ranges (Španěl, P. 2007; Enderby, B 2009; Smith, D. 2010) 
and during exercise (Senthilmohan, S. T. 2000).  
 
As a result disease state profiling has now become the target of the growing body of scientists 
that use the SIFT-MS. The technique has been used to study bacteremia in blood cultures 
(Scotter, J.M. 2006; Allardyce, R. A 2006), lung cancer (Sulé-Suso, J. 2009; 35 Smith, D. 
2003; Rutter, A. V. 2013) bladder and prostate cancers (Španěl, P. 1999), pseudomonas 
associated with cystic fibrosis (Enderby, B. 2009; Carroll, W. 2005), urinary tract infection 
(Smith, D. 1999; Storer, M. K 2011) and diabetes (Turner, C. 2009). 
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As mentioned previously, lung cancer is particularly problematic due to the late stages in 
which it is currently being diagnosed or perhaps that symptoms do not occur until the later 
stages of the disease. This is primarily because patients present late to clinics with symptoms. 
Therefore in order to improve diagnosis the disease needs to be recognised at the very early 
stages of tumour growth, preferably before the tumour causes symptoms. Ideally, if early 
stage tumours release VOCs into the breath of the patient, the SIFT-MS could be used to 
identify the disease.  
 
Exhaled breath as a profiler for lung cancer has also been reviewed previously (and discussed 
in some detail in the introduction) (Mazzone, P. J. 2012; Amann, A. 2011; Phillips, M. 1999) 
but no clinical tool has yet been used as standard in clinical practice. As discussed in these 
reviews, different sampling techniques can be used to sample the breath of patients with 
suspected lung cancer, such as direct breath sampling and bag sampling. The first being 
advantageous as it avoids the potential loss of useful VOCs. Direct breath sampling also 
allows for the real-time observation of a single compound to be monitored, from oral 
exhalation to the end-tidal part of a person’s exhalation (Smith, D. 2014). However, direct 
breath sampling also has its limitations. The sampling mode itself is limited by the exhalation 
time being provided by the patient. In patients with disease, this exhalation time maybe 
relatively small and therefore the sensitivity of the instrument to detect and quantify VOCs 
that are present in low concentrations may not be possible. Direct sampling may also be 
limited by the patient’s capacity to move to the machine itself. This could have serious 
implications for the use of direct sampling methods as a clinical tool unless small portable 
instruments are developed.  
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Bag sampling however offers an alternative to direct breath sampling and in some ways 
overcomes some of the pitfalls listed above. For example, allowing the storage of a sample; 
particularly relevant in a busy clinical setting. The bag sampling method also allows for a 
longer sampling time, not being limited to the exhalation time provided by a patient. This 
will also increase the sensitivity of the instrument for VOCs trace compounds. Bag sampling 
is however not without its disadvantages, for example the potential loss of valuable VOCs 
due to diffusion from the sampling vessel and/or surface absorption and 
adsorption (Smith, D. 2015). A previous study has already assessed the suitability of bag 
sampling for a study specific to the identification of cystic fibrosis in 
children (Gilchrist, F. J. 2012), with a focus on hydrogen cyanide and acetone. The study 
highlights that bag sampling needs to be considered on a single VOC basis, some being 
suitable for analysis with this method, such as hydrogen cyanide and acetone, which 
maintain concentrations up to a 24 hour period. Some compounds could however be more 
problematic. Water vapour itself fell within the bags quickly, within 24 hours becoming the 
equivalent to the lab air. This highlights the need to perhaps examine the suitability of bag 
sampling on a case by case basis.  
 
SIFT-MS studies are needed to continue this work, expanding the technique to assess if a 
viable profile of lung cancer can be generated above a “normal” counterpart. This chapter 
will explore the suitability of bag sampling and also bottling sampling for the breath of 
healthy volunteers but with a focus on those compounds that have already been identified as 
VOCs of interest by the cell line work with lung cancer cells (ie. acetaldehyde) 
(Sulé-Suso, J. 2009; Rutter, A.V. 2013). 
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Following this, using SIFT-MS, the VOCs profile from patients with lung cancer and 
patients with basal cell carcinoma (BCC) or squamous cell carcinoma (SCC) of the skin were 
studied in order to characterise any differences between the groups. Healthy volunteers are 
also recruited in order to serve as a further control of breath profiling.  
 
5.2 Aims of the Study  
1. To establish a methodology suitable for the acquisition of breath samples from 
patients with lung cancer. 
2. To be able to profile lung cancer patients and differentiate them from those without 
lung cancer with use of SIFT-MS analysis.  
.  
5.3 Materials and Methods 
 
5.3.1 Patients 
This study has received ethical approval form the Local Ethics Committee. Patients with 
lung cancer and patients with BCC or SCC of the skin but without lung cancer attending the 
Oncology Department at the Royal Stoke University Hospital were recruited. All patients 
were given an information sheet explaining what the study entailed and were given time to 
ask questions. They were then given 24 hours before signing a consent form. Patients with 
lung cancer had their disease previously diagnosed both radiologically and histologically. 
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Control cases (patients with BCC or SCC of the skin) were asked to have a Chest X-Ray in 
order to rule out the presence of a lung tumour. Patients with previous history of other 
malignant tumours were not included in the study.  This was a pilot study including 50 cases 
with lung cancer and 50 control cases. This is still an ongoing study. The data presented here 
is preliminary data from 15 lung cancer patients and 12 control cases. 
 
5.3.2 Sampling Methods for Control Healthy Participants 
Healthy participants were asked not to consume anything but water following their evening 
meal the night before, except for medications where needed. Participants were also asked 
not to brush their teeth or use cleaning products before the sampling was taken. Each sample 
was taken at 9 am. Table VI shows the sampling methods taken for healthy participants; that 
is direct, bag and bottle sampling at different time points and in triplicate.  
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Table VI Participant type and details of sampling modes and methods. 
Participant 
Type Precursors 
Sampling 
Method Time Points (hours) 
Healthy 
Participants 
H3O
+, NO+ 
Direct 0 (in triplicate)  
Bag  0 (in triplicate), 1, 3, 6, 24 
Bottle 0 (in triplicate), 1, 3, 6, 24 
Lung Cancer 
Patients H3O
+, NO+ Bag  0 (within 30 minutes) 
Patients with 
BCC or SCC of 
the skin H3O
+, NO+ Bag  0 (within 30 minutes) 
 
 
5.3.3 Bottle Sampling from Control Healthy Participants 
Control participants were asked to fill 150 mL sterile glass bottles using a straw that was 10 
cm in length, protruding into the bottles around 8 cm. Participants were asked to fill the 
bottles with deep breaths. The bottles where then sealed tightly with caps containing a 
septum, suitable for puncture by the SIFT-MS sampling needle. Bottles were then sealed 
with parafilm until sampled from. Unless sampled from immediately, bottles were kept at 
room temperature, under ambient conditions. Preliminary work was done to assess the 
number of breaths. One exhalation did not provide higher levels of VOCs when compared 
to ambient air. On the other hand, 5 exhalations did not provide VOCs in higher 
concentration when compared to 3 exhalations.  
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Figure 33 SIFT-MS sampling bottle, with steel screw cap and penetrable rubber 
septum. 
 
5.3.4 Bag Sampling from Control Healthy Participants 
SIFT-MS bags were produced as detailed in chapter 2 (Chapter 2, SIFT-MS) and participants 
were asked to fill each bag with three direct breaths. Each bag was then sealed with a lure 
lock syringe and wrapped in parafilm. Bags were stored at room temperature, under ambient 
conditions until sampling time. 
 
Figure 34 SIFT-MS bag sampling method, comprised of a nalophan sheet, cable 
ties and poly tubing sampling orifice. 
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5.3.5 Direct Breath Sampling from Control Healthy Participants 
Direct breath samples were obtained through a sterile sampling tube attached to the sampling 
arm of the SIFT-MS, in replacement of the sampling needle. Participants were asked to give 
one long, continuous breath, directly into the sampling line of the SIFT-MS tube. Healthy 
participants were asked to breathe out for as long as possible, in order to maximise the 
sample for analysis. Samples were obtained between 5 and 20 seconds. Participants gave 
these breaths in triplicate, and for each precursor ion (H3O
+ and NO+). 
 
5.3.6 Profiling Lung Cancer and “Control” Patients 
For both lung cancer patients and control cases alike, bag sampling was used to collect a 
sample of the participant’s breath. Each participant was given two bags to breathe into and 
asked to provide full bags using 3 separate breaths. All participants managed to supply this.  
 
Each participant would arrive at 8 am for sampling, having not eaten or drank anything other 
than water since the night before. Participants also refrained from brushing their teeth. Prior 
to breathing into the bag, a cup of water was provided to rinse the mouth with. From the 
sampling room, 2 bags were also filled with room air using a 50 mL syringe, in order to 
provide an air control. The bags were then sealed with a lure lock syringe inserted into the 
sampling pipe and parafilmed. Bags were then taken directly to the laboratory where the 
SIFT-MS is located (approximately 5 minutes away). 
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5.3.7 Spectrometry – SIFT-MS Sampling 
SIFT-MS (Profile 3) 
A Profile 3 SIFT-MS was used to analyse the breath samples provided by participants. Two 
precursors, H3O
+ and NO+ were used in the analysis. Both MUI and FSM were utilised for 
both healthy participant breath and patient breath analysis. For bottle sampled breath, the 
bottle environment pressure was equilibrated by using a bag of dry purged air attached to a 
puncturing needle, placed through the septum of the sampling vessel. Please refer to 
chapter 2 for a detailed method using the SIFT-MS.  
 
5.3.8 Processing 
As previously described in chapter 2, all data ascertained using the MUI method was 
corrected to 6% water by flow rate adjustment in the SIFT-MS software, followed by a final 
adjustment to precisely 6% in excel. 
 
5.3.9 Analysis 
Data was further examined using PCA to detect any differences between sampling groups. 
PCA was performed using The Unscrambler Software (Camo, Norway) and plotted in 3D 
using the same software package. 2D plots were created using Graph Pad Prism 6. 
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3.4 Results 
5.4.1 Identification of Optimum Sampling Vessel Using Control 
Samples 
Table VII gives an approximation of the relative humidity (RH) taken directly from the 
different sampling vessels (bags or bottles) and direct measurements from healthy controls 
without a water correction applied (mean of 5 independent experiments). The table illustrates 
that the RH in bags has decreased rapidly after one hour of storage at room temperature but 
the bottles are maintaining a relatively stable level of RH inside them. 
 
Table VII. Average relative humidity before 6% correction is applied. Data 
procured using H3O+ precursor ion. 
 
Average Relative Humidity with H3O+ Before 
Correction (%) 
Time 
(Hours) Direct SD Bottle SD Bag SD 
0 5.74 0.22 4.65 0.22 4.72 0.05 
1 N/A N/A 4.59 0.62 2.55 0.71 
3 N/A N/A 4.84 0.23 2.00 0.61 
6 N/A N/A 5.84 0.74 1.87 0.81 
24 N/A N/A 5.68 2.29 2.27 0.88 
 
103 
 
5.4.2 The variation of Acetaldehyde between controls at 0 hours 
Figure 35 shows control data taken in triplicate at 0 hours for direct, bag and bottle sampling 
techniques. It demonstrates the real time fluctuation of acetaldehyde across samples taken 
by the SIFT-MS Profile 3. 
 
 
Figure 35 Control participant data for acetaldehyde release (ppbv) analysed using 
H3O+ precursor ion for 3 different sampling methods; direct, bag and bottle N=1. 
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5.4.3 The variation of acetaldehyde over time in bottles and 
bags. 
Figure 34 shows the levels of acetaldehyde at different time points for 3 individual cases. 
All the graphs in this figure demonstrate a fluctuation from 0 hours to 24 hours and a 
divergence between bag and bottle sampling. Table VIII shows the percentage difference 
between each condition. The first column indicating the difference between samples taken 
at 0 and 24 hours from a bottle, the second column 0 and 24 hours taken from a bag, the third 
column the difference between a bag and bottle sample taken at 0 hours and the final, fourth 
column show the differences between the bag and bottle samples taken at 24 hours. Those 
shaded cells with a bold border indicate those changes that are within the 10% instrumental 
error margin of the SIFT-MS, Profile 3. 
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Figure 36 Acetaldehyde release in control participants 1, 2, and 3 for both bottle (blue) and bag (orange) sampling methods across time (hours). 
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Table VIII. The % difference of acetaldehyde release (ppbv) seen at different time points for 3 control participants (Boxed section 
indicates those samples within SIFT-MS error margin). 
 % Differences 
 0-24 Hours Bottle 0-24 Hours Bag Bag - Bottle 0 Hours Bag - Bottle 24 Hours 
Control 1 -37.56 -27.33 29.65 39.55 
Control 2 23.26 22.78 6.64 6.06 
Control 3 55.28 28.04 55.02 27.63 
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5.4.4 VOCs released by lung cancer patients and control cases 
Using the MUI system, no differences between the levels of acetaldehyde released in the 
breath of lung cancer patients (mean of 128 ppbv, SD 99) and control cases (mean of 120 
ppbv, SD 90) were seen. On the other hand, acetone was present in higher concentration in 
the breath of control cases (mean of 1002 ppbv, SD 608) when compared to patients with 
lung cancer (mean of 540 ppbv, SD 240). Also, propanol was present in higher concentration 
in the breath of control cases (mean of 482 ppbv, SD 64) when compared to the breath of 
lung cancer patients (mean of 209 ppbv, SD 174). Regarding full scan using H3O
+, Figure 
35 shows the ratio of VOCs present on the breath of patients with lung cancer over VOCs 
present on the breath of control cases.  
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Only 3 m/z seem to be present in higher concentration in the breath of patients with lung 
cancer when compared to control cases. While m/z 44 has not been assigned yet, m/z 62 
corresponds to nitromethane. Interestingly, m/z 42 was present at much higher concentration 
in the breath of patients with lung cancer when compared to other analytes. m/z 42 
corresponds to acetonitrile, a component of tobacco (Abbott, S.M.  2003).  
 
 
 
 
 
 
Therefore, the next step was to plot acetonitrile against the smoking status of the participants 
used in this study (Figure 38). Levels of the compound were higher in smokers and decreased 
with the level of time the participant had quit smoking. 
  
Figure 38 The biochemical structure of acetonitrile. 
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5.5 Discussion 
Using breath diagnosis to try and improve the outcome of those suffering from lung cancer 
presents itself with many challenges, both experimentally and clinically. This study has 
faced several facets of these challenges, starting from the sampling methods that could be 
used to gather viable samples for analysis and also meeting some of the clinical challenges 
provided by a clinical cohort of participants. 
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Figure 39 A graph of levels of acetonitrile (ppbv) in the breath of patients plotted 
with smoking status. 
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5.5.1 Establishing a suitable method of sampling breath 
Following previous studies that discuss the optimum methods for breath sampling, including 
those communications that discuss the main pitfalls of the use of breath analysis itself 
(Smith, D.  2015) as well as those that are more specific to the disease/clinical need 
(Gilchrist, F.J. 2012), this study started with the aim of identifying the most suitable and 
available technique to gather breath samples. Control, healthy participants’ breath was 
analysed using a variety of sampling methods through direct sampling (blowing directly into 
the machine), bottle and bag sampling. 
 
Table VII examines the RH loss from direct, bottle and bag samples and also compares the 
sampling efficiency to a direct breath measurement that would give a level of 6% (when the 
SIFT-MS is running under optimum conditions). Samples were also analysed at different 
time points to assess the suitability of the methods to be used in the long term, such as in a 
clinical setting where immediate analysis may not be practical. The first time point at zero 
hours shows that the RH seen within both bags and bottles is similar (4.65-4.72 %). The 
direct breath measurement giving the appropriate value of 5.74%. This illustrates the 
stability of the SIFT-MS profile 3 and suitability for the instrument to be used across 
different clinical times. The disparity between RH across sampling methods therefore is 
mostly likely the sampling methods itself, such as the materials used and the methods for 
making the samples air tight. This could be improved upon in several ways in future work; 
firstly the bottle sampling method is filled by an open straw which could eventually become 
an enclosed unit. The septum and lid itself could become a single structure allowing for a 
more tight fit seal. This would allow easier storage and transport when compared to bags. 
Bags are currently sealed with a syringe, a process that could allow a small exchange of the 
sample with the atmosphere, decreasing the relative humidity. Despite both methods being 
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sealed with parafilm it is clear there is a slight loss in the RH within the samples. Both bags 
and bottles provide the same standard of sampling collection as at 0 hours the sampling 
methods are similar with little deviation. 
 
The story is less clear for 1, 3, 6 and 24 hour time points8. Bottle sampling vessels seem to 
maintain the RH levels although the standard deviation of measurements here starts to 
become larger with time. In bag sampling, the RH decreases quickly, losing nearly half the 
RH after one hour. Bag sampling maintains a 2% RH level for the 24 hour experimental 
duration. 
 
Figure 35 shows the effect this loss has on the measurement of acetaldehyde, as the 
compound of interest. Direct sampling shows acetaldehyde present between 7-18 ppbv. This 
is far from bag samples that deviate between 82 ppbv and 164 ppb and bottle samples at 38 
ppbv to 115 ppbv of acetaldehyde. This difference in compounds could be owed to a variety 
of factors influencing each sampling method differently. There is a difference in the nature 
of the breath collected between direct sampling and both bottle and bag sampling. Direct 
sampling is measuring in real time a full exhalation of a person breath and is considered 
advantageous for a number of reasons. Firstly, a direct sample avoids the problematic loss 
of trace compounds that could occur during depositing the sample. Direct sampling also 
allows the analysis of the end-tidal portion of a person’s exhalation by itself 
(Španěl, P. 2011). Direct breath sampling is not without its limitations, unfortunately the 
quality of the analysis is affected by the exhalation time of the sample. Compounds that are 
                                                          
8 Direct samples are not relevant here as they cannot be stored. 
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present at low concentrations within the breath could be overlooked. Particularly with lung 
cancer patients, exhalation times could be very limited.  
 
As mentioned, bag sampling allows the storage of samples which is highly desirable in a 
clinical setting. By extension the sampling method also offers longer analysis time and 
therefore increased sensitivity in identifying compounds that could be at low concentrations 
within the breath of patients. The limitation of bag sampling being the loss of useful trace 
compounds during the sample deposit into the balloon and also the loss that could occur due 
to the surface adsorption/diffusion through the materials that compromise the bag 
(Gilchrist, F.J. 2012).  
 
Bottle sampling methods offer the same limitations and advantages as bag sampling, 
however the inflexibility of the sampling vessel does offer challenges for prolonged 
measurements or repeats, as the sample pressure inside the bottle needs to be equilibrated. 
In this study, dry purged air was used to re-establish equilibrium, diluting the sample slightly.  
 
5.5.2 The variation of acetaldehyde over time in bottles and 
bags. 
Both table VIII and Figure 35 demonstrate large differences in the acetaldehyde levels 
between 0 hours and 24 hours sampling time. In the bottles a range of acetaldehyde loss and 
gain is seen. Acetaldehyde is seen to increase up to 55% in bottles, but is also seen to be 
sampled at a loss of 38% after 24 hours in 1 case. Bag sampling also tells a similar story, 
losses of 27% and acetaldehyde increases of 28%.  
113 
 
 
When bag and bottle sampling is compared at 0 hours, acetaldehyde levels were found to 
differ in measurement by as much as 55%. Only 1 sample, control 2, differed within a range 
under the 10% error allowance of the SIFT-MS Profile 3. A similar story is also seen for a 
comparison of the sampling vessels at 24 hours.  
 
These results demonstrate a problematic variance that is occurring in the sampling of 
acetaldehyde. As the previous figures have shown, RH decreases at different rates within 
both sampling vessel types as time progresses. Acetaldehyde levels are also dependent on 
this. Despite the 6% H2O
+ water vapour correction applied to the data it is clear that further 
work to establish the effects a wait time on analysis has on the acetaldehyde levels caused 
by the presence of other compounds (and therefore have the potential to interact with) as 
well as the sampling materials. Previous work has discussed (Smith, D. 2011) and explored 
the interactions of acetaldehyde with metabolites present in the breath and atmosphere 
(Španěl. P. 2008). The study concludes acetaldehyde has considerable interactions with CO2 
present in the exhaled breath, which must be accounted for when quantify acetaldehyde. This 
work studies these reactions in real-time analysis but perhaps there are also consequences to 
storing acetaldehyde with CO2 for longer durations of time, such as the 24 hours in this study.  
 
5.5.3 Variation between Control Patients and Lung Cancer 
Patients 
The comparison between the VOCs present in the breath of patients with lung cancer and 
control cases has shown that the main difference lies on the levels of acetonitrile. 
Furthermore, these levels clearly separated smokers from non-smokers. And the levels 
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decreased the longer patients had quitted smoking. Acetonitrile has already been found in 
the breath of smokers using PTR-MS (Hansel, A. 1995) and SIFT-MS previously 
(Abbott, S.M. 2003; Španěl, P. 1996). Previous studies found acetonitrile being produced 
within a range of 17 ppb – 124 ppb (with a mean of 69 ppb) and also dependent on the 
number of cigarettes smoked per day, which is similar to the range seen here. These findings 
show the suitability of the bag sampling method to assess the current smoking status of a 
patient when needed, for example during treatment advice and also assessment of the 
suitability of lung transplant.  
 
This has important implications in clinical practice, especially in lung transplant. In potential 
cases where lung transplant is required, it is prudent that patients should have stopped 
smoking for at least 6 months, ideally, but 12 months have been recommended 
(Todd, J.L. 2010). Smoking status is presently assessed by measuring the levels of cotinine, 
the main breakdown product of nicotine, in blood and urine. SIFT-MS could become a non-
invasive tool to assess smoking patterns in patients requiring lung transplant. 
 
5.5.4 Conclusions 
The SIFT-MS technique has demonstrated a degree of suitability for the profiling of patients’ 
breath, that is, bag and bottle sampling has provided a suitable method for which breath 
samples can be taken with ease and implemented directly into a clinical setting.  
 
An established methodology still needs further work before an ideal sampling method is 
chosen due to the difficulties faced with wait time and the chosen metabolites of interest (in 
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this case acetaldehyde). This can be addressed through re-visiting the sealing methods for 
the sample vessels, materials, storage temperatures and times.  
 
As of yet, very preliminary data does not show clear differences in the profiling of the breath 
of participants has allowed us to identify lung cancer patients from control counterparts. This 
too can be revisited, perhaps with the refinement of the nature of the profile taken, to include 
FSM of each participant. 
The overall impact of this chapter on the field of breath analysis serves to identify the 
difficulties and practicalities encountered during a clinical study. Having identified the 
sampling vessel as the main limitation, imposing both time and analytical restraints over the 
field of breath analysis. The literature analysis and the methods used within this chapter 
show the lack of clear sampling methods identified by the field as a whole. As of yet the 
field of breath diagnosis is still yet to identify the gold standard substrate.  
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Chapter 6 FTIR Methodologies; 2D v 3D, Collagenase and DAPI 
6.1 Introduction 
Having already established the value of studying lung cancer with spectrometry and 
spectroscopic techniques, it is important to discuss the practical implications of the 
microspectroscopy of these cells. Previous studies have already addressed the practicalities 
of preparing biological substrates for study with FTIR microspectroscopy 
(Movasaghi, Z. 2008; Krafft, C. 2008; Miller, L.M. 2005) and also the implications of 
different fixatives used on biological samples (Ó Faoláin, E. 2005). Further to this, it is vital 
that we establish the best preparation of the biological sample itself. That is, how can we 
create viable biological samples that best mimic an in vivo environment or that best serve to 
answer our research question? 
 
A starting point is to look at what sample formats have been used so far. FTIR 
microspectroscopy can be applied to a broad range of sample types, each with positives and 
negatives (this has been discussed in some details in the introduction of this thesis). Briefly, 
single cells can be prepared by cytospinning cells onto the substrate or a population of cells 
can be grown directly onto the sample substrate. A choice of fixative then follows, or cells 
can be measured live. Tissue maybe applied to a substrate, following sectioning into a 
specific thickness (typically mimicking the thickness a histologist would use within the 
clinical setting, between 5-10 µm). Biofluids can also be sampled using FTIR 
microspectroscopy. 
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S-FTIR based work is highly suited to the single cell analysis of samples, given the small 
aperture size and improved signal/noise ratio over that of current benchtop instruments 
available. The main focus of this work was on the single-cell analysis of lung cells, collecting 
spectra from the nuclei of the cell. Previous studies have shown that the nucleus provides a 
source of spectral information that enables us to characterise lung cancer cells efficiently 
(Pijanka, J.K. 2009). 
 
As this thesis has a focus on lung cell lines grown within a tissue culture lab and transported 
to a synchrotron, the focus will also be on those cells that are fixed and either cytospun onto 
the substrate or part of a sectioned tissue model containing the cells. The aim of this chapter 
is to identify the most appropriate sample format to prepare for S-FTIR analysis using lung 
cells.  
 
In order to create the most physiological environment possible for cell lines, cells are grown 
in a 3D model comprised of the natural polymer collagen. As the main component of 
mammalian derived extracellular matrices, it is no surprise that it is the most widely used 
natural polymer. The 3D models created for this purpose are typically 100 µL in size, around 
5 mm in thickness and too large to be used for S-FTIR analysis. These samples as a whole 
would also be far from any clinical samples used for diagnosis. Therefore models are either 
sectioned to mimic clinical histological samples or cells are removed from the model and 
cytospun to mimic that of a cytological sample. In order to remove cells in a viable state 
from the 3D model, collagenase can be used. Collagenase is an enzyme that is able to digest 
collagen without affecting cell proliferation and/or survival as it will be shown later.  
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6.2 Aims 
1. To establish a methodology to increase homogeneity in our cellular populations. 
2. To identify if passage in our 3D models will cause spectral differences. 
3. To establish a method to confirm the identification of cells in the 3D models using FTIR 
microspectroscopy. 
4. To establish a method to analyse 3D grown cells using S-FTIR microspectroscopy and 
assess how the presence of the collagen scaffold modifies the S-FTIR spectra.  
 
1.2 Materials and Methods 
6.3.1. Cell Culture 
CALU-1, a non-small cell lung cancer cell line (ECACC, Salisbury, UK) was used in this 
study. The cell line belongs to the squamous epithelial group of cells and was grown under 
the 2D Cell Culture Conditions 1, listed in Table I of this thesis. 
 
6.3.2 Improving Homogeneity - Experimental Setup of Clonal 
Populations of CALU-1 
Clonal populations of CALU-1 were produced as described in the previous section, chapter 
2, of this thesis. Following the establishment of a clonal population the cells were then 
transferred into 2D, or 3D cultures for the next stage of the experiment. 
 
Once the clonal population has been established each population is then split into four. The 
first subdivision is kept for 2D samples, used to prepare samples taken at different passages 
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of this population (passages 1, 3 and 5). The second sub-division is used for 3D samples that 
will have an end point at 24 hours. The third sub-division is used for 3D samples that will 
have an end point at 48 hours. The fourth sub-division is used for 3D samples that will have 
an end point of 72 hours. 
 
Please see the Figure 40 below as an explanation of this process. 
 
Figure 40 The subdivision of a clonal population of CALU-1 into 6 different 
samples. 
 
3D Samples were prepared in 100 µL of collagen as previously described in chapter 2. Cells 
were not counted in this process to avoid losing part of an already small population, instead 
each quarter of the population was simply transferred to a new well.  
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6.3.3 Improving Cell Signal – Preparation of NaCl 2D and 3D 
Samples 
In order to try and improve the IR signal obtained from cells, NaCl was used to grow the cell 
populations. This is because the media contains proteins and other biological molecules that 
may contribute to the IR spectral information (see Appendix 4 for a full list of the 
components of media). 
 
Cell samples were prepared in both 2D and 3D formats. 2D samples were prepared as usual 
standard cell culture conditions but replacing the DMEM medium base with NaCl, the added 
extra components were the same as listed in Table I, chapter 2, 2D Culture Conditions 3. 
This was also applied to 3D samples, the conditions being the same as those listed in Table 
I, chapter 2, 3D Culture Conditions 3. For the preparation of the 3D gel scaffold 10x NaCl 
was used and the pH adjusted to 7 (adjustment with NaOH, 1M). 
 
Following survival assay of cells grown in NaCl, it was determined that cells would be kept 
in NaCl culture for 24 hours before being fixed, and prepared onto the substrate. 
 
6.3.4 Preparation of Cell Populations onto the Substrates 
When assessing the difference between parental and clonal populations, cells were cytospun 
onto 0.5 mm CaF2 slides as described in chapter 2 and then fixed as also listed previously 
(Chapter 2). Samples were prepared in duplicate. 
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Where tissue sections are used, 3D samples were physically removed from their well and 
flash frozen in liquid nitrogen (-150°C). Following this, the samples were mounted in Cryo-
OCT Compound mounting medium (Tissue-Tek) and sectioned into 15 µm sections straight 
onto the CaF2 slides. The samples were then fixed with 4% PFA and washed as per listing 
in chapter 2. Each sample was created in duplicate. 
 
For those cells that were grown in 3D but were to be removed from the matrix enzymatically, 
200 µL of collagenase was added to each gel for 1 hour (described in detail in chapter 2). 
The whole suspension was then centrifuged and the cells resuspended in 200 µL of NaCl 
before being cytospun onto CaF2 slides, in duplicate, 100 µL of suspension being used per 
spin. 
 
6.3.5 Identification of Cells within 3D, Cryocut Samples 
FTIR spectra produced from collagen and cells are hard to distinguish without the aid of 
multivariate statistical techniques. Cells that are embedded into the collagen are also difficult 
to identify by microscopy alone. In order to overcome this, cells were stained with DAPI 
stain (as described in chapter 2), Figure 41 is a typical example of a stained 3D cryocut 
sample. 
 
2D Samples were also DAPI stained as a control, to determine whether any spectral artefacts 
may occur as a result.  
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In order to see the DAPI stain, the Nicolet microscope was coupled with an Olympus 
fluorescence accessory (Olympus, U-LH100HGAPC), fitted with an Ushio USH102D 
mercury lamp, and a U-MWU cube corner filter (excitation 330-385 nm, dichroic 400nm, 
barrier filter 420 nm). An image was captured before switching to MidInfrared acquisition 
mode. 
 
6.3.6 S-FTIR Microspectroscopy 
Spectra for all experiments in this chapter were obtained at both Soleil (France) and 
Diamond Light Source (Oxford) synchrotrons. Further details of which are listed in chapter 
2. Detection settings were duplicated. That is; 256 scans per samples, 4 cm-1 resolution and 
a 15 x 15 µm aperture were used. 
 
Figure 41 A cyrocut sample of a 3D collagen 
model containing CALU-1 cells stained with 
DAPI stain. 
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6.3.7 Data Processing 
EMSC was used to correct for the Mie Scattering artefact created by Dr Achim Kohler 
(Kohler, 2008), this was performed in Matlab Software (Mathworks, Natick, USA). The 
spectra were then processed within Unscrambler software for baseline (linear-offset), 
normalised (SNV) and smoothed (Savitsky-Golay). Data was then cropped to the areas of 
interest (See chapter 2) at the fingerprint and lipids regions. 
 
6.3.8 Data Analysis 
Analysis of the spectra was completed in The Unscrambler Software (Version X, Camo, 
Oslo, Norway). PCA was used to visualise the differences between the spectra and where 
those differences lay (loading plots). 
 
6.4 Results 
6.4.1 Increasing the Homogeneity of Cell Samples 
Figure 41 shows an example of 2 cell populations, 1 parental and 1 clonal, after passage 3 
and kept in 3D culture conditions for 1 day.  
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Figure 42 A PCA showing parental and clonal populations of CALU-1 cells (A) 
scores of the lipid region (B) loading of the lipid region, (C) scores of the fingerprint 
region and (D) loading of the fingerprint region (N=70). 
  
 
The plots demonstrate that the populations are similar, there is some degree of overlap 
between the two and this is expected as they are originally the same cell line. The main 
message is seen within the spread of the scores plots. The scores plots for the parental 
population are far wider spread in both lipid and fingerprint regions when compared to the 
tighter scores plots of the clonal population. This points toward a clonal cell population that 
is of higher homogeneity than its parental counterpart, even after 3 passages. 
 
6.4.2 Does Passage make a Difference? 
Figure 42 shows the scores plots of 1 clone at different passages. It can be seen that the early 
passages of clonal populations still maintain a degree of homogeneity. The spread of data in 
A B 
C D 
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the scores plots for each example of a passage number start off close together and spread out 
ass passage number increases, passage 5 showing the widest spread of points.  
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Figure 43 PCA depicting 3 different passage numbers of clonal populations of 
CALU-1 (A) the scores plot of the lipid region, (B) the loading plot of the lipid 
region, (C) the scores plot of the fingerprint region and (D) the loading plot of the 
fingerprint region. 
 
6.4.3 Identification of Cells within 3D, Cryocut, Samples 
Figure 44A shows unstained CALU-1 cells while Figure 44B shows DAPI stained CALU-1 
cells. Figure 44 shows CALU-1 cells within a 3D following staining with DAPI. While cells 
can easily be identified in cytospun models as seen in Figure in 44A, this might become 
more difficult with smaller cells in 3D collagen gel models. However, the use of the DAPI 
stain allows the clear identification of cells within the 3D samples Figure 44. 
A B 
C D 
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Figure 44 Light microscopy image of 2D, cytospun CALU-1 cells unstained (A), 
and ultraviolet (UV) image of DAPI stained cells (B). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
A B 
Figure 45 The UV image of a DAPI stained 3D collagen 
model containing CALU 1 cells. 
127 
 
-0 .1 0 -0 .0 5 0 .0 0 0 .0 5 0 .1 0
-0 .1 0
-0 .0 5
0 .0 0
0 .0 5
L ip id  S c o r e s
P C 1 (6 7 % )
P
C
2
(2
6
%
)
P re -D A P I
P o s t-D A P I
2 7 0 02 8 0 02 9 0 03 0 0 03 1 0 0
-0 .2
-0 .1
0 .0
0 .1
0 .2
0 .3
L ip id  L o a d in g s
W a v e n u m b e r  c m
-1
A
b
s
o
r
b
a
n
c
e
 (
a
.u
)
P C -1
P C -2
-0 .2 -0 .1 0 .0 0 .1 0 .2 0 .3
-0 .1 0
-0 .0 5
0 .0 0
0 .0 5
0 .1 0
0 .1 5
0 .2 0
F in g e r p r in t  S c o r e s
P C 1 (6 2 % )
P
C
2
(2
8
%
)
P re -D A P I
P o s t-D A P I
1 0 0 01 2 0 01 4 0 01 6 0 01 8 0 0
-0 .1
0 .0
0 .1
0 .2
F in g e r p r in t  L o a d in g s
W a v e n u m b e r  c m
-1
A
b
s
o
r
b
a
n
c
e
 (
a
.u
) P C -1
P C -2
 
Figure 46 PCA of pre and post DAPI stained, 2D grown CALU-1 cells. (A) The 
scores plot of the lipid region, (B) the loading plot of the lipid region, (C) the 
scores plot of the fingerprint region and (D) the loading plot of the fingerprint 
region. 
The scores and loadings plots taken from these spectra demonstrate that the DAPI stain has 
a slight contribution to the spectra taken from the cells post exposure. It could be argued that 
if the spectral changes caused by DAPI stain could be well characterised, then this 
methodology could help to better identify cells within a 3D matrix prior to obtaining their 
FTIR spectra. 
 
6.5 Discussion 
The first aim of this chapter was to produce cell populations with increased homogeneity. 
This was established through producing clonal populations of the lung cancer cell line 
CALU-1. The PCA plots for these results were compelling, Figure 42 showing clearly that 
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parental populations of CALU-1 were more spread across scores plots in both lipid and 
fingerprint regions. The loadings plots show that there is a degree of difference between the 
two populations, not large enough to highlight a different cell type but enough to suggest 
differences in the populations. The lipid region loadings show a difference at 3000cm-1 
which is indicative of CH2 and CH3 stretching and also at  ̴2850cm-1 which also indicates a 
change in symmetrical C-H stretch of CH2 in fatty acid chains (Barth, A. 2009). The loadings 
displayed as the fingerprint region display similar spectra for PC1 and PC2, with the main 
differences occurring around 1550cm-1 suggesting changes within amide II and separation 
around  ̴1240 – 1310cm-1 that suggest amide III band components of proteins (Barth, A. 
2009).  This indicates that parental populations of cells are less similar to each other. The 
clustering of the clonal populations of cells is far tighter within both lipid and fingerprint 
scores plots, indicating a more homogenous population. The overlap of both types of 
samples, that is, clonal and parental is a positive result. It has shown that the cloning process 
of the CALU-1 cell line has not affected the phenotype of the cell and that the PCA itself 
cannot clearly distinguish between clonal and parental populations.  
 
In order to produce large enough cellular populations for S-FTIR and statistically viable 
samples, clonal populations have to be passaged in cell culture. This chapter addresses the 
extent to which passage has an effect on these cells. The scores of the PCA plot of a single 
clone can be seen in Figure 43, displaying the clone at 3 different passage numbers. There 
is little difference seen between passages 1 and 3. Passage 5 is when the differentiation of 
cells begins to occur. The loading plots indicate that the change is occurring within the lipid 
region at ~2950 cm-1, which is due to the C-H stretching vibrations of the CH3 and CH2 
groups of acyl chains (Lewis, R.N.A.H. 2006). The fingerprint region suggests the main 
differences here are between 1200-900cm-1 which are the wavenumbers assigned to C-O, 
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C-C stretching, C-O-H, C-O-C deformation of carbohydrates (Barth, A. 2009). The main 
separation seen within the scores plots of this PCA analysis are seen within the fingerprint 
region, which suggests this is where the SFTIR is first able to detect changes, perhaps 
mutations, that are seen as the clonal population begins to lose clonality.  
 
In the introduction to this chapter, the question was asked, “How can we create viable 
biological samples that best mimic an in vivo environment or that best serve to answer our 
research question?” This chapter utilised 3D collagen models to mimic the in vivo 
environment that has already been identified in the introduction of this thesis as a suitable 
matrix in which to grow cells (Lee, K.Y. 2001). This is a compromise when producing 
biological samples that best enable us to answer our research question. 3D collagen models 
as kept in culture are not suitable to direct analysis with S-FTIR due to their large size. 
Therefore in order to produce samples that, “best answer our research question”, the samples 
needed to be cryocut into thin slices that are eligible for analysis with S-FTIR.  
 
Cryocutting of samples in 3D collagen models brings with it the challenge of identifying 
cells in the sample effectively. As mentioned earlier in this chapter some cells are small and 
less obvious in these sectioned pieces. This chapter overcame these challenges by utilising 
a DAPI stain to successfully identify cells within these difficult samples. The use of the 
DAPI stain did show some slight differences on the PCA plots in Figure 45 although this 
could attributable to noise on the spectrum. This is particularly obvious within the fingerprint 
loadings of the PCA plots where PC1 is seen as noisy. The lipid loadings suggest that there 
is a slight baseline shift in the data obtained, which could be attributed to the DAPI stain or 
the quality of the spectra obtained itself. Cryosectioned collagen gels have provided a 
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challenging substrate in which to cryo-section, the samples are highly susceptible in changes 
to temperature, warmth meaning the gel contracts behind the OCT cutting medium and lower 
temperatures meaning that the gel becomes too fragile for sufficient preparation. A change 
in baseline shift could also suggest that the sample surface is not entirely homogenous when 
prepared in this way. Besides a baseline shift and the presence of noise within the spectra 
there are changes in the loadings plots at  ̴2850cm-1 which wavenumber has been assigned 
to the C-H symmetrical stretching of CH2 of fatty acids. The loadings plots on the fingerprint 
region show clear changes at bands 1650cm-1 and 1550cm-1, these wavebands are assigned 
to amide I of α-helical structures and amide II. Further work will be needed to clarify the 
nature of these differences if the DAPI stain is to be utilised in further work. 
 
6.6 Conclusions 
Clonal populations do provide a cellular population with increased homogeneity that can 
be maintained for an early number of passages. 
 
DAPI stained can be used to identify cells within 3D collagen models, but further work is 
needed to identify the true effects the stain has on the cells’ spectra.  
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Chapter 7 A Study of Gemcitabine Sensitive/Resistant Lung Cancer 
Cells by Cell Cloning and FTIR Microspectroscopy 
7.1 Introduction 
The application of chemotherapy drugs in medicine is based on multicentre studies that have 
identified the most appropriate anticancer drugs (or combination of) for individual types of 
cancer. Unfortunately, not all cells exhibit the same sensitivity to anticancer drugs within 
tumours and therefore success rates can differ among patients. The development of new 
drugs is also thwarted by the lack of a clear method to establish tumour cell sensitivity that 
has a direct clinical application that can improve the outcome of patients with cancer 
(Schrag, D. 2004; Samson, D. J. 2004). Current assays include those such as gene expression 
profiling, in vitro clonogenic and proliferation assays, cell metabolic activity, molecular 
assays, in vivo tumour growth and survival assays to name a few 
(Chang, J.C. 2003; Robert, J. 2004; Blumenthal, R. D 2007; Cree, I .A. 2009). Positively, 
they are applied across a wide spectrum of cancer types. However, as they are proving 
difficult to apply within a clinical setting, they are currently holding back the delivery of a 
tailored treatment for each individual patient. 
 
This is perhaps where spectroscopy could step up to the treatment challenge. Already several 
tentative studies have shown detectable differences between cells prior to, and after the 
application of anticancer drugs, using benchtop FTIR techniques (Gasparri, F. 2003; 
Sulé-Suso, J. 2005; Gasper, R. 2009; Derenne, A. 2012; Derenne, A.2012; Machana, 
S. 2012) and synchrotron based FTIR microspectroscopy (Draux, F. 2009; 
Bellisola, G. 2010). Both techniques have been previously discussed in depth in chapter One 
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and Two. Therefore, in brief, we can consider here the advantages of synchrotron facilities 
for treatment development. 
 
S-FTIR microspectroscopy can offer us the opportunity to examine a cancer cell’s 
interaction with a drug on a subcellular level, helping to characterise spectral biomarkers of 
sensitivity. S-FTIR microspectroscopy can also characterise differing cellular morphology 
through the spectral deformations caused by Mie scattering and dispersive artefacts caused, 
amongst others, by the domed shape of the cell nucleus (Marcsisin, E.J.S. 2012; 
Mohlenhoff, B. 2005; Romeo, M. 2005; Pijanka, J.K. 2009). While this may prove useful in 
some scenarios, here as we are applying chemotherapy agents, changes in cell morphology 
are indicative to dying cells rather than those that maybe sensitive or resistant to drugs.  
 
7.2 Aims 
1. To better characterize spectral biomarkers of cell sensitivity to chemotherapy in 2D 
models of lung cancer, following the addition of the drug. 
2. To be able to identify sensitivity/resistance of lung cancer cells to a given drug prior to 
the addition of the drug. 
 
7.3 Materials and Methods 
7.3.1 Cell Culture 
CALU-1, a non-small cell lung cancer cell line was used in this study. The cell line belongs 
to the squamous epithelial group of cells and was grown under the 2D cell culture conditions 
1, listed in Table I of this thesis. 
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7.3.2 Experimental Setup of Clonal populations of CALU-1 
In order to be able to assess the sensitivity of the cells to be characterised by S-FTIR 
microspectroscopy and to maintain a higher level of homogeneity across a cellular 
population, clonal culture methods were established. 
 
The cells were cultured in standard conditions within T75 flasks and dissociated according 
to the details under “2D Culture Conditions 1” (Table I, chapter Two). Following 
dissociation, cells were then counted using the trypan blue exclusion method and seeded in 
96 well plates at a concentration of 0.5 cells/well. Each well was then topped up to a total of 
200 µL with fresh medium. A total of 5 x 96 well plates were used to ascertain between 25-
30 clonal populations. Once seeded, the stack of plates were foil wrapped to avoid 
dehydration, stored in a 37 °C, 5% CO2 incubator and allowed to culture for two weeks. 
After 1 week, a single media change was performed, replacing 180 µL with fresh medium 
to avoid disturbing fragile clonal populations. Each well was inspected regularly to ensure 
that only populations formed from a single clonal cluster would be selected. 
 
Once the 2 week culture was complete, the selected clones were dissociated from their plate 
using 10 µL of trypsin-EDTA for 5 minutes within the culture incubator. 190 µL of fresh 
medium was used to quench the trypsin. Each clonal population was then split proportionally 
across five wells of a new flat bottomed 96 well plate (40 µL into each well) and topped with 
160 µL of medium (Figure 48). Cells were not counted here to avoid the loss of cells from 
an already relatively low cell number. The cells were then left to acclimatise for 24 hours 
before the addition of the chemotherapy drug (Figure 48). 
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Figure 47 96 well plate layout of CALU-1 clonal population. (A) Clonal 
populations before passage and (B) the subdivision of passaged, clonal 
populations of CALU-1 exposed to 3 different doses of gemcitabine and a control 
case. 
 
 
Figure 48 Illustration of the CALU-1 cloning process and the identification of 
viable clonal populations of cells. 
7.3.3 The Application of Chemotherapy Agents to Clonal 
Populations 
Gemcitabine was applied at doses of 25, 50 and 100 nM and a control well with 0 nM. The 
dose was determined by preliminary experiments that showed at 25 nM all clones were able 
to survive and that 1 mM was a 100 % cytotoxic dose for all cell clones. Table IX shows the 
list of clones produced for this study following the addition of gemcitabine at different doses. 
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Clones were exposed to gemcitabine for 5 days. In order to be able to measure sensitive cells 
with S-FTIR microspectroscopy, some cells had to be salvageable from the 100 nM wells. 
Five days was a compromise, allowing enough time to establish if the cell population was 
sensitive to the drug but also to be able to harvest a few cells for characterisation. 
Synchrotron beam time is limited in its allocation, this means only a few clones were selected 
for analysis (clones 4, 5, 6, 8, 12 and 13 were chosen, in bold in Table IX). Clones were 
selected based on their quality, choosing examples of obvious sensitive clone (populations 
that were few in number) or resistant clones (populations that were greater in number) to 
different doses of gemcitabine.  
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Table IX. CALU-1 clones produced for this study, following the addition of 
gemcitabine agent for 5 days. 
 
 
 
 
 
 
 
 
 
Confluent wells were labelled with two crosses, semi-confluent wells were labelled with 
one cross, wells with sparse number of cells were labelled +/- and wells without cells were 
labelled with a minus sign. Figure 49 shows some examples. 
  
Clone 
number 
0 nM 50 nM 100 
nM 
Clone 
number 
0 nM 50 nM 100 
nM 
1 ++ ++ + 15 ++ ++ +/- 
2 ++ ++ ++ 16 ++ ++ +/- 
3 ++ ++ + 17 ++ ++ ++ 
4 ++ ++ ++ 18 + +/- +/- 
5 ++ ++ +/- 19 + + +/- 
6 ++ ++ ++ 20 ++ + +/- 
7 ++ + - 21 ++ ++ ++ 
8 ++ +/- - 22 ++ ++ ++ 
9 ++ ++ +/- 23 ++ ++ ++ 
10 ++ ++ + 24 ++ ++ ++ 
11 ++ ++ + 25 ++ ++ ++ 
12 ++ - - 26 ++ - - 
13 ++ - - 27 + + +/- 
14 ++ ++ - 28 ++ ++ ++ 
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Figure 49 Example of clonal populations of CALU-1 of (A) Resistant (B) Semi-
Sensitive (C) Sensitive to gemcitabine 
 
Sensitive populations were not counted in order to maximise cells available for S-FTIR 
analysis. Control and resistant cell population’s survival was greater than 90% on collection. 
 
7.3.4 Sample Preparation 
Collected clones were cytospun at 1000 rpm for 1 minute onto 0.5 mm thick CaF2 slides 
(Crystan) and fixed with 4% paraformaldehyde in 0.9% NaCl in H2O for 20 minutes at room 
temperature. Samples were then washed once with NaCl and three times with distilled water. 
Samples were then air dried at room temperature. 
 
7.3.5 S-FTIR microspectroscopy 
SFTIR spectra were obtained at the SMIS beamline, Soleil Synchrotron. A Nicolet Nexus 
6700 FTIR Spectrometer was used, coupled to a Nicolet Continuum XL Infrared 
Microscope, which was fitted with a 32x infinity corrected Schwarzschild objective. A liquid 
nitrogen cooled 50 µm S MCT /A detector was used. The system was able to collect spectra 
at a resolution of 4 cm-1 using an aperture size of 15 x 15 µm. This aperture was based around 
the size of a cell’s nucleus, a point of interest due to gemcitabine’s mode of action being 
within this part of the cell and also because previous work had already determined the size 
138 
 
of the CALU-1 nucleus when cytospun as 10 µm in diameter (Pijanka J.K., 2009). Therefore, 
on this basis a 15 x 15 µm aperture was applied, centred to incorporate a whole cell’s nucleus. 
 
For each clone 50 control cells were measured. Where gemcitabine had been applied varying 
numbers of spectra were obtained due to varying cell numbers being harvested for sample 
preparation. In the latter case, as many cells were analysed as possible. Images of the cell 
population were obtained throughout and cells labelled so each cell was analysed only once 
(Figure 49). 
 
 
Figure 50 Image of cytospun cells, depicting the labelled cells that FTIR 
measurement had been taken from in order to only analyse each cell once. 
 
Spectra were then pre-processed as follows. A nonresonant Mie correction was applied (an 
extended multiplicative signal correction, EMSC) developed by Dr Achim Kohler (Kohler, 
A. 2008). Mie scatter is a well characterised spectral component (often seen as a shift in the 
Amide I region) which is confounded by the rounded shape of a cell, especially the cells 
nucleus. Here, cytospinning of the samples helped reduce this artefact by producing flatter 
cellular samples and no major amide I shift in the spectra was observed. Therefore due to 
the quality of the raw spectra obtained we did not apply the resonant Mie scatter correction. 
100 µm 100 µm 
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Following this consideration, spectra were cropped to specific regions to be analysed; 
2700 -3100 cm-1 for lipid regions and 1000-1800 cm-1 for the fingerprint region. Then 
spectral groups were normalised (using the standard normal variate, SNV). 
 
7.3.6 Analysis 
Spectra analysis using multivariate statistics, principle component analysis in particular, was 
performed within Unscrambler Software (CAMO). 
 
7.4 Results  
7.4.1 FTIR Analysis of Clonal Populations Exposed to 
Gemcitabine 
The premises of this study were, first, to identify spectral markers of tumour cell sensitivity 
to gemcitabine. Second, to obtain S-FTIR spectra of resistant and sensitive cells prior to the 
addition of the chemotherapy agent, in order to avoid measuring any morphological changes 
that would be caused by the apoptosis process that the cells would undergo as a result of 
drug exposure. Firstly, the mean spectra of each clonal population was analysed, comparing 
cells of the same clonal population that had been exposed to different concentrations of 
gemcitabine. Figures 51 A-C shows the mean spectra of the individual CALU-1 clones with 
different degrees of sensitivity to gemcitabine. Figures 51 A-B (chosen clones 6 and 5) are 
both examples of resistant clones; those cells that did not respond to the drug treatments at 
50 nM and 100 nM. Figure 51 C (chosen clones 8) is an example of a clone that is semi-
resistant. That is, C is representative of a clone that is mostly resistant to a 50 nM dose of 
140 
 
gemcitabine but still shows signs of death when exposed to the 100 nM dose; only 16 cells 
were recovered suitable for S-FTIR analysis following sample preparation.  
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Figure 51 Mean spectra of (A) Resistant clonal population, (B) semi-resistant clonal population 
and (C) sensitive clonal population, exposed to 0 nM (blue), 50 nM (green) and 100 nM (red) 
doses of gemcitabine. 
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Figure 52 PCA of resistant clone 4 including (A) scores plot of lipid region, (B) 
loading plot of lipid region, (C) scores plot of fingerprint regions and (D) loading 
plot of fingerprint region. Inserts in (A) and (C) depict 3D scores plot. 
 
The PCA for resistant clone 4 (Figure 52) does not show any major separations between 
the control samples (0 nM, squares) and those exposed to 50 nM of gemcitabine (circles), 
however if we plot the PCA scores within a 3D scatter plot (see inserts of A&C) a slight 
separation can be seen with the 100 nM exposed samples (triangles) in both the lipid and 
fingerprint regions. 
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Figure 53 PCA of resistant clone 6 depicting (A) scores plot of fingerprint region, 
(B) loading plot of fingerprint region, (C) scores plot of lipid regions and (D) 
loading plot of lipid region. 
 
PCA for resistant Clone 6 (Figure 53) did not show well defined separation within the lipid 
regions between any of the samples. In the fingerprint regions (A and B, above) we can see 
a slight separation between 100 nM dosed cells (crosses) when compared to 50 nM (dots) 
and 0 nM (triangles). 
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Figure 54 PCA of semi- resistant clone 5 (A) scores plot of fingerprint region, (B) 
loading plot of fingerprint region, (C) scores plot of lipid regions and (D) loading 
plot of lipid region. 
 
The PCA for semi-resistant clone 5 (Figure 54) shows a far more well-defined separation in 
both the lipid and fingerprint regions for 100 nM dosed cells (crosses) when compared to 
50 nM (dots) and 0 nM (triangles). 
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Figure 55 PCA of semi-resistant clone 8 (A) scores plot of fingerprint region, (B) 
loading plot of fingerprint region, (C) scores plot of lipid regions and (D) loading 
plot of lipid region. 
 
The PCA for clone 8 (Figure 55) shows a strong separation between the control sample 
(0 nM, triangles) and the 50 nM exposed sample (dots). This can be seen clearly for both 
lipid and fingerprint regions in the loading plots (B and D above). Interestingly, clone 8 is 
the most sensitive of the semi-resistant clones analysed, no cells having survived when 
exposed to 100 nM compared to clone 5 above, where some cells were able to survive the 
100 nM drug exposure. 
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Individual PCA for sensitive clones 12 and 13 were not performed as only control samples 
(0 nM) were obtained. 
 
One of the aims of this study was to assess if it is possible to identify spectral differences 
between sensitive and resistant cells prior to the addition of gemcitabine. Therefore, the 
following figure is a PCA of resistant clone 6 (triangles) and sensitive clone 13 (dots) 
exposed to 0 nM of gemcitabine. 
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Figure 56 PCA plots for sensitive and resistant clonal populations (A) scores plot 
of fingerprint region, (B) loading plot of fingerprint region, (C) scores plot of 
lipid regions and (D) loading plot of lipid region. 
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There is a clear separation between sensitive and resistant clones here both in the lipid and 
the fingerprint regions, which can be seen clearly in the scores plots of Figure 56. The 
loading plots also represent this difference, the fingerprint loading plot in particular 
illustrating changes at 1468-1455 cm-1. These band regions as mentioned earlier are 
indicative of CH3 and CH2 groups of lipids and proteins. The lipid loading plot indicates a 
less clear separation. This could suggest that S-FTIR microspectroscopy distinguishes 
sensitive and resistant clones prior to the addition of drugs, and therefore that sensitive and 
resistant clones have different spectral profiles. However, we have to acknowledge that some 
of the differences may be due to the fact that they are different clones. 
 
Figure 56 also serves to demonstrate that the spectral differences seen between the cells is 
not due to biochemical changes induced by the drug. The PCA was completed using the 
clones from 0 nM, control conditions and still shows clear separation between both cell 
types. 
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Figure 57 PCA of sensitive clones 12 and 13 at 0 nM exposure of gemcitabine (A) 
scores plot of fingerprint region, (B) loading plot of fingerprint region, (C) scores 
plot of lipid regions and (D) loading plot of lipid region. 
 
The PCA for both sensitive clones 12 (triangles) and 13 (dots) in Figure 57 shows that there 
is no clear separation between the two in both lipid and fingerprint regions, the lipid region 
showing a well-mixed population of scores. This is markedly different from the clear 
separation seen between a PCA of sensitive and resistant clones (Figure 57). 
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Figure 58 PCA of 2 resistant clones 4 and 6 at 0 nM gemcitabine exposure (A) 
scores plot of fingerprint region, (B) loading plot of fingerprint region, (C) scores 
plot of lipid regions and (D) loading plot of lipid region. 
 
Figure 58 shows the PCA scores and loadings for two resistant clones (Clones 4, triangles, 
and 6, dots). Again, as we see with the sensitive clones, there is no particular clear separation 
of the two when compared to the separation we see when we compare a sensitive with a 
resistant clone. 
 
Figures 57 and 58 address an important point. They would suggest that the spectral 
differences seen between the sensitive and resistant clones are not just due to the fact that 
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they are different cell populations or samples. Two control cases from sensitive clones do 
not show separation and neither do two control cases from resistant clones.  
 
The data indicate that the spectral differences between sensitive and resistant control clones 
are possibly produced by the innate characteristics of tumour cell sensitivity to the drug. 
Further studies to clarify this with more cancer cell lines and drugs are required.  
 
7.5 Discussion 
As discussed, a widely known character indicative of cancer cells within a tumour is the 
nonhomogenous nature of cells themselves (Aktipis, C. 2013). This, of course poses the 
problem that some cells could be sensitive to a chemotherapy agent whilst others are 
resistant, with varying degrees of sensitivity between these two possibilities. This 
unfortunately means that we are currently unable to predict a tumour’s response to the 
assigned treatment. Previous methods have been applied to assess the tumour cell response 
to treatment, although they are not currently practiced within the clinical setting yet 
(Cree, I.A. 2009) leaving the management of patients with lung cancer to be based on data 
taken from multicentre studies. 
 
A majority of the work completed so far, using vibrational spectroscopy, to assess a variety 
of cancer types’ response to drugs has used these mixed populations, studying the cells both 
prior to and after the addition of the drug itself 
(Draux, F. 2011; Bellisola, G. 2010; Derenne, A. 2012; Marcsisin, E.J.S. 2012; Sulé-Suso, 
J. 2005; Machana, S. 2012; Gasper, R. 2009; Gasparri, F. 2003). Some of the architecture of 
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the spectra presented in these studies could be as a result of the drug itself and/or the 
metabolites present after the addition of the chemical. This study perhaps avoids this 
confounding factor; within the data collected from the resistant 2D clones with both the 
addition and absence of gemcitabine we cannot see any major spectral changes. This could 
indicate the lack gemcitabine’s contribution to the obtained spectra. Perhaps this is due to 
the inhibition of the transport of gemcitabine in resistant cells; that is perhaps the resistance 
here was due to the drug not being internalised by the cells. Or perhaps due to an inhibition 
of the metabolical pathway gemcitabine must undergo to become an active compound in the 
resistant cells (Moysan, E. 2012). 
 
Another factor when considering a mixed population of cells is the idea that perhaps within 
this population are resistant cells that have suffered damage from the drug dose but are then 
able to recover from this damage, or perhaps sensitive cells that are damaged but still alive 
when collected for S-FTIR analysis. These damaged cells could perhaps elicit perceived 
spectral differences between those cells that have and have not been exposed to drugs, 
making the interpretation of any useful information difficult. This highlights a need for a 
system that can reduce these variables as much as possible. 
 
Here we have aimed to control this by implementing the study of cancer cells that have 
originated from a single cell (Zarcone, D. 1987). This provides the study with a population 
of cells with far more uniform characteristics given they are analysed having only undergone 
few cell divisions after the clone has been identified in culture. Using the experimental setup 
described previously (Chapter 2), it was possible to study the spectral differences of both 
sensitive and resistant clones within a far more uniform population.  
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Earlier studies of chemotherapy drugs applied to cancerous populations of cells have shown 
spectral differences within the lipid regions (Liu, K.Z. 2001), amide regions 
(Gasparri, F. 2003; Zhou, J. 2001), nucleic acids (Sulé-Suso, J. 2005; Liu, K.Z. 2001) and 
the lower lipid:protein ratio within resistant cells (Gaigneaux, A. 2002). But these 
differences could be indicating a difference within the mixed populations of cells. The data 
presented in this study has shown clearly that the more sensitivity shown by cells to 
gemcitabine, the larger the difference between cells prior to and after the addition to the 
drug. Therefore within mixed populations, the spectral changes would be magnified, 
following the addition of a drug, if the mixed population were to contain a higher number of 
cells sensitive (and still alive when collected for S-FTIR analysis). However, further work 
is needed to clarify this hypothesis. Our sensitive populations did show an increased intensity 
within the peaks at 2850 and 2920 cm-1, which corresponds to CH2 stretching of methylene 
chains within lipid membranes, and also at the peak 1740 cm-1 which corresponds to the 
carbonyl C=O stretching of the phospholipid (Jamin, N. 1998, Holman, M. 2000). 
 
This relative increase in the intensity of the lipid peaks has already been well documented 
amongst different cell lines (Zhou, J. 2001; Travo, A. 2012; Gasper, R. 2009; 
Liu, K. Z. 2001; Machana, S. 2012). The sensitive clones studied here also show this 
increased intensity, that indicates the increase of lipids with the increase of apoptosis within 
cells (Liu, K. Z. 2001). It has been discussed that this is a consequence of the cell membrane 
changes within the apoptotic state; phosphatylserine exposure, membrane blebbing and 
vesicle formations (Zelig, U. 2009). The changes seen here at the peak 1740 cm-1 have also 
been described as a biomarker for oxidative stress (Vileno, B. 2010), which is also associated 
with apoptosis (Holman, H.Y.N. 2000). 
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Before we can consider the change in lipid intensity as a form of marker for tumour 
sensitivity to gemcitabine, we must take into account the changes that could be caused by 
the fixation methods used in this study. The use of paraformaldehyde as a fixative induces 
CH2 groups into the samples. This would contribute to the spectral regions where the lipid 
fatty acyl chain CH2 groups would also be seen. It is therefore required that further work is 
needed to understand the implications that paraformaldehyde has imposed on any 
conclusions that could be drawn about tumour sensitivity from changes within lipid 
intensities. It is unknown whether paraformaldehyde may interact differently with those 
sensitive and resistant cells, as permeability of the cells has already been previously 
discussed. Conversely, no prominent differences were observed at the phosphate bands 
following the addition of the chemotherapy agent gemcitabine. This indicates that the 
1740cm-1 band may be more discriminative within the fingerprint region of the spectra. 
 
Interestingly these data show that S-FTIR microspectroscopy can separate between resistant 
and sensitive, 2D cultured, clonal populations prior to the addition of the drug gemcitabine. 
Although it has been considered that some of these differences could be attributed to the 
differences between the actual populations of clones themselves, it has been described that 
differences within the 1740 cm-1 band can separate between multiresistant and sensitive cells 
(Gaigneaux, R. 2002) and that differences between the mechanisms of resistance to the drug 
that are inherent to each individual cell which might provide us with a different spectral 
characteristics for sensitive and resistant clones (Fryer, R.A. 2011; Bergman, A. M. 2002) 
leaving our results to look promising. This would have to be confirmed with further studies 
of differing cancer types and a wider range of chemotherapy agents.  
 
154 
 
Conclusions 
To summarise, this work has presented a proof of concept, using a clonal lung model based 
around the previously reported work on lung cancer and gemcitabine. The experimental 
methods using clonal techniques have refined the study of the effects of chemotherapy agents 
on populations of cancer cells with vibrational spectroscopy. This work could be applied to 
examine a wider range of cancer treatments, such as radiotherapy and other non-
chemotherapy based techniques. The methodology could also be applied to correlating cell 
spectra with apoptotic pathways within more uniform cell populations (Holman, H. 2000; 
Holman, H.Y.N. 2000). Cell studies with clonal populations could also be expanded to 
include lung models, applying the 3D systems previously discussed in this thesis to examine 
the effects that sensitivity could have on the spectra of cells grown in an environment with 
increased physiological relevance.  
Tentatively, we can confirm that SFTIR was able to separate gemcitabine sensitive and 
resistant lung cells. To the vibrational spectroscopy community this conclusion points 
towards the expansion of clonal work, to identify if these changes are unique to lung 
cancer/this culture model. Broader ramifications of this work are also considered, that is, the 
conclusions here point towards a potential diagnostic tool that could support currently 
utilised techniques.  
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Chapter 8 Conclusions and Further Work 
There is great demand for a complimentary diagnostic tool, that could support current 
pathological techniques, to improve the management of lung cancer. The disease is 
currently plagued by a poor prognosis, which has been largely attributed to the cancer 
being diagnosed at a late stage, by which time curative treatment may not be available. 
In order to address this problem, novel diagnostic tools could be used to compliment 
current diagnostic practices used within the clinic. This thesis aimed to examine 2 
techniques, addressing some of the practical issues associated with both clinical and 
scientific application, with the purpose of leading towards better management of lung 
cancer.  
 
The first experimental chapter (Chapter 3) is focused on the use of the SIFT-MS to 
quantify acetaldehyde release by lung cells. As a novel technique, SIFT-MS offers 
non-destructive and real-time analysis of VOCs given out by lung cells. This analysis 
could be used to identify a profile of cancerous lung cells that is different from non-
cancerous lung cells. Acetaldehyde was identified by previous studies as a VOC of 
interest, in part because early studies had associated lung cancer cells with releasing 
higher amounts of the VOC (Sulé-Suso, J. 2009). It is also of interest because other 
studies had found conflicting results, that acetaldehyde levels in cell culture medium 
decreased in the presence of the lung cancer cell line CALU-1 (Filipiak,W. 2008). The 
chapter therefore had 3 main aims; firstly to widen the examination of the release of 
acetaldehyde in different lung types. Secondly, to improve upon the cell culture 
environment the cells were grown in, to a more physiological representation of a lung 
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tissue. Thirdly, to investigate the impact of using different cell culture mediums on the 
VOCs released by lung cell lines.  
 
The study reiterated the findings from previous studies, that acetaldehyde is released 
above the quantity of that seen in the cell culture medium headspace 
(Sulé-Suso, J. 2009; Smith, D. 2003) within 3D cell culture models. The levels of AC 
were raised in 3D collagen models above those found in 2D models. This indicated that 
changes in the environment the cells are cultured in have ramifications on the 
acetaldehyde metabolism the cells will undergo. The same chapter continued to 
investigate how changes to this environment affected VOCs released by cells. This was 
done through changing the different types of culture medium cells were initially cultured 
in (in 2D, cell culture flasks) before being transferred to a 3D model and also by 
changing the base culture medium used to create the 3D collagen model.  
 
Through changing the cell culture medium in the models, it has been found that the 
effect can be dramatic on the cell metabolism of acetaldehyde. The presence of DMEM 
cell culture medium causing the cells to produce higher levels of acetaldehyde than the 
Ham’s F12 medium alternative. It is not yet clear why these changes are happening. It 
is suggesting that a component of the DMEM cell culture medium is contributing to 
some of the metabolical processes of the cell that are involved in acetaldehyde 
production. Further work therefore would lend itself to the investigation of some of the 
components that are known to have roles within mammals in this pathway and are 
present in different quantities’ within the cell culture mediums. As already discussed in 
chapter 3, pyridoxal and L-threonine are obvious starting points for further work. The 2 
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components could be added to the cell culture medium or 3D collagen model and 
changes in the VOCs measured using the SIFT-MS. 
 
Another immediate avenue for further work would also be to study how the different 
media and the subsequently added components (such as the L-threonine and Pyridoxal) 
affect the function of the ALDH enzymes present within the cells. As mentioned, this 
could be investigated using flow cytometry. The ALDEFLOUR TM Kit 
(Stemcell Technologies, 01700) allows for the study of ALDH (non-specifically). A 
comparison of ALDH activity and cell culture medium could be examined.  
 
Chapter 3 has met the aims set out for the chapter having examined the release of 
acetaldehyde in differing lung types using a refined 3D collagen model using SIFT-MS, 
which has led to a publication (Rutter, A. V. 2013). The chapter has also gone some way 
to address the differences seen between previous studies on the release of acetaldehyde 
by lung cancer cells, pointing the research towards the contribution that cell culture 
medium has on the metabolism of cells. The chapter has also given further work a firm 
direction. That is, to understand the role of specific cell culture medium components on 
the VOCs released by lung cell lines. The chapter has also contributed well to the main 
aim of the thesis. It works towards the understanding of the metabolical pathways of 
lung cells that may help to identify useful VOCs given out by lung cancer cells using a 
clinically viable tool (the SIFT-MS).  
 
The second experimental chapter, chapter 4, also used the novel technique SIFT-MS as 
a diagnostic tool. The chapter addresses the use of labelled glucose (labelled at 13C) as 
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a marker for metabolism within the lung cell lines given its association with the 
Warhburg effect within the cancerous populations (Koppenol, W.H. 2011; 
Ngo, D.C. 2015), and also previous studies that have already explored the use of labelled 
glucose to identify changes in the VOCs in the breath of participants. This chapter also 
compliments chapter 3, leading on to another way of examining the metabolical effects 
of the components of cell culture medium we have already seen.  
 
The first aim of the study was to establish a refined 3D collagen model for use with 
SIFT-MS analysis. The PBS based 3D collagen model allowed for the 3D structure 
needed to improve the physiological architecture of cell culture but lacked some of the 
components of cell culture medium that have been affecting the release of VOCs by the 
lung cells. This was demonstrated by production of a 3D model containing PBS and by 
the cell viability seen within the chapter. 
 
The second aim of chapter 4 was to utilise labelled glucose for the study of VOCs 
produced by metabolical markers. The study identified no trend in the release of 
acetaldehyde between 12C and 13C glucose across all lung cell types. Acetaldehyde was 
found in lung cell samples to be below that of the PBS cell culture medium alone, 
implying there was a change in metabolism of the cells grown in the new 3D collagen 
model, but this was not identifiable using the 13C labelled glucose. PCA of full scan data 
did show a difference between 12C and 13C glucose samples and so shows promise for 
the use of labelled compounds for the study of metabolical pathways using SIFT-MS, 
although some issues still need refinement as discussed in chapter 4 if this technique is 
to be used to its full potential. 
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Chapter 5 was also a dedicated chapter to using the novel tool SIFT-MS. The chapter 
aimed to establish a suitable methodology for the acquisition of breath samples for lung 
cancer patients. It also aimed to be able to separate these breath profiles from those 
taken from participants without lung cancer.  
 
Chapter 5 found that establishing a suitable sampling method was a challenging task, 
each method (direct, bag and bottle) had its own challenge. Direct sampling methods 
may obviate the loss of any sample but are difficult to obtain from those patients with 
poor lung function or who are unable to attend clinics. FSM sampling is also a challenge 
for direct breath as a patient must provide a full exhalation for the desired scanning 
time. Bag and bottle sampling methods overcome this by allowing for large measuring 
times but have the downside of losing some of the sample and being difficult to store 
efficiently. Although chapter 5 demonstrates it is reasonable to still obtain useful data 
from these sampling methods, further work could be done to increase the efficiency of 
the materials. Overall bag and bottle sampling methods have proved useful, they are 
portable and cost effective mode of sample acquisition and storage. They also collect a 
full exhalation from the patient, which they can provide easily.  
 
Future work for chapter 5 is therefore clear; the sampling methods can be refined further, 
creating sampling bags and bottles with increasingly sufficient seals. Also, the 
investigation of the storage temperature of these vessels could also improve the 
sampling efficiency. Reducing the temperature of the vessels to below -80°C, for 
example, would slow down the loss of VOCs. This could potentially decrease the overall 
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loss of VOCs on sampling and also lengthen the sampling time. Vessels would need to 
be returned to 37 °C upon sampling, but temperature alteration would be a cost efficient 
and fast avenue of sample storage to explore. 
 
The second aim of chapter 5 was to distinguish between the breath of people with and 
without lung cancer. There were no clear differences between the profiles of those with and 
without lung cancer using the MUI analysis. This work could be revisited, in part with the 
refinement of the sampling method, but also to incorporate the FSM of each participant, that 
would give details on a broader amount of VOCs. The main separation within the FSM data 
showed that the differences that did occur between those patients with lung cancer and those 
without was acetonitrile; a VOC found in the breath of smokers (Abbott, S. M 2003; 
Španěl, P. 1996). 
 
Although not an aim of the study, chapter 5 demonstrated the use of SIFT-MS to identify 
the smoking status of the participants involved. The amount of acetonitrile present in the 
breath of participants being correlated with the smoking history. This demonstrates the SIFT-
MS and the bag sampling method’s suitability as a tool to assess smoking status. This is 
clinically relevant as being able to accurately assess smoking status can provide help for the 
patient with regard to treatment advice and the assessment of the suitability of the patient for 
lung transplant.  
 
Chapter 6 turned to the use of S-FTIR microspectroscopy as a tool to study lung cancer. The 
aim of the chapter was centred on establishing methodologies that increased the suitability 
of the cellular models for S-FTIR sampling. Firstly, through increasing the homogeneity of 
161 
 
our samples (where relevant) and also investigating if fundamental 3D cell culture practises, 
that is passage, affects the data acquired from S-FTIR microspectroscopy. The chapter also 
addressed the identification of the cells with the 3D collagen models and the effect of the 
presence of the 3D collagen model itself. 
 
Chapter 6 demonstrated that producing clonal populations of cells does increase the 
homogeneity of the sample population compared to the parental counterparts. This is 
particularly useful and has been used in chapter 7 to assess the sensitivity of lung cancer 
cells to a chemotherapy agent, gemcitabine.  
 
The chapter also demonstrated that early passages do not make a difference, however the 
ongoing passage of cells will mean a differentiation from the original parental body, which 
is to be expected. If studies were to incorporate cells grown over large amount of time and 
passaged regularly this would have to be a consideration. Findings here meant that later work 
is based on cells that are close in passage number to avoid any variance caused by this to be 
seen as differences in cell populations.  
 
Chapter 6 also showed the challenges faced when working with 3D collagen models for S-
FTIR analysis, although this challenge can also be applied to all forms of spectroscopy. 
DAPI provided confirmation of the location of cells within these tissues easily, however 
there were slight changes to the spectra produced from cells after being stained. This 
methodology needs to be further assessed to establish that the changes in spectra are 
definitely just due to noise. If not a refinement of the DAPI stain method itself could be 
changed to reduce any differences down. This could be done by reducing down the exposure 
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of the stain through time or concentration and to also look at the suspension fluid that the 
stain is delivered in.  
Chapter 6 illustrates the use of an important methodology for the field of spectroscopy, the 
first experiment highlighting that differences seen within cellular populations could be due 
to general differences that could mask smaller experimental changes. In order for the cloning 
method to be justified the same chapter also illustrates the practicalities of using the clonal 
method and how many passages should be taken before a population. DAPI staining could 
be of use to a wide community, being an attractive method to be applied to a variety of 
regenerative medicine studies, where the confirmation of cell nuclei is important. The overall 
impact of the chapter is perhaps modest, but vital in the experimental set up of how we 
prepare cells for SFTIR spectroscopy.   
 
Chapter 7 utilised the findings from chapter 6, incorporating the use of clonal populations to 
assess the sensitivity of lung cancer cells to the chemotherapy agent gemcitabine. The 
chapter’s aims were to establish a biomarker of sensitivity in clonal populations of CALU-1 
grown in 2D culture conditions. The second aim of the chapter was also to identify sensitivity 
and resistance to the drug prior to the addition of the drug.  
 
The work in chapter 6 did show differences between sensitive and resistant clonal 
populations of cells. It is not straightforward to identify a biomarker of sensitivity from this 
work intrinsically, as there were other variables that needed to be accounted for such as the 
role of the fixative PFA used. Further work to assess the full extent of the effect of fixatives 
in drug dosed, clonal populations of cells needs to be explored. Although the results in this 
chapter are promising, showing differences between sensitive and resistant groups of cells, 
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further work to expand the study needs to be implemented before any main conclusions can 
be drawn. Firstly, the work needs to be expanded to assess different lung cancer and general 
cancer types to ensure the features seen here contributing to the differences in the spectra are 
not specific to the CALU-1 cell line alone. The work also needs to be expanded to include 
other chemotherapy agents used for the treatment of cancer.  
The second aim of the chapter was clearly answered. The characterisation of drug sensitivity 
and resistance in cells prior to the addition of the drug was fulfilled by utilising the clonal 
methodology expanded in chapter 6. Differences among the control portions of clonal 
populations that were not exposed to the drug, clearly identifying profiles that are indicative 
of sensitivity. The clonal methodology also demonstrates that changes seen in the spectra 
are also due to differences in sensitivity and not due to other features caused through the 
application of the drug. This chapter lead to a publication on the findings and methodology 
used here on the identification of gemcitabine sensitivity in cells post drug application. 
 
In conclusion, this thesis has answered a majority of the aims set out for each chapter. Future 
work is clearly outlined from each study on ways to improve the methodology where in some 
cases these aims have not been met in their entirety. The future direction of the research to 
improve the management of lung cancer as a whole is also outlined and this thesis has laid 
appropriate foundations for the continuation of this improvement. The potential of SIFT-MS 
as a novel tool to help diagnose lung cancer as a non-invasive and economical technique 
seems promising but still has much more work to establish trends in larger populations and 
also to refine the sampling techniques used. S-FTIR microspectroscopy also shows much 
promise in the in vitro study of cell characterisation. This technique could be used in support 
of pathological practises to identify cells that are cancerous. S-FTIR microspectroscopy also 
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has the potential to be used to support the identification of appropriate treatment for patients, 
characterising how cancerous population will respond to drugs.  
Overall, this thesis has made a contribution to the methodological preparations that will be 
undertaken in both the fields of mass spectrometry and vibrational spectroscopy. It has also 
demonstrated the potential of two techniques that could support the current diagnostic 
practises that are currently used to diagnose lung cancer.  
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Appendices 
Appendix 1. WHO Histological Classification of Tumours of The Lung 
 
Benign epithelial tumours Lymphoproliferative tumours 
Papillomas Lymphoma 
Adenomas Lymphomatoid granulomatosis 
 Langerhans cell histiocytosis 
Malignant epithelial tumours 
Squamous cell carcinoma Miscellaneous tumours 
Small cell carcinoma Hamartoma 
Adenocarcinoma Sclerosing haemangioma 
Large cell carcinoma Clear cell tumour 
Adenosquamous carcinoma Germ cell tumours 
Sarcomatoid carcinoma Intrapulmonary thymoma 
Carcinoid Melanoma 
Salivary gland tumours 
Preinvasive lesions Metastatic tumours 
Mesenchymal tumours   
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Appendix 2. Stages of Lung Cancer 
 
Small Cell Lung Cancer 
Limited disease.  Confined to the ipsilateral hemithorax 
Extensive disease. Beyond ipsilateral hemithorax, which may include malignant pleural 
or pericardial effusion or haematogenous metastases. 
Non Small Cell Lung Cancer (TNM) 
Primary tumour (T) 
Tx Primary tumour cannot be assessed, or the tumour is proven by the presence of 
malignant cells in sputum or bronchial washing but is not visualized by imaging or 
bronchoscopy 
T0 No evidence of primary tumour 
Tis Carcinoma in situ 
T1 Tumour ≤ 3 cm in greatest dimension, surrounded by lung or visceral pleura, no 
bronchoscopic evidence of invasion more proximal than the lobar bronchus (not in the 
main bronchus); superficial spreading of tumour in the central airways (confined to the 
bronchial wall ) 
T1a Tumour ≤ 2 cm in the greatest dimension 
T1b Tumour > 2 cm but ≤ 3 cm in the greatest dimension 
T2 Tumour > 3 cm but ≤ 7 cm or tumour with any of the following: 
- Invades visceral pleura 
- Involves the main bronchus ≥ 2 cm distal to the carina 
- Associated with atelectasis/obstructive pneumonitis extending to hilar region but 
not involving the entire lung 
T2a Tumour > 3 cm but ≤ 5 cm in the greatest dimension 
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T2b Tumour > 5 cm but ≤ 7 cm in the greatest dimension 
T3 Tumour > 7 cm or one that directly invades any of the following: 
- Chest wall (including superior sulcus tumours), diaphragm, phrenic nerve, 
mediastinal pleura, or parietal pericardium; 
- Or tumour in the main bronchus < 2 cm distal to the carina but without 
involvement of the carina 
- Or associated atelectasis/obstructive pneumonitis of the entire lung or separate 
tumour nodule(s) in the same lobe 
T4 Tumour of any size that invades any of the following: mediastinum, heart, great 
vessels, trachea, recurrent laryngeal nerve, oesophagus, vertebral body, or carina; or 
separate tumour nodule s) in a different ipsilateral lobe 
Regional lymph nodes (N) 
Nx Regional lymph nodes cannot be assessed 
N0 No regional node metastasis 
N1 Metastasis in ipsilateral peribronchial and/or ipsilateral hilar lymph nodes and 
intrapulmonary nodes, including involvement by direct extension 
N2 Metastasis in the ipsilateral mediastinal and/or subcarinal lymph node(s) 
N3 Metastasis in the contralateral mediastinal, contralateral hilar, ipsilateral or 
contralateral scalene, or supraclavicular lymph nodes 
Distant metastasis (M) 
Mx Distant metastasis cannot be assessed 
M0 No distant metastasis 
M1 Distant metastasis 
M1a Separate tumour nodule(s) in a contralateral lobe; tumour with pleural nodules 
or malignant pleural (or pericardial) effusion 
M1b Distant metastasis 
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Anatomical Stage 
 
Stage T N M 
IA 
T1a N0 M0 
T1b N0 M0 
IB T2a N0 M0 
IIA 
T1a N1 M0 
T1b N1 M0 
T2a N1 M0 
T2b N0 M0 
IIB 
T2b N1 M0 
T3 N0 M0 
IIIA 
T1 N2 M0 
T2 N2 M0 
T3 N1 M0 
T3 N2 M0 
T4 N0 M0 
T4 N1 M0 
IIIB 
T4 N2 M0 
T1 N3 M0 
T2 N3 M0 
T3 N3 M0 
T4 N3 M0 
IV Any T Any N M1a or M1b 
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Appendix 3. Typical Operating Conditions of the SIFT-MS  
 
Table adapted from (254 Smith, D.  2011) 
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Appendix 4. A List of Media Components (Lonza and Sigma) 
 
 
DMEM High Glucose w/o L3Glutamine w/ Sodium Pyruvate 
 
 
CAS n_ Description Formulation Quantity 
1119-34-2 L-Arginine Monohydrochloride C6H14N4O2.HCL 84.00 mg/l 
73-22-3 L-Tryptophan C11H12N2O2 16.00 mg/l 
72-19-5 L-Threonine C4H9NO3 95.00 mg/l 
61-90-5 L-Leucine C6H13NO2 105.00 mg/l 
56-45-1 L-Serine C3H7NO3 42.00 mg/l 
30925-07-6 L-Cystine Dihydrochloride C6H12N2O4S2.2HCL 62.60 mg/l 
72-18-4 L-Valine C5H11NO2 94.00 mg/l 
56-40-6 Glycine C2H5NO2 30.00 mg/l 
73-32-5 L-Isoleucine C6H13NO2 105.00 mg/l 
69847-45-6  L-Tyrosine Disodium Salt Dihydrate C9H11N03+2Na+2H2O 103.79 mg/l 
71-00-1 L-Histidine Monohydrochloride monohydrate C6H9N3O2 42.00 mg/l 
63-91-2 L-Phenyalanine HO2CCH(NH2)CH2C6H 66.00 mg/l 
63-68-3 L-Methionine C5H11NO2S 30.00 mg/l 
657-27-2 L-Lysine Monohydrochloride C6H14N2O2.HCL 146.00 mg/l 
7487-88-9 Magnesium Sulfate Anhydrous MgSO4 97.67000 mg/l 
7647-14-5 Sodium Chloride NaCl 6400.00000 mg/l 
10043-52-4 Calcium Chloride Dihydrate CaCl2 265.00000 mg/l 
7558-80-7 Sodium Phosphate Monobasic Anhydrous NaH2PO4 109.00000 mg/l 
7447-40-7 Potassium Chloride KCL 400.00000 mg/l 
50-99-7 D-Glucose Anhydrous C6H12O6 4500.00000 mg/l 
7782-61-8 Ferric Nitrate Nonahydrate Fe(NO3)3•9H2O 0.10000 mg/l 
67-48-1 Choline Chloride C5H14NO.Cl 4.00000 mg/l 
137-08-6 D-Ca Pantothenate C9H17NO5 4.00000 mg/l 
59-30-3 Folic Acid C19H19N7O6 4.00000 mg/l 
87-89-8 Myo-inositol C6H12O6 7.20000 mg/l 
98-92-0 Nicotinamide (Nicotinic Acid Amide) C6H6N2O 4.00000 mg/l 
65-22-5 Pyridoxal Hydrochloride C8H9NO3.HCl 4.00000 mg/l 
83-88-5 Riboflavin C17H20N4O6 0.40000 mg/l 
67-03-8 Thiamine Hydrochloride C12H17N4OS+Cl-.HCl 4.00000 mg/l 
34487-61-1  Phenol Red Sodium Slat C19H13NaO5S 15.90000 mg/l 
113-24-6 Sodium Pyruvate C3H3NaO3 110.00000 mg/l 
144-55-8 Sodium Bicarbonate NaHCO3 3,700.00 mg/l  
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Ham's F-12 Medium     
 
w/ L-Glutamine            
 
       
 
  Concentration Molarity 
 
Description Chemical Formula g/L mg/L mM uM 
 
      
 
Calcium Chloride Anhydrous CaCl2 3.330E-02 33.300 0.300 300.027 
 
       
Cupric Sulfate Pentahydrate CuSO4 • 5H2O 2.500E-06 2.500E-03 1.001E-05 0.010 
 
       
Dextrose C6H12O6 1.802 1.802E+03 10.000 1.000E+04 
 
       
Ferrous Sulfate Heptahydrate FeSO4 • 7H2O 8.300E-04 0.830 2.986E-03 2.986 
 
       
Potassium Chloride KCl 0.224 223.650 3.000 3.000E+03 
 
       
Sodium Bicarbonate NaHCO3 1.176 1.176E+03 13.998 1.400E+04 
 
       
Sodium Chloride NaCl 7.599 7.599E+03 130.031 1.300E+05 
 
       
Sodium Phosphate, Dibasic Anhydrous Na2HPO4 0.142 142.020 1.000 1.000E+03 
 
       
Zinc Sulfate Heptahydrate ZnSO4 • 7H2O 8.600E-04 0.860 2.991E-03 2.991 
 
       
L-Alanine HO2CCH(NH2)CH3 8.910E-03 8.910 0.100 100.011 
 
       
L-Arginine Monohydrochloride C6H14N4O2 • HCl 0.211 210.700 1.000 1.000E+03 
 
       
L-Asparagine Monohydrate NH2COCH2CH(NH2)COOH • H2O 1.501E-02 15.010 9.998E-02 99.980 
 
       
L-Aspartic Acid HO2CCH(NH2)CH2CO2H 1.331E-02 13.310 0.100 100.000 
 
       
L-Cysteine Monohydrochloride Monohydrate C3H7NO2S • HCl • H2O 3.512E-02 35.120 0.200 200.000 
 
       
L-Glutamic Acid C5H9NO4 1.471E-02 14.710 0.100 100.000 
 
       
L-Glutamine C5H10N2O3 0.146 146.200 1.000 1.000E+03 
 
       
Glycine HO2CCH2NH2 7.510E-03 7.510 0.100 100.040 
 
       
L-Histidine Monohydrochloride Monohydrate C6H9N3O2 • HCl • H2O 2.096E-02 20.960 0.100 100.000 
 
       
L-Isoleucine HO2CCH(NH2)CH(CH3)CH2CH3 3.940E-03 3.940 3.004E-02 30.037 
 
       
L-Leucine HO2CCH(NH2)CH2CH(CH3)2 1.312E-02 13.120 0.100 100.023 
 
       
L-Lysine Monohydrochloride C6H14N2O2 • HCl 3.654E-02 36.540 0.200 200.055 
 
       
L-Methionine HO2CCH(NH2)CH2CH2SCH3 4.480E-03 4.480 3.003E-02 30.027 
 
       
L-Phenylalanine HO2CCH(NH2)CH2C6H5 4.960E-03 4.960 3.003E-02 30.026 
 
       
L-Proline C5H9NO2 3.453E-02 34.530 0.300 299.922 
 
       
L-Serine HO2CCH(NH2)CH2OH 1.051E-02 10.510 0.100 100.010 
 
       
L-Threonine HO2CCH(NH2)CH(OH)CH3 1.191E-02 11.910 9.998E-02 99.983 
 
       
L-Tryptophan C11H12N2O2 2.040E-03 2.040 9.989E-03 9.989 
 
       
L-Valine HO2CCH(NH2)CH(CH3)2 1.171E-02 11.710 0.100 100.000 
 
       
D-Biotin (Vitamin H) C10H16N2O3S 7.000E-06 7.000E-03 2.865E-05 0.029 
 
       
D-Calcium Pantothenate (Vitamin B5) C18H32CaN2O10 2.400E-04 0.240 5.036E-04 0.504 
 
       
Choline Chloride HOCH2CH2N(CH3)3Cl 1.396E-02 13.960 9.998E-02 99.979 
 
       
Cyanocobalamin (Vitamin B12) C63H88CoN14O14P 1.360E-03 1.360 1.003E-03 1.003 
 
       
Folic Acid C19H19N7O6 1.320E-03 1.320 2.990E-03 2.990 
 
       
I-Inositol C6H12O6 1.800E-02 18.000 9.989E-02 99.889 
 
       
DL-α-lipoic acid (thioctic acid) C8H14O2S2 2.100E-04 0.210 1.018E-03 1.018 
 
       
Niacinamide (Nicotinamide) C6H6N2O 3.700E-05 3.700E-02 3.030E-04 0.303 
 
       
Pyridoxine Monohydrochloride C8H11NO3 6.200E-05 6.200E-02 3.016E-04 0.302 
 
       
Riboflavin (Vitamin B2) C17H20N4O6 3.800E-05 3.800E-02 1.010E-04 0.101 
 
       
Thiamine Monohydrochloride (Vitamin B1) C12H18N4OSCl2 3.400E-04 0.340 1.008E-03 1.008 
 
       
Thymidine C10H14N2O5 7.300E-04 0.730 3.014E-03 3.014 
 
       
Phenol Red C19H14O5S 1.242E-03 1.242 3.300E-03 3.300 
 
       
Pyruvic Acid Sodium Salt CH3COCO2Na 0.110 110.000 1.000 999.636 
 
       
Putrescine Dihydrochloride NH2(CH2)4NH2 • 2HCl 1.600E-04 0.160 9.933E-04 0.993 
 
       
L-Tyrosine Disodium Salt, Dihydrate C9H9NO3Na2 • 2H2O 7.842E-03 7.842 3.002E-02 30.024 
 
       
Linoleic Acid Methyl Ester C19H34O2 8.800E-05 8.800E-02 2.988E-04 0.299 
 
       
Hypoxanthine Disodium Salt C5H2N4ONa2 5.460E-03 5.460 3.031E-02 30.315 
 
       
Magnesium Chloride, Anhydrous MgCl2 5.719E-02 57.190 0.601 600.672 
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Appendix 5. Table of ADH and ALDH information 
Enzyme Activator Inhibitor Metabolite 
 Occurrence 
DMEM Occurrence Hams 
ADH 
Sulfhydryl activating reagents 
Heavy metals and -
SH reagents 
  
    
  Mercaptoethanol Thiourea       
  
Dithiothreitol 
Purine and pyrimidine 
derivatives 
  
    
  
Cysteine 
Chloroethanol and 
fluoroethanol 
  
L-Cysteine 
hydrochloride-H2O, 
L-Cystine 2HCl 
L-Cysteine 
Monohydrochloride 
Monohydrate 
  Heavy metal chelating agents N-alkylmaleimides       
    Iodoacetamide       
    1,10-phenanthroline       
    8-hydroxyquinoline       
    Beta-NAD analogs       
            
Enzyme 
Enzyme Specifics/ where effect is/ 
details Inhibitor Metabolite 
 Occurrence 
DMEM Occurrence Hams 
ALDHs ALDH 1 & 3 
Ampal (4-amino-4-
methyl-2-pentyne-1-
al) 
Thioampal   
  
  ALDH 2 Benomyl MBT     
  ALDH 2 
Citrala Neral and 
geranial     
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  NAD+ Chloral hydratea  Chloral hydrate     
  ALDH 3 
Chlorpropamide 
analogs NPI-1 API-1 
NPI-1 
    
  esterase 
Coprine 1-Amino 
cyclopropanol     
  catalase Cyanamide HNO     
  anti-dipsotropic Daidzin Daidzin     
    CVT-10216 CVT-10216     
  
Confers sensitivity to 
cyclophosphamide-resistant cells. 
DEABa  DEAB 
    
    DPABa  DPAB     
  
Inhibits dopamine β-hydroxylase; 
displays copper chelation activity; 
inhibits carboxylesterase and 
cholinesterase 
Disulfiram Disulfiram 
    
    DDTC-SO       
    DDTC-SO2       
    DETC-SO       
    DETC-SO2       
  
Inhibits several other dehydrogenase 
enzymes. Interacts with alcohol in 
system to form a toxic metabolite,  
Gossypol Gossypol 
    
  
Tryptophane metabolites in the 
kynurenine pathway seem to have 
the potential for ALDH2 specific 
inhibition. 
Kynurenine 
Tryptophan 
metabolites 
KA 
L-Tryptophan L-Tryptophan 
    3-HK       
    3-HAA       
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  ALDH Molinate Molinate     
    Molinate sulfoxide       
    Molinate sulfone       
  DTT but not GSH (ALDH2) 
Nitroglycerina  NO3− 
    
  
Activated by CYP2E1 in liver 
microsomes; irreversible inhibitor of 
monoaminoxidase 
Pargylinea  Propiolaldehyde 
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Appendix 6. Table of suppliers for media and components 
 
General Culture Components Supplier and Code 
    
DMEM High Glucose Biosera, LM-D1112 
Ham's F12 Lonza, BE12-615F 
Fetal Bovine Serum   
 Fetal Bovine Serum (South America Origin) LabTech, FCS-SA/500 
Antibiotic Antimycotic Solution 100x, Sigma Aldrich, A5955 
L - Glutamine 200nM, Sigma Aldrich, G7513 
Hepes Buffer Solution 1M, Sigma Aldrich, H0887 
Non-Essential Amino Acids  100X, Sigma Aldrich, M7145 
Sodium Pyruvate Solution 100mM, Sigma Aldrich, S8636 
Powdered glucose Sigma Aldrich, G7021 
    
Trypsin-EDTA Solution 10x, Sigma Aldrich,  T4174 
Dulbecco's Phosphate Buffered Saline 1x, Gibco, 14190 
Hank's Balanced Salt Solution 1x, Gibco, 14175-046 
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